On this page
Quick Reference
Overview and Recommendations
Background
- •Breast cancer is a malignant neoplasm arising from the terminal ductal-lobular unit, with an estimated 2.3 million new cases and 685,000 deaths globally in 2020. It is the most frequently diagnosed cancer among women worldwide and the leading cause of cancer-related death in women, with geographic variation: incidence highest in high-income countries, mortality highest in low- and middle-income countries (LMICs) due to late-stage presentation and limited treatment access, 5-year survival in LMICs is <40% versus >90% in high-income settings.
- •Molecular subtypes defined by gene expression, luminal A (ER+/HER2-, low Ki-67, best prognosis), luminal B (ER+/HER2±, higher Ki-67), HER2-enriched (HER2+, aggressive but targetable), and basal-like (triple-negative, poor prognosis), guide treatment and prognosis. Triple-negative breast cancer (TNBC) is three times more common in women of African descent and premenopausal women, and accounts for 10-20% of all breast cancers.
- •Genetic predisposition accounts for 5-10% of cases, with high-penetrance genes: BRCA1 (57% lifetime risk by age 70), BRCA2 (49%), PALB2 (35%), TP53 (80-90%), PTEN (>50%), and CDH1 (42% for lobular breast cancer). Moderate-penetrance genes include CHEK2 (OR 2.4), ATM (OR 2.16), and BARD1/RAD51C/RAD51D, which are associated with TNBC risk. ASCO-SSO guidelines recommend BRCA1/2 testing for all newly diagnosed patients ≤65 years and for all TNBC at any age.
- •Risk factors: age, mammographic breast density (4- to 6-fold risk increase), obesity (35-40% higher risk of recurrence and death), alcohol (dose-dependent), hormonal contraceptives (HR 1.24 for current use), and PM2.5 air pollution (HR 1.28 per 10 μg/m³). Protective factors include breastfeeding (pOR 0.77-0.79), physical activity ≥6 h/week (HR 0.72), and parity (reduces luminal risk by 25%). The MAP.3 trial showed that exemestane reduces invasive breast cancer by 65% in high-risk postmenopausal women.
- •The paradigm shift in management over the past three decades: from radical mastectomy to breast-conserving surgery with sentinel lymph node biopsy, and from empirical chemotherapy to genomically guided therapy (TAILORx, MINDACT) and targeted therapy (HER2 blockade, CDK4/6 inhibitors, immune checkpoint inhibitors, PARP inhibitors). The residual cancer burden (RCB) after neoadjuvant therapy is a powerful prognostic tool, with 10-year relapse-free survival ranging from 86% (RCB-0) to 23% (RCB-III) in TNBC.
Evaluation
- •Suspect breast cancer in any patient with a painless, firm, irregular breast lump; skin dimpling, erythema, ulceration, or nipple retraction; spontaneous bloody nipple discharge; or axillary adenopathy. Inflammatory breast cancer (IBC) presents with diffuse breast enlargement, erythema, warmth, and peau d'orange without a discrete mass, urgent biopsy is required as it is often mistaken for mastitis.
- •Evaluate with diagnostic mammography (preferably with tomosynthesis) and ultrasound. For high-risk patients (BRCA1/2, lifetime risk >20%, prior chest radiation), annual breast MRI starting at age 30 (or 25 for BRCA1/2) reduces breast cancer mortality by 80% (HR 0.20; 95% CI 0.10-0.43). In dense breasts, MRI detects 2.5 vs 5.0 interval cancers per 1000 screenings (DENSE trial).
- •Obtain core needle biopsy (CNB) as the preferred method for tissue diagnosis; place in 10% neutral buffered formalin with cold ischemia time <1 hour. Fine-needle aspiration (FNA) is inadequate for distinguishing invasive from in situ disease. For suspicious calcifications, stereotactic or vacuum-assisted biopsy is required.
- •Assess histologic type (e.g., invasive ductal NST, invasive lobular, tubular, mucinous, medullary) and Nottingham grade (tubule formation, nuclear pleomorphism, mitotic count). Invasive lobular carcinoma (ILC) shows discohesive single-file cells and requires E-cadherin IHC for confirmation; it often presents as subtle thickening rather than a discrete mass.
- •Determine ER/PR status by IHC: ER-positive if ≥1% nuclear staining; report 1-10% as ER Low Positive with a comment on limited data for endocrine therapy benefit. HER2 testing by IHC with reflex ISH for IHC 2+: positive if IHC 3+ (uniform intense membrane staining in >10% of cells) or ERBB2/CEP17 ratio ≥2.0 with average copy number ≥4.0 signals/cell. HER2-low is defined as IHC 1+ or IHC 2+/ISH-negative and is now targetable with deruxtecan (T-DXd).
- •Order Ki-67 proliferation index (prognostic, though lack of standardization limits standalone use; Ki-67 ≥20% is commonly considered high). Consider multigene assay: Oncotype DX (21-gene recurrence score) for node-negative HR+/HER2- disease, TAILORx showed RS ≤10: endocrine therapy alone, RS 11-25: no chemo benefit, RS 26-100: chemo improves outcomes. MammaPrint (70-gene) is an alternative for clinical high-risk/genomic low-risk patients.
- •Stage with AJCC 8th edition, integrating anatomical TNM and prognostic factors (grade, ER/PR, HER2, genomic assays). For clinical stage IIA-IIIC, consider 18F-FDG PET/CT as an alternative to CT chest/abdomen/pelvis + bone scan; it identifies distant metastases in 14% and upstages nodal disease in 37%, with lower radiation dose (14 mSv vs 21 mSv) and shorter time to treatment initiation.
- •In patients with metastatic disease, rebiopsy for receptor discordance (up to 40% of cases for PR and HER2). Consider liquid biopsy (ctDNA) to detect ESR1 mutations (guides elacestrant use), PIK3CA mutations (alpelisib), and for monitoring treatment response. Post-surgical ctDNA detection predicts metastatic recurrence with a lead time of 8.9-10.7 months (sensitivity 89-96%).
- •For high-risk patients (HER2+ or TNBC), consider screening brain MRI at baseline and at progression; occult brain metastases are found in 9.8% at baseline, rising to 19.6% by third-line therapy. In patients with HER2+ brain metastases, tucatinib combined with trastuzumab and capecitabine improves overall survival (HER2CLIMB: median OS 21.6 vs 12.5 months).
Management
- •For early-stage breast cancer, decide between neoadjuvant and adjuvant systemic therapy. Neoadjuvant is preferred for inflammatory breast cancer, locally advanced disease, and when downstaging enables breast-conserving surgery. Achieving pathologic complete response (pCR) is strongly prognostic (HR 0.31 for event-free survival across subtypes), especially in TNBC (HR 0.18) and HER2+ disease (HR 0.32).
- •For HR+/HER2- disease: initiate endocrine therapy. For premenopausal women, tamoxifen 20 mg/day ± ovarian function suppression (OFS) with exemestane 25 mg/day; SOFT trial showed 12-year DFS 79.0% with OFS+exemestane vs 71.9% with tamoxifen alone (HR 0.79). For postmenopausal women, aromatase inhibitors (letrozole 2.5 mg/day, anastrozole 1 mg/day, exemestane 25 mg/day) are standard.
- •For high-risk HR+/HER2- disease (node-positive, grade 3, high Ki-67, or genomic high risk), add a CDK4/6 inhibitor: abemaciclib 150 mg BID for 2 years (monarchE: 7-year OS 86.8% vs 85.0%, HR 0.842) or ribociclib 400 mg/day for 3 years (NATALEE: 4-year iDFS 88.5% vs 83.6%, HR 0.72). These are recommended for patients with stage II-III disease with additional risk factors.
- •For HER2+ disease: use dual HER2 blockade with trastuzumab (8 mg/kg loading then 6 mg/kg q3w) and pertuzumab (840 mg loading then 420 mg q3w) plus chemotherapy. For neoadjuvant therapy, ddAC (doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 q3w) followed by THP (paclitaxel 80 mg/m2 weekly + trastuzumab + pertuzumab) is standard. For residual disease after neoadjuvant therapy, switch to T-DM1 3.6 mg/kg q3w for 14 cycles (KATHERINE: 3-year iDFS 88.3% vs 77.0%, HR 0.50).
- •For metastatic HER2+ disease: first-line T-DXd 5.4 mg/kg q3w + trastuzumab + pertuzumab (DESTINY-Breast03: 12-month PFS 75.8% vs 34.1%, HR 0.28). For brain metastases, add tucatinib 300 mg BID (HER2CLIMB: OS 21.6 vs 12.5 months, HR 0.60). For HER2-low metastatic disease, T-DXd improves PFS vs chemotherapy (DESTINY-Breast04: 13.2 vs 8.1 months, HR 0.62).
- •For triple-negative breast cancer (stage II-III): neoadjuvant pembrolizumab 200 mg q3w + carboplatin AUC 1.5 weekly + paclitaxel 80 mg/m2 weekly for 12 weeks, followed by doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 q3w for 4 cycles, then adjuvant pembrolizumab 200 mg q3w for 9 cycles (KEYNOTE-522: pCR 64.8% vs 51.2%, 5-year OS 86.6% vs 81.7%). For residual disease after neoadjuvant chemotherapy, give adjuvant capecitabine 1250 mg/m2 BID days 1-14 q3w for 6 cycles (CREATE-X: 5-year DFS 74.1% vs 67.6%, HR 0.70).
- •For metastatic TNBC: first-line pembrolizumab + chemotherapy (for PD-L1 CPS ≥10) or atezolizumab + nab-paclitaxel (for PD-L1 IC ≥1%). Second-line: sacituzumab govitecan 10 mg/kg on days 1 and 8 of 21-day cycles (ASCENT: OS 12.1 vs 6.7 months, HR 0.48). For BRCA1/2-mutated metastatic TNBC, consider PARP inhibitors: olaparib 300 mg BID or talazoparib 1 mg/day (OlympiAD: PFS 7.0 vs 4.2 months, HR 0.58).
- •Locoregional management: breast-conserving surgery (lumpectomy) with whole-breast irradiation is standard. For women ≥70 years with stage I, ER+ disease, omission of radiotherapy after lumpectomy is an option (CALGB 9343: 10-year LR 10% vs 2%, no OS difference). Axillary management: sentinel lymph node biopsy (SLNB) is standard for clinically node-negative. For cN1 converting to ypN0 after neoadjuvant therapy, regional nodal irradiation does not improve outcomes (NSABP B-51: HR 0.88, p=0.51). Omission of axillary surgery can be considered for cT1-T2 N0 with negative axillary ultrasound (SOUND trial).
- •Monitoring: post-treatment surveillance includes clinical exam every 3-6 months for 3 years, then every 6-12 months, and annual mammography. Routine imaging for asymptomatic patients is not recommended except for annual mammography. Adjuvant bisphosphonates (zoledronic acid 4 mg IV q6 months for 3-5 years) reduce bone recurrence in postmenopausal patients. For patients on aromatase inhibitors, monitor bone density and consider calcium/vitamin D supplementation.
- •Avoid: non-dihydropyridine CCBs (diltiazem, verapamil) in patients with heart failure; trastuzumab during pregnancy (causes oligohydramnios); radiotherapy during the first trimester; tamoxifen in patients with history of thromboembolic events. Do not use anthracyclines in patients with cardiac risk factors if alternative regimen is available. Refer to genetic counseling for all patients ≤65 years, TNBC at any age, or family history suggestive of hereditary syndrome. Refer to fertility preservation specialist before starting systemic therapy.
Board Review — High Yield
- •Triple-negative breast cancer - ER-/PR-/HER2-, associated with BRCA1 mutations, peak recurrence within 3 years. KEYNOTE-522: neoadjuvant pembrolizumab + chemotherapy improves pCR (64.8% vs 51.2%) and 5-year OS (86.6% vs 81.7%).
- •Oncotype DX - 21-gene recurrence score (RS) for HR+/HER2- node-negative breast cancer. TAILORx: RS ≤10 → endocrine therapy alone; RS ≥26 → chemo + endocrine; RS 11-25 → no chemo benefit (for age >50) or consider chemo for age ≤50 with RS 16-25.
- •HER2-targeted therapy - Trastuzumab + pertuzumab + taxane for HER2+ disease (APHINITY: 8-year iDFS 86.1% vs 81.2% for node-positive). T-DM1 for residual disease after neoadjuvant therapy (KATHERINE: HR 0.50). T-DXd superior to T-DM1 in metastatic setting (DESTINY-Breast03: HR 0.28).
- •CDK4/6 inhibitors - Ribociclib, palbociclib, abemaciclib improve PFS in metastatic HR+/HER2-. Adjuvant: abemaciclib (monarchE) for high-risk node-positive, ribociclib (NATALEE) for stage II-III with risk factors.
- •Inflammatory breast cancer - Clinical triad: erythema, edema (peau d'orange), warmth without discrete mass. Requires urgent biopsy and neoadjuvant chemotherapy. Not a histologic diagnosis but a clinical syndrome.
- •BRCA1/2 testing - Offer to all patients ≤65 years, all TNBC, all male breast cancer, and family history of BRCA-related cancers. PARP inhibitors (olaparib, talazoparib) effective in adjuvant (OlympiA: HR 0.68 for OS) and metastatic settings.
- •Residual cancer burden (RCB) - After neoadjuvant chemotherapy, RCB index predicts prognosis. 10-year relapse-free survival: 86% (RCB-0) to 23% (RCB-III) in TNBC. Guides adjuvant therapy: capecitabine for TNBC, T-DM1 for HER2+.
- •Sentinel lymph node biopsy omission - Can be omitted in cT1-T2 N0 with negative axillary ultrasound (SOUND trial: noninferior 5-year iDFS). Also in select postmenopausal women with small HR+/HER2- tumors (INSEMA trial).
- •Omission of radiotherapy in elderly - Women ≥70 with stage I, ER+ breast cancer: tamoxifen alone is an option (CALGB 9343: 10-year LR 10% vs 2%, no OS difference). PRIME II: 5-year LR 4.1% without RT vs 1.3% with RT.
- •Pregnancy-associated breast cancer - Worse prognosis (HR 1.44 for death). Chemotherapy safe in 2nd/3rd trimester; trastuzumab contraindicated (oligohydramnios). Delay RT and endocrine therapy until postpartum. POSITIVE trial: temporary interruption of endocrine therapy to attempt pregnancy did not increase short-term relapse risk.
Deep Dive — Evidence Details
Definition and Epidemiology
- ▸Breast cancer is the most common malignancy in women worldwide, with an estimated 2.3 million new cases in 2020.
- ▸Mortality rates have declined by 39% in the US since 1990, but remain high in low- and middle-income countries.
- ▸The four major molecular subtypes (luminal A, luminal B, HER2-enriched, basal-like) differ in prognosis and treatment approach.
Breast cancer is a malignant neoplasm arising from the epithelial cells of the mammary gland, most commonly from the terminal ductal-lobular unit. Also called: breast carcinoma, mammary carcinoma, BC. Ductal carcinoma in situ (DCIS) refers to malignant epithelial cells confined within the basement membrane of the mammary ducts; invasive (infiltrating) carcinoma denotes penetration of the basement membrane with potential for metastasis. The histologic grades (1 to 3) reflect increasing nuclear atypia and loss of differentiation. Molecular subtypes - luminal A, luminal B, HER2-enriched, and basal-like - are defined by gene expression profiles and guide treatment and prognosis.
Breast cancer is the most frequently diagnosed malignancy among women worldwide and the leading cause of cancer-related death in women globally [75]D5[117]B2c. In 2020, an estimated 2.3 million new cases and 685,000 deaths occurred, with marked geographic variation [75]D5. Age-standardized incidence rates are highest in high-income countries (e.g., >90 per 100,000 in Western Europe) and lowest in low- and middle-income countries (LMICs; <30 per 100,000), but mortality rates are disproportionally higher in LMICs because of late-stage presentation and limited treatment access [56]D5[75]D5. In sub-Saharan Africa, breast cancer is the most common cancer among women, accounting for 129,400 new cases in 2020 [88]D5. Over the past three decades, incidence has increased globally, driven by lifestyle changes, delayed childbearing, and improved detection [110]B2c. Conversely, age-standardized mortality has declined in many high-income countries due to screening and advances in therapy: in the United States, breast cancer mortality has fallen by 39% since 1990 [30]D5.
Subtype Distribution
| Subtype | Approximate Prevalence | Key Features |
|---|---|---|
| Luminal A | 40-50% | ER+ and/or PR+, HER2-, low Ki-67, best prognosis |
| Luminal B | 15-20% | ER+ and/or PR+, HER2+/-, high Ki-67, intermediate prognosis |
| HER2-enriched | 10-15% | ER-, PR-, HER2+, aggressive but targetable |
| Basal-like (triple-negative) | 10-20% | ER-, PR-, HER2-, high grade, poor prognosis, peak risk of recurrence in first 3 years [56]D5 |
Triple-negative breast cancer is three times more common in women of African descent and in premenopausal women [56]D5. accounts for <1% of all cases and shares similar histology but is more often hormone receptor-positive [77]D5.
Age, Gender, and Survival
Breast cancer risk increases with age; the median age at diagnosis in the United States is 62 years, but younger women - particularly those of African ancestry - are more likely to present with aggressive subtypes [56]D5[67]B2c. Five-year relative survival exceeds 90% in high-income countries for localized disease but falls below 40% in many LMICs [75]D5. Prevalence of breast cancer survivors is rising: in Canada, 2.1% of women are survivors [67]B2c. Understanding these patterns of incidence, mortality, and subtype distribution is essential for allocating resources and identifying high-risk populations; the next section examines the established risk factors that drive this burden.
Pearl: Breast cancer incidence is rising globally, but mortality is declining in high-income countries - a disparity driven by late-stage diagnosis in low-resource settings, where the 5-year survival can be <40% versus >90% in regions with screening and multimodal treatment [75]D5.
Risk Factors and Prevention
- ▸Genetic risk is concentrated in BRCA1/2 (high penetrance), PALB2/CHEK2/ATM (moderate penetrance), with cumulative risks modifiable by lifestyle and reproductive factors
- ▸Modifiable factors, hormonal contraceptives, HRT, obesity, physical inactivity, alcohol, and PM2.5, each carry effect sizes of 20-40% risk change and represent population-level prevention targets
- ▸NCCN recommends risk-stratified screening: annual mammography from age 40 (average risk), adding MRI from age 25-30 for women with ≥20% lifetime risk
From the preceding epidemiological picture emerges a portfolio of established risk factors that inform both screening stratification and prevention strategies. Breast cancer risk reflects a complex interplay of non-modifiable and modifiable factors, with distinct profiles across molecular subtypes.
Non-Modifiable Risk Factors
Age remains the strongest single risk factor. Genetic predisposition accounts for 5-10% of cases, with pathogenic variants in BRCA1 (OR 7.62, 95% CI 5.33-11.27) and BRCA2 (OR 5.23, 95% CI 4.09-6.77) conferring high risk [220]B3b. Moderate-risk genes include PALB2 (OR 3.83, 95% CI 2.68-5.63), CHEK2 (OR ~2.5), and ATM [167]B3b[220]B3b. BARD1, RAD51C, and RAD51D variants increase risk of ER-negative and triple-negative disease, while ATM, CDH1, and CHEK2 are associated with ER-positive breast cancer [220]B3b. First-degree family history approximately doubles risk and acts synergistically with genetic variants [229]B3b.
Endogenous hormonal exposure powerfully shapes risk. Breast cancer risk increases by 5.0% for each year younger at menarche (RR 1.050, 95%) and by 3.0% for each year older at [159]B2a. Mammographic breast density confers a 4- to 6-fold risk increase for extremely dense versus fatty breasts and independently limits mammographic sensitivity [173]D5. Prior chest radiotherapy before age 30 carries substantial risk, with major coronary events rising 7.4% per Gy mean heart dose (linear, no threshold) [219]B3b[171]D5.
Modifiable Risk Factors
Reproductive factors carry subtype-specific effects. Parity reduces luminal cancer risk by 25% (pOR 0.75, 95% CI 0.70-0.81), while later age at first birth increases luminal risk (pOR 1.15, 95% CI 1.00-1.32) [155]B2a. Ever protects against both luminal (pOR 0.77, 95% CI 0.66-0.88) and triple-negative (pOR 0.79, 95% CI 0.66-0.94) subtypes [150]B2a[155]B2a.
Current use of hormonal contraceptives elevates risk (HR 1.24, 95% CI 1.20-1.28), driven more by progestin-only (HR 1.21, 95% CI 1.17-1.25) than combined formulations (HR 1.12, 95% CI 1.07-1.17), and risk increases with duration [225]B2b. For BRCA1 carriers, ever use increases risk (HR 1.29, 95% CI 1.04-1.60) with a 3% increase per year of use [193]B2a. Estrogen-progestin HRT consistently elevates risk, whereas estrogen-alone has little effect in postmenopausal women [178]D5.
Obesity is associated with a 35-40% higher risk of recurrence and death, most clearly for ER-positive disease, mediated by aromatase-driven estrogen production and inflammatory pathways [196]D5[156]B2a. Physical activity is protective: women with stable high exercise trajectories had lower risk (HR 0.92, 95% CI 0.87-0.98), and current exercise of ≥6 h/week reduced risk by 28% (HR 0.72, 95% CI 0.62-0.84) compared with no exercise [197]B2b. Alcohol consumption increases risk in a dose-dependent manner, even at low levels [87]D5. Fine particulate matter (PM2.5) is an emerging risk factor, with a 28% increased incidence per 10 μg/m³ (HR 1.28, 95% CI 1.08-1.51) [152]B2b.
Prevention Strategies
Risk assessment begins with validated tools (Tyrer-Cuzick, Gail, BOADICEA). NCCN recommends annual mammography from age 40 for average-risk women [170]A1c[30]D5. For women with ≥20% lifetime risk, including BRCA1/2 carriers, other high-penetrance mutations, or prior chest radiation, annual mammography plus MRI starting at age 30 (or age 25 for BRCA1/2) is recommended [145]A1c[175]A1c[227]B2b. Screening MRI in BRCA1 carriers reduces breast cancer mortality by 80% (HR 0.20, 95% CI 0.10-0.43, P<0.001) [227]B2b.
Chemoprevention is an option for high-risk women. Exemestane reduced invasive breast cancer by 65% over a median 35 months in the MAP.3 trial; tamoxifen reduces risk by approximately 50% in high-risk premenopausal women [165]D5[144]A1c. NCCN recommends discussing risk-reducing agents in women aged ≥35 years with a 5-year Gail risk ≥1.7% or a history of lobular carcinoma in situ [144]A1c. Risk-reducing is cost-effective at a lifetime risk threshold of approximately 34% in 30-year-old women per UK health-economic modelling [231]D5. Bilateral after childbearing is recommended for BRCA1/2 carriers [143]A1c[263]B2a.
| Risk Factor | Effect (OR/RR/HR, 95% CI) | Evidence Level |
|---|---|---|
| BRCA1 pathogenic variant | OR 7.62 (5.33-11.27) [220]B3b | High |
| BRCA2 pathogenic variant | OR 5.23 (4.09-6.77) [220]B3b | High |
| PALB2 pathogenic variant | OR 3.83 (2.68-5.63) [220]B3b | High |
| CHEK2 pathogenic variant | OR ~2.5 [167]B3b | High |
| Younger menarche (per year) | RR 1.050 (1.044-1.057) [159]B2a | High |
| Hormonal contraceptives (current use) | HR 1.24 (1.20-1.28) [225]B2b | High |
| PM2.5 (per 10 μg/m³) | HR 1.28 (1.08-1.51) [152]B2b | Moderate |
| Ever breastfeeding (vs never) | pOR 0.77-0.79 (protective) [155]B2a | High |
| Physical activity ≥6 h/week | HR 0.72 (0.62-0.84, protective) [197]B2b | High |
| Obesity (breast cancer mortality) | HR 1.37 (1.22-1.53) [156]B2a | High |
Pearl: A woman with a BRCA1 mutation faces a 16% 10-year cumulative contralateral breast cancer risk [192]B2b; risk-stratified prevention combining annual MRI starting at age 25, chemoprevention discussion by age 35, and risk-reducing salpingo- after childbearing can substantially alter her lifetime trajectory.
Genetics and Hereditary Predisposition
- ▸BRCA1/2, PALB2, TP53, PTEN, and CDH1 are high-penetrance genes; CHEK2 and ATM are moderate-penetrance.
- ▸ASCO-SSO recommends BRCA1/2 testing for all newly diagnosed breast cancer patients ≤65 years and for all men with breast cancer.
- ▸Detection of a germline PV in BRCA1/2 or PALB2 opens eligibility for PARP inhibitors and risk-reducing surgeries, improving survival.
Germline pathogenic variants (PVs) account for 5-10% of breast cancer diagnoses and represent the strongest individual risk factors, mandating a distinct clinical decision point from population-level risk assessment [274]A1c[188]C4. Identification of a PV gates risk-reducing surgery, enhanced surveillance, and cascade testing for relatives, and is increasingly mandated by NCCN Genetic/Familial High-Risk Assessment guidelines [143]A1c[169]A1c.
High-Penetrance Genes
BRCA1 and BRCA2 are the most clinically impactful. Meta-analytic lifetime breast cancer risk by age 70 years is 57% (95% CI, 47-66%) for BRCA1 and 49% (95% CI, 40-57%) for BRCA2 carriers [302]A1a. BRCA1 PVs are strongly associated with triple-negative breast cancer (TNBC); BRCA2 PVs with hormone receptor-positive disease [286]B3a[346]C4. Ovarian cancer risk is also elevated: 40% for BRCA1 and 18% for BRCA2 by age 70 [302]A1a. Additional risks include (RR 4.30 for BRCA1, 44.0 for BRCA2), pancreatic cancer, and (BRCA2 only) [343]B2b.
PALB2 confers a cumulative breast cancer risk of 35% (95% CI, 26-46%) by age 70, overlapping with BRCA2 risk [360]B2b. Odds ratio (OR) for breast cancer is 4.30 (95% CI, 3.68-5.03) in population-based studies [286]B3a. PALB2 PVs are enriched in TNBC [346]C4.
TP53 (Li-Fraumeni syndrome) carries a lifetime breast cancer risk of 80-90%, with onset often before age 40 [321]D5. Annual breast MRI and whole-body MRI are recommended for surveillance, and is favored to avoid radiotherapy-related second cancers [321]D5.
PTEN ( ) and CDH1 (hereditary diffuse gastric cancer) also confer high breast cancer risk: PTEN-associated lifetime risk exceeds 50%; CDH1 carriers have a 42% (95% CI, 23-68%) risk of lobular breast cancer by age 80 [226]B2b[306]D5.
Moderate-Penetrance Genes
CHEK2 and ATM are associated with ORs of approximately 2.40 (95% CI, 2.21-2.62) and 2.16 (95% CI, 1.93-2.41), respectively, with stronger association for estrogen receptor-positive disease [286]B3a. CHEK2 PVs are also linked to increased contralateral breast cancer risk (HR >1.9) [345]B2b. ATM PVs do not significantly elevate contralateral risk [345]B2b. These genes do not currently qualify for PARP inhibitor therapy but inform enhanced screening [274]A1c.
BARD1, RAD51C, and RAD51D are associated with TNBC risk, with ORs of 2.34, 1.53, and 1.76, respectively, in population-type breast cancer [286]B3a.
Testing Criteria and Clinical Implications
ASCO-SSO guidelines recommend BRCA1/2 testing for all newly diagnosed patients ≤65 years and for select older patients based on personal history, family history, ancestry, or PARP inhibitor candidacy [274]A1c. All men with breast cancer should be offered genetic testing [273]A1c. NCCN guidelines further endorse multigene panel testing for patients with TNBC diagnosed at any age, and for those with family history patterns suggestive of hereditary syndromes [143]A1c[169]A1c.
Detection of a PV in BRCA1/2 or PALB2 opens eligibility for PARP inhibitors (olaparib, talazoparib) in both metastatic and adjuvant settings [277]A1b[278]A1b[295]A1b[296]A1b. In the OlympiA trial, adjuvant olaparib improved 4-year overall survival from 86.4% to 89.8% (HR 0.68; 98.5%) [277]A1b.
Risk-reducing mastectomy (RRM) and risk-reducing (RRSO) are associated with significant survival benefit in young BRCA carriers: adjusted HR for overall survival 0.65 for RRM and 0.58 for RRSO [314]B2b. Variants of uncertain significance (VUS) should not alter ; in a large cohort, VUS results did not lead to overutilization of surgery or surveillance [317]B2b.
| Gene | Penetrance | Breast Cancer Lifetime Risk | OR (population-based) | Associated Features |
|---|---|---|---|---|
| BRCA1 | High | 57% by age 70 | 8.73 (7.47-10.20) | TNBC, ovarian, male breast, pancreatic |
| BRCA2 | High | 49% by age 70 | 5.68 (5.13-6.30) | ER+ breast, ovarian, male breast, prostate, pancreatic |
| PALB2 | High | 35% by age 70 | 4.30 (3.68-5.03) | TNBC, (biallelic) |
| TP53 | High | 80-90% | 3.62 (1.98-6.61) | Li-Fraumeni syndrome, early onset, sarcoma, brain tumors |
| PTEN | High | >50% | , | Cowden syndrome, macrocephaly, thyroid cancer |
| CDH1 | High | 42% by age 80 | , | Lobular breast cancer, diffuse gastric cancer |
| CHEK2 | Moderate | ~25% | 2.40 (2.21-2.62) | ER+ breast, contralateral risk, thyroid, kidney |
| ATM | Moderate | ~20% | 2.16 (1.93-2.41) | ER+ breast, ataxia telangiectasia (biallelic) |
| BARD1 | Moderate | , | 2.34 (1.85-2.97) | TNBC |
| RAD51C/D | Moderate | , | 1.53-1.76 | TNBC, ovarian |
Pearl: In a patient with newly diagnosed breast cancer at age ≤65 years or with TNBC at any age, initiate multigene panel testing for BRCA1/2, PALB2, CHEK2, ATM, and TP53, detection of a high-penetrance PV directly alters surgical decisions, enables PARP inhibitor therapy, and triggers cascade testing for relatives.
Histopathology and Molecular Biology
- ▸Histologic subtypes (tubular, mucinous, cribriform, adenoid cystic, medullary) confer favorable prognosis independent of grade, and chemotherapy can be omitted in HR+/node‑negative favorable‑histology tumors.
- ▸Intrinsic molecular subtypes (Luminal A/B, HER2‑enriched, Basal‑like, Claudin‑low) determined by PAM50 or gene‑expression signatures drive prognosis and treatment selection, with proliferation as the dominant prognostic axis in luminal disease.
- ▸TNBC is molecularly heterogeneous; immune‑activated (BLIA) and luminal androgen receptor (LAR) subtypes have distinct biology and therapeutic vulnerabilities, including AR inhibition and immune checkpoint blockade.
The genetic alterations detailed above give rise to a wide spectrum of histologic and molecular phenotypes that determine breast cancer's clinical trajectory and therapeutic sensitivity. Histologic classification remains the initial diagnostic framework, but molecular subtyping now drives treatment decisions.
Histologic Classification
Invasive ductal carcinoma of no special type (NST) accounts for 70-80% of breast cancers. Invasive lobular carcinoma (ILC) constitutes 10-15% and is defined by discohesive cells due to loss of E‑cadherin ( mutations) [423]D5. Special favorable subtypes include tubular, mucinous, papillary, cribriform, and adenoid cystic carcinomas, all associated with excellent overall survival (94-99% at 5 years) and for which chemotherapy may be safely omitted in hormone receptor‑positive, node‑negative disease [394]B2a. Medullary carcinoma, despite its high‑grade appearance, confers a better prognosis than grade‑matched ductal carcinoma (14‑year distant recurrence‑free interval 89% vs. 63%) [400]B2b.
| Histologic type | Frequency | Key features | Prognosis |
|---|---|---|---|
| Ductal (NST) | 70-80% | Glandular or solid sheets, variable grade | Intermediate; depends on molecular subtype |
| Lobular | 10-15% | Single‑file infiltration, E‑cadherin loss | Similar to ductal stage‑for‑stage; occult nodal involvement higher [506]B2b |
| Tubular / Mucinous / Papillary / Cribriform / Adenoid cystic | <5% | Well‑differentiated, low proliferative index | Excellent; systemic chemotherapy often not warranted [394]B2a |
| Medullary | <2% | Syncytial growth, prominent lymphocytic infiltrate | Better than high‑grade ductal [400]B2b |
Molecular Subtypes
Gene‑expression profiling has identified five intrinsic subtypes: Luminal A, Luminal B, HER2‑enriched, Basal‑like, and Claudin‑low [425]D5. The clinically validated PAM50 assay assigns these subtypes, which carry distinct prognostic and therapeutic implications:
- Luminal A (HR+/HER2-, low Ki67): best prognosis, strong endocrine sensitivity. Recurrence risk is low; genomic signatures such as Oncotype DX (21‑gene recurrence score) and MammaPrint (70‑gene signature) identify patients who can safely forgo chemotherapy (5‑year distant metastasis‑free survival ~95% in low‑genomic‑risk groups) [298]A1b[405]B2b.
- Luminal B (HR+/HER2- or HR+/HER2+, higher Ki67): worse prognosis than Luminal A, often with PI3K pathway alterations and higher proliferation [409]B2b[425]D5.
- HER2‑enriched: driven by amplification; responds to anti‑HER2 therapy. pCR rates after neoadjuvant ‑based regimens are highest in this subtype [472]A1a.
- Basal‑like: largely overlaps with triple‑negative breast cancer (TNBC). Characterized by high TP53 mutation rate (≥80%), low expression of ER, PR, and HER2, and frequent genomic instability [256]D5[441]C4.
- Claudin‑low: mesenchymal features, stem‑cell‑like signature, poor prognosis [425]D5.
Genomic Signatures and Key Drivers
Proliferation is the dominant biological process driving prognosis in HR+/HER2- tumors, while immune activation and tumor invasion are more relevant in TNBC and HER2+ disease [434]D5. The most commonly mutated genes in breast cancer are TP53 (30-40% overall, >80% in basal‑like) and PIK3CA (30-40%, enriched in luminal disease) [441]C4[458]B3b. CDH1 loss is pathognomonic for lobular histology [423]D5. Activating mutations in (HER2) occur in ~2% of HER2‑amplification‑negative tumors and are targetable with neratinib‑based therapy [390]B2b[477]D5.
TNBC Heterogeneity
TNBC comprises at least four molecular subtypes: basal‑like immune‑activated (BLIA), basal‑like immune‑suppressed (BLIS), mesenchymal (MES), and luminal androgen receptor (LAR) [497]B3b. BLIA tumors have robust immune infiltration and better prognosis, while BLIS and MES are immune‑cold and associated with early recurrence [402]A1b[441]C4. LAR tumors express androgen receptor and may benefit from AR‑targeted agents [437]D5.
HER2‑Low and Emerging Categories
Approximately 65% of breast cancers classified as HER2‑negative by traditional criteria express low levels of HER2 (IHC 1+ or 2+/ISH-) [474]B2b. This category, HER2‑low, has gained clinical relevance because antibody-drug conjugates like show efficacy in this population (DESTINY‑Breast04). HER2‑low tumors are enriched for hormone receptor positivity and may have a slightly lower pCR rate to neoadjuvant chemotherapy compared with HER2‑zero [474]B2b.
Tumor Microenvironment
Tumor‑infiltrating lymphocytes (TILs) and PD‑L1 expression are prognostic in TNBC and HER2+ breast cancer. Higher TIL levels are associated with improved survival, especially in basal‑like and immune‑activated subtypes [398]B2a[413]A1a[475]B2b. Immune gene signatures (e.g., DetermaIO) predict benefit from neoadjuvant immune checkpoint inhibitors independently of PD‑L1 [418]B2b.
Pearl: The combination of histologic type (e.g., lobular vs. ductal) and molecular subtype (especially PAM50) refines prognosis beyond classical markers; in HR+/HER2- disease, a low Oncotype DX recurrence score (≤10) identifies patients with a 5‑year distant recurrence rate of <1% with endocrine therapy alone, allowing safe omission of chemotherapy [405]B2b.
Clinical Presentation
- ▸Inflammatory breast cancer presents with erythema and peau d'orange without a discrete mass, requiring urgent multidisciplinary evaluation.
- ▸Triple-negative breast cancer more often presents as a rapidly growing, high-stage mass with early peak recurrence within 3 years.
- ▸Globally, the proportion with distant metastatic disease at diagnosis varies from <6% in North America to >30% in sub-Saharan Africa, driven by disparities in access to early detection.
The histopathologic subtypes described above translate into distinct clinical presentations that vary by stage, molecular profile, and patient demographics.
Presenting Symptoms
A painless, firm, irregular breast lump is the most common symptom, often discovered incidentally or by screening. Skin dimpling (peau d'orange), erythema, ulceration, or nipple retraction signals deeper involvement. Spontaneous bloody nipple discharge suggests ductal pathology. Axillary adenopathy may be the initial finding, especially in aggressive subtypes.
Locally Advanced and Inflammatory Breast Cancer
(IBC) presents with diffuse breast enlargement, erythema, warmth, and peau d'orange, often without a discrete mass [550]D5. Any woman with persistent breast erythema and edema requires urgent biopsy; a discrete mass is frequently absent on imaging.
Metastatic Presentation
The proportion of patients with distant metastases at diagnosis ranges from <6% in North America to as high as 31% in sub-Saharan Africa [539]B2a. Common sites include bone (pain, pathologic fracture), lung (dyspnea), liver (abdominal pain, jaundice), and brain (headache, focal deficits, seizure). occur in approximately 1.9% of patients over 10 years, with highest incidence in the first year after diagnosis [140]B2b. cause visual deterioration and are most common from breast and lung primaries [524]B2a. Leptomeningeal disease presents with multifocal neurologic deficits and carries a median survival of months [82]D5[555]D5.
Atypical Presentations
manifests as a persistent eczematous, crusting lesion of the nipple-areola complex, often with underlying ductal carcinoma in situ. (ILC) frequently presents as subtle thickening or architectural distortion rather than a discrete mass due to its discohesive growth [306]D5[423]D5. (<1% of cases) typically presents as a painless subareolar lump, but >40% of men have stage III or IV disease at diagnosis because of delayed presentation [77]D5. Pregnancy-associated breast cancer (diagnosed during pregnancy or within 1 year postpartum) is often detected later, as physiologic breast changes mask lesions [84]D5[119]C4.
Variations by Subtype and Demographics
(TNBC), comprising 10-20% of invasive cancers, disproportionately affects younger and African-American women and typically presents as a rapidly growing, high-grade mass [56]D5[586]B2b. The risk of distant recurrence peaks at approximately 3 years and then declines steeply [586]B2b. Hormone receptor-positive disease carries a more protracted recurrence risk over decades [563]D5. (AYA) breast cancer (age ≤40 years, 6.6% of US cases) is enriched for high-grade, hormone receptor-negative, and HER2-positive tumors [287]D5. Globally, older age and lower socioeconomic status are associated with higher proportions of stage IV disease at presentation [539]B2a.
| Subtype | Typical Presentation | Key Imaging Feature | Common Pitfall |
|---|---|---|---|
| Invasive lobular carcinoma | Vague thickening, architectural distortion | Underestimation of extent on mammography; MRI more sensitive [306]D5[423]D5 | May be missed on clinical exam and mammography |
| Inflammatory breast cancer | Diffuse erythema, peau d'orange, warmth | Skin thickening on ultrasound; no discrete mass [550]D5 | Mistaken for mastitis; urgent biopsy needed |
| Paget disease | Eczematous, crusting nipple lesion | May show underlying DCIS on MRI | Misdiagnosed as dermatitis |
| Male breast cancer | Painless subareolar lump | Often retroareolar on mammography | Late presentation; >40% stage III/IV [77]D5 |
Red Flags
Symptoms that mandate urgent evaluation: inflammatory breast changes; progressive headache, vomiting, or new neurologic deficits (possible brain metastases); unexplained dyspnea or bone pain; visual changes (possible choroidal metastasis). In any patient with known breast cancer, the triad of headache, nausea, and papilledema should prompt emergent neuroimaging.
Pearl: The absence of a discrete palpable mass does not exclude breast cancer, inflammatory breast cancer and invasive lobular carcinoma often present with skin thickening or architectural distortion alone, and male breast cancer is frequently subareolar and advanced at diagnosis.
Biopsy and Histologic Diagnosis
- ▸Core needle biopsy is the preferred diagnostic method, providing adequate tissue for histologic subtyping, grading, and immunohistochemistry.
- ▸ER, PR, and HER2 testing must follow ASCO/CAP guidelines, with HER2-low (IHC 1+ or 2+/ISH-) and HER2-ultralow (IHC 0 with membrane staining) now clinically actionable categories.
- ▸Receptor discordance between primary and metastatic sites is common (up to 40%); rebiopsy of recurrent disease is recommended to guide therapy.
Once a suspicious lesion is identified on clinical examination or imaging, tissue acquisition is required for definitive diagnosis. The choice of biopsy technique and adherence to standardized tissue handling are critical to ensure accurate histologic classification and biomarker assessment.
Biopsy Techniques
Core needle biopsy (CNB) is the preferred method for initial diagnosis of breast lesions because it provides intact tissue architecture and sufficient material for histologic subtyping, grading, and immunohistochemistry (IHC) [145]A1c. Fine-needle aspiration (FNA) may be used for palpable masses when rapid diagnosis is needed, but it lacks architectural detail and cannot reliably distinguish invasive from in situ disease [633]C4. Surgical excision biopsy is reserved for cases where CNB is inconclusive, for high-risk lesions (e.g., atypical ductal hyperplasia, lobular carcinoma in situ), or when microcalcifications cannot be adequately sampled percutaneously [526]D5.
Tissue Handling and Processing
Biopsy specimens should be immediately placed in 10% neutral buffered formalin and fixed for 6-72 hours to preserve antigenicity for IHC and in situ hybridization (ISH) [145]A1c[594]A1c. Cold ischemia time should be kept under 1 hour, especially for HER2 testing, to avoid false-negative results [595]A1c. Core biopsies are oriented, embedded in paraffin, and sectioned at 4-5 μm. For residual disease after neoadjuvant chemotherapy, the tumor bed should be extensively sampled and the histologic response reported (e.g., residual cancer burden) [640]D5.
Histologic Evaluation
On hematoxylin and eosin (H&E) staining, the pathologist determines the presence of invasive carcinoma, histologic type (e.g., invasive carcinoma of no special type, invasive lobular carcinoma), and Nottingham histologic grade (tubule formation, nuclear pleomorphism, mitotic count). The presence of ductal carcinoma in situ (DCIS) and lymphovascular invasion is documented. Invasive lobular carcinoma often shows discobesive, single-file cells and requires E-cadherin IHC for confirmation [306]D5.
Immunohistochemistry
Estrogen receptor (ER) and progesterone receptor (PR) testing is performed by validated IHC. Per ASCO/CAP guidelines, a tumor is considered ER-positive if ≥1% of tumor nuclei stain; results of 1-10% should be reported as ER Low Positive with a recommended comment, as data on endocrine therapy benefit in this range are limited [594]A1c. PR testing is primarily prognostic in ER-positive disease [620]A1c.
HER2 testing follows a dual algorithm: IHC scored as 0 (no staining), 1+ (faint incomplete membrane staining in >10% of cells), 2+ (weak to moderate complete membrane staining in >10% of cells), or 3+ (strong complete membrane staining in >10% of cells). Tumors with IHC 3+ are HER2-positive; IHC 0 or 1+ are negative; IHC 2+ requires reflex ISH to determine gene amplification [595]A1c[598]A1c. Laboratories must achieve high concordance with validated assays and participate in external quality assurance [272]D5.
HER2-low is defined as IHC 1+ or IHC 2+/ISH-negative and represents approximately 60-65% of traditionally HER2-negative breast cancers [610]B2b[630]C4. The DESTINY-Breast06 trial established a new category of HER2-ultralow (IHC 0 with membrane staining), which is now targetable with deruxtecan [208]C4[612]D5. Accurate distinction between IHC 0 and 1+ is clinically relevant but shows poor interobserver concordance (Fleiss κ = 0.230) [658]C4; standardized training and digital pathology may improve reproducibility [662]C4.
Ki-67 proliferation index is used as a prognostic marker, though lack of standardization limits its standalone use. Ki-67 ≥20% is commonly considered high proliferative activity [656]B2b.
Special Considerations: Discordance and Liquid Biopsy
Receptor discordance between primary tumor and metastatic sites occurs in up to 40% of cases, particularly for PR and HER2 [640]D5[684]B2b. Rebiopsy of recurrent or metastatic disease is recommended to guide therapy selection. HER2 loss after treatment with trastuzumab deruxtecan has been observed in 32% of patients [676]C4.
Liquid biopsy (circulating tumor DNA, circulating tumor cells) offers a non-invasive alternative for detecting ESR1 mutations, targetable alterations (e.g., PIK3CA), and monitoring treatment response, though it is not yet a substitute for tissue biopsy in initial diagnosis [624]B2b[637]D5[674]D5.
Axillary staging in clinically node-negative patients is achieved by sentinel lymph node biopsy (SLNB) using dual tracer (radioisotope and blue dye) [593]A1c[617]B2a. In patients with cT1-2, node-negative breast cancer, omission of SLNB may be considered in select postmenopausal women with small, hormone receptor-positive, HER2-negative tumors [659]A1b[660]A1b[112]A1b. After neoadjuvant chemotherapy, SLNB is accurate if ≥3 sentinel nodes are retrieved; the false-negative rate is 14% when conversion to cN0 occurs [631]B2b[647]D5[667]B2b. can be safely omitted in patients with one to two sentinel node macrometastases who receive nodal irradiation [660]A1b[603]A1b.
Pearl: Core needle biopsy with adequate formalin fixation (6-72 hours) is essential for accurate histologic and biomarker assessment; receptor discordance between primary and metastatic sites occurs in up to 40% of cases, warranting rebiopsy at progression.
| IHC Score | Interpretation | Reflex ISH Required? | Final HER2 Status |
|---|---|---|---|
| 0 | No staining or ≤10% faint incomplete membrane staining | No | Negative |
| 1+ | Faint incomplete membrane staining in >10% cells | No | Negative (HER2-low) |
| 2+ | Weak to moderate complete membrane staining in >10% cells | Yes | Positive if ISH amplified; negative if not (HER2-low) |
| 3+ | Strong complete membrane staining in >10% cells | No | Positive |
Adapted from ASCO/CAP guidelines [595]A1c[598]A1c.
Imaging
- ▸PET/CT in stage IIA-IIIC breast cancer upstages 37% of patients, reduces false-positive findings by half, and shortens time to chemotherapy compared with conventional staging [705][709].
- ▸Supplemental MRI screening in extremely dense breasts reduces interval cancer rate by 50% (2.5 vs 5.0 per 1000 screenings) [47].
- ▸FES-PET/CT provides a noninvasive alternative to biopsy for determining ER status in metastatic disease, with sensitivity 95% and specificity 80% [691].
After histologic confirmation, imaging defines the anatomic extent of disease and guides treatment decisions. Modality choice and sequencing follow guideline recommendations based on disease stage, biologic subtype, and clinical scenario.
Diagnostic Imaging
Mammography is the primary screening tool, but its sensitivity falls with increasing breast density, where it can miss 30-50% of cancers [173]D5. Digital mammography with tomosynthesis (3D) improves detection of invasive cancers and reduces false-positive recalls compared with 2D alone [245]D5. For women with extremely dense breasts, supplemental MRI screening reduces interval cancer rates: the DENSE trial reported 2.5 versus 5.0 interval cancers per 1000 screenings (P<0.001) with MRI [47]A1b.
Breast MRI is reserved for specific high-risk populations: BRCA1/2 carriers, lifetime risk >20%, chest radiation before age 30, or TP53/PTEN mutations [175]A1c[704]D5. In BRCA1 carriers, MRI surveillance was associated with a 80% reduction in breast cancer mortality (HR 0.20, 95% CI 0.10-0.43) [227]B2b. Preoperative MRI in newly diagnosed breast cancer detects otherwise occult contralateral cancer in 3.1% of patients (sensitivity 91%, specificity 88%) [544]B2b; however, it does not reduce local or distant recurrence (HR 0.88, 95% CI 0.52-1.51) [690]A1a and is associated with increased rates and surgical delays [745]B2b.
Ultrasound is the first-line problem-solving tool for mammographic abnormalities and guides biopsy. In triple-negative breast cancer, ultrasound sensitivity is high but benign features (21-41% of lesions) can be misleading [545]D5.
Staging and Restaging
For patients with clinical stage IIA-IIIC breast cancer, 18F-FDG PET/CT identifies distant metastases in 14% and upstages regional nodal disease in 37% of patients, at a comparable cost and lower radiation dose (14 mSv vs 21 mSv for CT+bone scan) [705]B2b[709]B2b. In a multicenter value analysis, PET/CT reduced false-positive findings by half (11.1% vs 22.1%) and shortened time to chemotherapy initiation (37.5 vs 44.3 days) [709]B2b. The NCCN guidelines list PET/CT as an optional study for stage IIA-IIIC disease, but emerging evidence supports its use as an alternative to conventional staging (CT chest/abdomen/pelvis + bone scan) [590]A1c[705]B2b.
For bone metastases, 18F-NaF PET/CT has higher overall accuracy than 99mTc-MDP SPECT (84.3% vs 77.4%, P=0.016) in patients with high-risk breast cancer [698]B2b. Bone scan remains the recommended first-line imaging for asymptomatic patients [737]D5.
16α-[18F]Fluoro-17β-estradiol (FES) PET/CT assesses whole-body estrogen receptor (ER) expression, with sensitivity 95% and specificity 80% for predicting ER status in metastases [691]B2b. It is a valid alternative to biopsy when determining ER status in newly diagnosed metastatic disease, and its absence of uptake predicts lack of benefit from endocrine therapy [739]D5[755]D5.
| Modality | Primary Indication | Key Performance | Caveat |
|---|---|---|---|
| Mammography (with tomosynthesis) | Screening, initial workup | Sensitivity 70-90% in fatty breasts; drops to 30-50% in dense breasts [173]D5 | Limited by density; calcification detection is key |
| Breast MRI | Screening in high-risk; problem-solving | Sensitivity 91-100%; specificity 72-88% [544]B2b[704]D5 | High false-positive rate; requires MRI-guided biopsy capability |
| Ultrasound | Diagnostic workup, biopsy guidance | Sensitivity >90% for palpable masses; variable for DCIS [545]D5 | Operator-dependent; benign features in TNBC [545]D5 |
| 18F-FDG PET/CT | Staging stage IIA-IIIC; restaging | Upstages 37% of stage IIA-IIIC; distant mets in 14% [705]B2b | Not recommended for stage I or axillary staging alone [724]D5 |
| 18F-NaF PET/CT | Bone metastasis detection | Accuracy 84.3% vs 77.4% for SPECT [698]B2b | Higher cost; limited availability |
| FES-PET/CT | ER status in metastatic disease | Sensitivity 95%, specificity 80% [691]B2b | Not widely available; impacted by menopausal status and concurrent endocrine therapy |
Surveillance Imaging
After curative-intent treatment, routine surveillance imaging is not recommended for asymptomatic patients with early-stage breast cancer. However, in women treated with breast conservation, annual mammography of the ipsilateral and contralateral breast is recommended [590]A1c. For men with breast cancer, annual ipsilateral mammogram should be offered after ; contralateral mammogram may be offered if a genetic mutation is present [273]A1c.
In patients with metastatic disease, imaging frequency is guided by clinical scenario, disease site, and tumor subtype. The pattern of reimaging varies by metastatic site: time-to-first reimaging is shortest for brain (HR 4.27 vs bone), followed by lung and liver [708]B2b. CT of chest, abdomen, and pelvis plus bone scan, or PET/CT, are the most common modalities for monitoring treatment response [708]B2b.
For patients with advanced HER2-positive or triple-negative breast cancer, screening brain MRI in asymptomatic patients detects occult in 9.8% at baseline, rising to 19.6% by the start of third-line therapy [160]C4. Serial MRI screening identified two-thirds of brain metastases at an asymptomatic stage, with median overall survival after brain metastasis diagnosis of 23.3 months [160]C4.
Pearl: In stage IIA-IIIC breast cancer, PET/CT is an efficient alternative to the conventional staging workup, it reduces false-positive findings, shortens time to treatment, and delivers a lower radiation dose [705]B2b[709]B2b.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Preoperative breast MRI in early breast cancer | NCCN: Consider for evaluation of extent of disease and contralateral screening, especially if at increased risk [618]D5 | Meta-analysis (IPD): No reduction in local or distant recurrence (HR 0.88 and 1.18) [690]A1a | IA vs 1A | MRI staging adds detection but does not improve outcome; guideline use is selective, not routine |
| PET/CT as initial staging for stage IIA-IIIC | NCCN: Optional after CT+bone scan [590]A1c | Emerging evidence: Comparable cost, lower radiation, shorter time to treatment [705]B2b[709]B2b | 2A vs 2B | PET/CT may replace conventional staging in centers with access; payer policies vary |
Molecular Diagnostics and Biomarkers
- ▸HER2 testing per ASCO-CAP guidelines is mandatory for all invasive breast cancers; the HER2-low distinction (IHC 1+ or 2+/ISH-negative) now determines eligibility for trastuzumab deruxtecan, but concordance between IHC 0 and 1+ is poor.
- ▸Multigene assays (Oncotype DX, MammaPrint, BCI) provide prognostic and predictive information for chemotherapy benefit in HR+/HER2- early breast cancer; the 21-gene recurrence score carries more prognostic information for breast cancer-specific outcomes than overall survival.
- ▸ctDNA detection in the post-treatment setting identifies minimal residual disease and predicts metastatic recurrence with a lead time of up to 10.7 months, though it is not yet standard of care for routine surveillance.
Imaging identifies the anatomic extent of disease, but the molecular portrait of the tumor dictates the systemic treatment strategy. Every invasive breast cancer must be profiled for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status; these three biomarkers define the fundamental therapeutic subgroups and are required by the 2018 ASCO-CAP guidelines [596]A1c. The NCCN Guidelines for Breast Cancer further emphasize that accurate assignment of HER2 status is essential for clinical decision-making in both adjuvant and metastatic settings [271]A1c[272]D5.
HER2 Testing and the HER2-Low Spectrum
HER2 status is determined by a validated algorithm: immunohistochemistry (IHC) scored 0, 1+, 2+, or 3+, followed by in situ hybridization (ISH) for IHC 2+ cases. Per ASCO-CAP, HER2-positive requires IHC 3+ (uniform intense membrane staining in >10% of tumor cells) or ERBB2/CEP17 ratio ≥2.0 with average HER2 copy number ≥4.0 signals/cell (dual-probe ISH group 1) [596]A1c. HER2-negative includes IHC 0 or 1+, or IHC 2+ with negative ISH. The 2023 ASCO-CAP update affirms these criteria but introduces a critical nuance: the distinction between IHC 0 and 1+ is now clinically relevant because deruxtecan (T-DXd) is approved for HER2-low cancers (IHC 1+ or IHC 2+/ISH-negative) [595]A1c[799]A1b. However, concordance between IHC 0 and 1+ is only 26% among pathologists, highlighting the need for rigorous quality assurance [662]C4. Tumors with IHC 0 but membrane staining (so-called HER2-ultralow) are under investigation; the DESTINY-Breast06 trial showed PFS benefit with T-DXd in this exploratory group [800]A1b.
Hormone Receptor and Ki-67
ER and PR positivity is defined as ≥1% nuclear staining by IHC; the St. Gallen Consensus and ASCO recommend using validated assays with standardized scoring [843]A1c. Ki-67, a proliferation marker, is prognostic and helps distinguish luminal A from luminal B subtypes, but lacks standardized cutoffs despite its use in the monarchE trial (Ki-67 ≥20% as an entry criterion for cohort 2) [778]A1b. The NCCN considers Ki-67 informative but not mandatory for treatment decisions [271]A1c.
Multigene Genomic Assays
For patients with HR+/HER2- early breast cancer, genomic expression profiling refines risk stratification and predicts chemotherapy benefit.
| Assay | Genes | Evidence | Clinical Use |
|---|---|---|---|
| Oncotype DX (21-gene recurrence score) | 16 cancer-related + 5 reference | TAILORx (n=8916): RS 0-10 low risk, 11-25 intermediate, 26-100 high; RS independently prognostic for BCSS (aHR 5.12 for midrange, 8.03 for high vs low) [770]B2b | Guides chemotherapy omission in node-negative, HR+/HER2-; NCCN Category 1 for N0 [271]A1c |
| MammaPrint (70-gene signature) | 70 genes | MINDACT trial | Identifies patients with clinical high-risk but genomic low-risk who can safely avoid chemotherapy |
| Breast Cancer Index (BCI) | HOXB13/IL17BR ratio + 5 genes | SOFT analysis: BCI(H/I)-high predicted OFS benefit in premenopausal [828]B3b | Predicts benefit from extended endocrine therapy and ovarian suppression |
| HER2DX | 27 genes + clinical factors | Predicts pCR probability and risk score in HER2+ disease [860]D5 | Emerging tool for HER2+ treatment personalization |
Oncotype DX remains the most widely adopted; TAILORx reported a 5.2% overall event rate for BCSS at 11.6 years, with the 21-gene RS carrying more prognostic information for breast cancer-specific outcomes than for overall survival [770]B2b. The NCCN gives a Category 1 recommendation for its use in node-negative, HR+/HER2- breast cancer [271]A1c.
Actionable Somatic Mutations
PIK3CA mutations occur in ~40% of HR+/HER2- advanced breast cancer and predict benefit from the PI3Kα inhibitor alpelisib. In SOLAR-1, alpelisib-fulvestrant improved PFS (11.0 vs 5.7 months; HR 0.65) in PIK3CA-mutated tumors [534]A1b; final OS showed a numeric 7.9-month improvement (39.3 vs 31.4 months) but did not reach significance [806]A1b. ESR1 mutations (especially Y537S and D538G) emerge under aromatase inhibitor therapy and confer resistance to antiestrogens; detection by ctDNA or tissue guides the use of fulvestrant-based combinations or the oral SERD elacestrant (PFS benefit in EMERALD: HR 0.55 for ESR1-mutated patients) [780]A1b[891]B3b. BRCA1/2 germline mutations are present in ~5% of unselected breast cancer patients and up to 11.2% of triple-negative cases [385]C4; they predict sensitivity to PARP inhibitors (olaparib in OlympiAD: PFS 7.0 vs 4.2 months, HR 0.58) [296]A1b and adjuvant olaparib in high-risk early disease (OlympiA: 3-year iDFS 85.9% vs 77.1%, HR 0.58) [295]A1b.
Liquid Biopsy: Circulating Tumor DNA
ctDNA analysis enables noninvasive monitoring of tumor burden and resistance mechanisms. In early-stage breast cancer, post-surgical ctDNA detection predicts metastatic recurrence with a lead time of 8.9 to 10.7 months (sensitivity 89-96%, specificity 100%) [889]B2b[574]B2b. The I-SPY2 trial showed that ctDNA clearance after 3 weeks of neoadjuvant therapy is associated with pCR in TNBC, and ctDNA negativity after chemotherapy predicts excellent outcomes even in patients with residual disease [844]B2b[880]B2b. A tissue-free epigenomic assay (Guardant Reveal) demonstrated 83% surveillance sensitivity and 99.5% specificity for recurrence in TNBC [829]B2b. ESMO guidelines acknowledge ctDNA as a promising tool but not yet standard for routine surveillance [898]D5.
Tumor-Infiltrating Lymphocytes and Immune Biomarkers
Stromal TILs, assessed on H&E sections, are a validated prognostic and predictive biomarker in TNBC and HER2+ breast cancer. A pooled analysis of 3771 patients showed that each 10% increase in TILs is associated with higher pCR rates across subtypes (TNBC: 31% low TILs vs 50% high TILs; HER2+: 32% vs 48%) and improved survival in TNBC [218]A1a. The NCCN recommends reporting TILs in TNBC, though a standardized threshold for clinical decision-making is lacking [862]D5. PD-L1 expression (combined positive score ≥10) identifies patients with TNBC who may benefit from immune checkpoint inhibitors, and immune-hot tumors (PD-L1 CPS ≥25, sTILs ≥10%) derived the greatest benefit from adjuvant in the CBCSG010 biomarker analysis [771]B2b[833]D5.
Pearl: The clinical distinction between IHC 0 and 1+ is now critical for T-DXd eligibility, but interobserver concordance is only 26%, centralized pathology review and standardized training are essential to avoid misassignment of therapy [662]C4[595]A1c.
| Assay | Genes | Clinical Use | Evidence |
|---|---|---|---|
| Oncotype DX (21-gene RS) | 16 cancer + 5 reference | Chemotherapy benefit in HR+/HER2- N0/N1 | TAILORx: RS 0-10 low risk, 11-25 intermediate, 26-100 high [770]B2b |
| MammaPrint (70-gene) | 70 genes | Chemotherapy de-escalation in clinical high-risk | MINDACT: genomic low-risk can safely omit chemotherapy |
| Breast Cancer Index (BCI) | HOXB13/IL17BR + 5 genes | Extended endocrine therapy, OFS benefit | SOFT: BCI(H/I)-high predicts OFS benefit [828]B3b |
| HER2DX | 27 genes + clinical | pCR probability, risk score in HER2+ | Predicts response to neoadjuvant therapy [860]D5 |
Staging
- ▸Breast cancer staging uses the AJCC 8th edition system, incorporating both anatomical (TNM) and prognostic (grade, receptors, genomic assays) components.
- ▸The post-neoadjuvant prognostic staging system provides more accurate risk stratification based on response to therapy [722].
- ▸Genomic assays (Oncotype DX, MammaPrint, HER2DX, etc.) refine prognosis and guide treatment decisions, particularly in hormone receptor-positive disease [298][917][714].
The transition from molecular classification to staging translates tumor biology into a clinical framework for prognosis and treatment decisions. Breast cancer staging follows the American Joint Committee on Cancer ( ) 8th edition, which integrates both anatomical and prognostic elements. The anatomical stage is defined by the classification (tumor size, nodal involvement, and distant metastasis), while the prognostic stage adds histologic grade, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) status, and, for select patients, genomic assay results [900]A1c. This dual system acknowledges that molecular features often outweigh tumor size alone in determining outcome [955]D5.
Anatomical TNM Staging
The anatomical T, N, and M categories are assigned based on clinical examination, imaging, and pathologic assessment of the surgical specimen. The table below summarizes the standard AJCC 8th edition anatomical stage groupings.
| Stage | T | N | M |
|---|---|---|---|
| 0 | Tis (DCIS) | N0 | M0 |
| IA | T1 (≤2 cm) | N0 | M0 |
| IB | T0 or T1 | N1mi (micro) | M0 |
| IIA | T0 or T1 | N1 (1-3 nodes) | M0 |
| T2 (>2-5 cm) | N0 | M0 | |
| IIB | T2 | N1 | M0 |
| T3 (>5 cm) | N0 | M0 | |
| IIIA | T0-T2 | N2 (4-9 nodes) | M0 |
| T3 | N1 or N2 | M0 | |
| IIIB | T4 (chest wall/skin) | N0-N2 | M0 |
| IIIC | Any T | N3 (≥10 nodes) | M0 |
| IV | Any T | Any N | M1 |
Prognostic Staging
The AJCC 8th edition prognostic stage groups incorporate biologic markers. For example, a T1N0M0 tumor that is grade 3, ER-negative, PR-negative, and HER2-positive is upstaged from anatomical stage IA to prognostic stage IB or IIA, reflecting higher risk. Conversely, a T2N0M0, grade 1, ER-positive, HER2-negative tumor may be downstaged to prognostic stage IA. Genomic assays such as the Oncotype DX Recurrence Score (21-gene) and MammaPrint (70-gene) are integrated into the prognostic staging for hormone receptor-positive, HER2-negative, node-negative breast cancer [298]A1b[837]D5. The MINDACT trial demonstrated that patients with high clinical risk but low genomic risk (MammaPrint) had a 5-year distant metastasis-free survival of 94.7% without chemotherapy, supporting the use of genomic testing to avoid overtreatment [298]A1b. Other assays, HER2DX, TNBC-DX, Prosigna, and Breast Cancer Index, provide additional prognostic and predictive information for specific subtypes [917]A1a[714]B2b[968]B2b[828]B3b.
Post-neoadjuvant (yp) Staging
Response to neoadjuvant chemotherapy profoundly alters prognosis. The yp staging system assigns a pathological stage based on the residual disease at surgery. A validated prognostic staging model using data from the National Cancer Database (140,605 patients) showed that patients achieving a pathologic complete response (pCR) had a 94.2% assignment to ypStage I, regardless of initial clinical stage, whereas those with no response had only 35.5% assigned to ypStage I. For high-grade triple-negative breast cancer, the 3-year overall survival ranged from 97% (cStage I with pCR) to 50% (cStage IIIB/IIIC with no response) [722]B2b. This framework underscores that the combination of initial clinical stage and pathologic response provides more accurate risk stratification than either alone.
Global Stage Distribution
Stage at diagnosis varies widely by region. In a meta-analysis of 2.4 million women from 81 countries, the proportion of distant metastatic disease at diagnosis ranged from 0-6% in North America to 5.6-30.6% in sub-Saharan Africa [539]B2a. Older age and lower socioeconomic status were associated with higher rates of advanced-stage presentation [539]B2a. These disparities highlight the importance of screening and early detection programs.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Should genomic assays be used for node-positive disease? | NCCN supports use of Oncotype DX for node-positive (1-3 nodes) HR+/HER2- disease [900]A1c | St. Gallen 2011 consensus considered genomic assays most useful for node-negative disease [955]D5 | NCCN is stronger; St. Gallen is older | Genomic testing is now widely accepted for selected node-positive patients |
| Is post-neoadjuvant yp staging ready for clinical use? | Proposed validated staging system [722]B2b shows strong prognostic performance | AJCC 8th edition does not include yp stage in its official staging system | AJCC has not yet adopted; the model is under consideration | Clinicians should use yp stage informally for prognostication but not for treatment assignment outside trials |
Pearl: The AJCC 8th edition prognostic stage groups often reclassify patients compared to anatomical stage alone, and post-neoadjuvant yp staging is essential for accurately estimating prognosis after neoadjuvant therapy [722]B2b.
| Stage | T | N | M |
|---|---|---|---|
| 0 | Tis (DCIS) | N0 | M0 |
| IA | T1 (≤2 cm) | N0 | M0 |
| IB | T0 or T1 | N1mi (micro) | M0 |
| IIA | T0 or T1 | N1 (1-3 nodes) | M0 |
| T2 (>2-5 cm) | N0 | M0 | |
| IIB | T2 | N1 | M0 |
| T3 (>5 cm) | N0 | M0 | |
| IIIA | T0-T2 | N2 (4-9 nodes) | M0 |
| T3 | N1 or N2 | M0 | |
| IIIB | T4 (chest wall/skin) | N0-N2 | M0 |
| IIIC | Any T | N3 (≥10 nodes) | M0 |
| IV | Any T | Any N | M1 |
Management Overview
- ▸Management is driven by stage, HR/HER2 status, genomic risk, and patient factors in a multidisciplinary framework.
- ▸Neoadjuvant therapy enables response-guided treatment: pCR and RCB are prognostic across all subtypes and inform adjuvant therapy decisions.
- ▸Adjuvant CDK4/6 inhibitors (abemaciclib for node-positive, ribociclib for broader stage II-III) improve outcomes in high-risk HR+/HER2- disease.
- ▸Dual HER2 blockade with trastuzumab/pertuzumab is standard for stage II-III HER2+ disease; T-DM1 for residual disease after neoadjuvant therapy.
- ▸Pembrolizumab plus chemotherapy is standard for stage II-III TNBC, improving pCR and overall survival.
Staging classifies the anatomic extent of disease, but of breast cancer is driven by the integration of stage with tumor biology, hormone receptor (HR) and HER2 status, and patient factors including menopausal status, genomic risk, and preferences. The NCCN, ASCO, and ESMO guidelines all emphasize a multidisciplinary approach involving surgical oncology, radiation oncology, and medical oncology, with treatment decisions tailored to both the cancer's molecular subtype and the patient's individual goals [982]A1c (1c).
Multidisciplinary Treatment Framework
Management proceeds along three parallel tracks: locoregional therapy (surgery and radiation), systemic therapy (chemotherapy, endocrine therapy, targeted therapy, immunotherapy), and supportive care. The sequence and intensity of these modalities depend on whether the patient presents with early-stage (stage I-III) or metastatic (stage IV) disease. For early-stage breast cancer, the choice between neoadjuvant (preoperative) and adjuvant (postoperative) systemic therapy is a critical first decision. Neoadjuvant therapy is preferred for locally advanced or , for patients in whom downstaging may enable breast-conserving surgery, and for those with high-risk biology where response to therapy guides post-surgical treatment [444]A1c (1c). The ASCO neoadjuvant guideline recommends that patients with inflammatory breast cancer, and those in whom residual disease may prompt a change in therapy, are appropriate candidates for neoadjuvant therapy [444]A1c (1c).
Neoadjuvant Versus Adjuvant Paradigm
A meta-analysis of 4,756 women in ten randomized trials found that neoadjuvant chemotherapy (NACT) increased the frequency of breast-conserving therapy (65% vs 49%) but was associated with a higher 15-year local recurrence rate (vs 15.9%; rate ratio 1.37, p=0.0001), with no difference in distant recurrence or breast cancer mortality [27]A1a (1a). Achieving a pathologic complete response (pCR) after NACT is strongly prognostic: a meta-analysis of 27,895 patients showed that pCR was associated with significantly better event-free survival (HR 0.31; 95% PI 0.24-0.39), particularly for triple-negative (HR 0.18) and HER2-positive (HR 0.32) disease [1001] (1a). The residual cancer burden (RCB) index further stratifies prognosis across subtypes, with higher RCB scores associated with worse event-free survival in all breast cancer subtypes [864]B2b (2b).
Systemic Therapy Selection by Subtype
HR-positive/HER2-negative: For patients with node-negative disease, genomic assays such as Oncotype DX, MammaPrint, Breast Cancer Index, and EndoPredict guide adjuvant chemotherapy decisions. The ASCO biomarker guideline recommends Oncotype DX in premenopausal patients with node-negative HR+/HER2- disease, and in postmenopausal patients with node-negative or 1-3 positive nodes [597]A1c (1c). For postmenopausal patients, aromatase inhibitors (AIs) are the preferred endocrine therapy. For premenopausal patients at higher risk, ovarian function suppression (OFS) combined with exemestane improves disease-free survival compared with tamoxifen alone (12-year DFS 79.0% vs 71.9%; HR 0.79) [989]A1b [990]A1b (1b). Adjuvant CDK4/6 inhibitors provide additional benefit for high-risk patients: abemaciclib (150 mg twice daily for 2 years) improved 7-year OS (86.8% vs 85.0%; HR 0.842, p=0.027) in monarchE [777]A1b (1b), and ribociclib (400 mg/day for 3 years) with an NSAI improved 4-year iDFS (88.5% vs 83.6%; HR 0.72) in NATALEE [51]A1b (1b). These data support a 2- to 3-year course of a CDK4/6 inhibitor in addition to adjuvant endocrine therapy for patients with high-risk features.
HER2-positive: Dual HER2 blockade with and pertuzumab plus chemotherapy is the standard neoadjuvant/adjuvant regimen for stage II-III disease. The APHINITY trial confirmed an iDFS benefit for pertuzumab in node-positive disease (8-year iDFS 86.1% vs 81.2%; HR 0.72) [992]A1b (1b). For patients with residual invasive disease after neoadjuvant HER2-directed therapy, adjuvant T-DM1 (3.6 mg/kg for 14 cycles) reduces the risk of recurrence by 50% (HR 0.50; 3-year iDFS 88.3% vs 77.0%) [803]A1b (1b). The DESTINY-Breast11 trial showed that neoadjuvant T-DXd (5.4 mg/kg) followed by THP achieved a higher pCR rate than ddAC-THP (67.3% vs 56.3%; ΔpCR 11.2%) with a lower rate of grade ≥3 adverse events (37.5% vs 55.8%) [773]A1b (1b).
Triple-negative: For stage II-III TNBC, neoadjuvant (200 mg every 3 weeks) plus and , followed by / and adjuvant pembrolizumab, improves pCR (64.8% vs 51.2%; p<0.001) and 5-year OS (86.6% vs 81.7%; p=0.002) [37]A1b [923]A1b (1b). A meta-analysis of 9 RCTs confirmed that neoadjuvant ICIs improve pCR in TNBC regardless of PD-L1 status (absolute improvement >10%) [48]A1a (1a). For patients with residual disease after neoadjuvant chemotherapy, adjuvant improves DFS (HR 0.70) and OS (HR 0.59) [802]A1b (1b).
Locoregional Management Overview
Breast-conserving surgery followed by whole-breast irradiation remains the standard for early-stage disease. For patients aged ≥70 years with clinical stage I, ER-positive disease, omission of radiation after plus tamoxifen is an option (10-year locoregional recurrence 10% vs 2% with RT; no OS difference) [810]A1b (1b). Axillary management has shifted toward less extensive surgery: the INSEMA trial showed that omission of in cT1-T2 N0 disease is noninferior for 5-year invasive disease-free survival (91.9% vs 91.7%; HR 0.91) [659]A1b (1b), and the SOUND trial confirmed noninferiority of no axillary surgery in patients with tumors ≤2 cm and negative axillary ultrasound [112]A1b (1b). After neoadjuvant chemotherapy, targeted axillary dissection (TAD) with clip localization yields a 5-year axillary recurrence rate of 1.0% [116]B3b (3b). The NSABP B-51 trial found that regional nodal irradiation does not improve outcomes in patients who convert from cN1 to ypN0 after neoadjuvant chemotherapy (HR 0.88; p=0.51) [607]A1b (1b).
Treatment Monitoring and Surveillance
Post-treatment surveillance includes regular clinical examination, mammography, and management of treatment-related side effects. Adjuvant bisphosphonates (zoledronic acid, clodronate, ibandronate) are recommended for postmenopausal patients to reduce bone recurrence and improve survival [996]A1c (1c). Circulating tumor DNA (ctDNA) monitoring is under investigation for early detection of molecular residual disease, though it is not yet standard practice [898]D5 (5).
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Omission of radiation in elderly | CALGB 9343, tamoxifen alone is reasonable for women ≥70 with T1N0 ER+ disease | NCCN, RT is still recommended in most patients; omission is a shared decision | Moderate | Omission is an option for select low-risk elderly patients; discuss absolute risk reduction [810]A1b [982]A1c |
| Adjuvant CDK4/6 inhibitor choice | NCCN, both abemaciclib (monarchE) and ribociclib (NATALEE) are listed as options for high-risk HR+/HER2- disease | ESMO, abemaciclib is recommended for node-positive high-risk; ribociclib is emerging based on NATALEE | Moderate | Patient selection differs: monarchE requires node-positive disease; NATALEE includes stage II N0 with risk factors [51]A1b [777]A1b [570]C4 |
| Role of anthracyclines in HER2+ neoadjuvant therapy | TRAIN-2, anthracycline-free carboplatin-taxane plus dual HER2 blockade yields equivalent pCR (68% vs 67%) | NCCN, anthracycline-containing regimens remain a standard option | Moderate | Anthracycline-free regimens are appropriate for patients with cardiac risk factors [792]A1b [832]D5 |
Pearl: Management of breast cancer requires simultaneous consideration of stage, molecular subtype, genomic risk, and patient factors; the neoadjuvant platform enables response-guided therapy, with pCR and RCB serving as powerful prognostic tools that inform adjuvant escalation or de-escalation decisions across all subtypes [1001] [864]B2b [27]A1a.
| Subtype | Regimen | Dose / Duration | Key Trial | Outcome | Evidence Level |
|---|---|---|---|---|---|
| HR+/HER2- (high-risk) | Abemaciclib + ET | 150 mg PO BID × 2 years | monarchE | 7-year OS 86.8% vs 85.0% (HR 0.842) | 1b [777]A1b |
| HR+/HER2- (stage II-III) | Ribociclib + NSAI | 400 mg PO daily (3 on/1 off) × 3 years | NATALEE | 4-year iDFS 88.5% vs 83.6% (HR 0.72) | 1b [51]A1b |
| HR+/HER2- (premenopausal, high-risk) | Exemestane + OFS | 25 mg PO daily + goserelin 3.6 mg q28d × 5 years | SOFT/TEXT | 12-year DFS 79.0% vs 71.9% (HR 0.79) | 1b [989]A1b |
| HER2+ (node-positive) | Pertuzumab + trastuzumab + chemo | 840/420 mg IV q3w × 1 year | APHINITY | 8-year iDFS 86.1% vs 81.2% (HR 0.72) | 1b [992]A1b |
| HER2+ (residual disease after neoadjuvant) | T-DM1 | 3.6 mg/kg IV q3w × 14 cycles | KATHERINE | 3-year iDFS 88.3% vs 77.0% (HR 0.50) | 1b [803]A1b |
| TNBC (stage II-III) | Pembrolizumab + chemo → adjuvant pembro | 200 mg IV q3w × 8 neoadjuvant + 9 adjuvant | KEYNOTE-522 | 5-year OS 86.6% vs 81.7% (p=0.002) | 1b [923]A1b |
| TNBC (residual disease after neoadjuvant) | Capecitabine | 2,000 mg/m²/day PO (days 1-14) q3w × 6-8 cycles | CREATE-X | 5-year DFS 74.1% vs 67.6% (HR 0.70) | 1b [802]A1b |
History and Evolution of Treatment
- ▸Landmark trials (TAILORx, CREATE-X, SOFT, CLEOPATRA, KATHERINE, DESTINY-Breast03, KEYNOTE-522, NATALEE, monarchE) established current standards of care across all subtypes.
- ▸The trajectory has moved from radical surgery toward de-escalation (axillary omission, regional nodal omission after pCR) and from cytotoxic chemotherapy toward targeted therapy, endocrine therapy, and immunotherapy.
- ▸Several approaches were abandoned (lapatinib in combination, anthracyclines in HER2+ dual blockade, routine first-line CDK4/6i sequencing) due to lack of benefit or equivalent outcomes with less toxicity.
The preceding section outlined the contemporary multidisciplinary approach to breast cancer . This section traces how that framework was built, through landmark trials that established, refined, or refuted prior standards.
The Shift from Radical to Breast-Conserving Surgery
For much of the 20th century, the Halsted radical dominated. The paradigm shifted after randomized trials demonstrated equivalent survival with breast-conserving surgery plus whole-breast irradiation. More recently, the focus turned to de-escalating axillary surgery. The EORTC 10981-22023 AMAROS trial showed that among sentinel-node-positive patients, axillary radiotherapy yielded comparable 5-year recurrence (vs 0.43% with ) with significantly less lymphedema [603]A1b. The ASCO guideline now recommends omitting axillary dissection in patients with one to two positive sentinel nodes who receive breast-conserving surgery and whole-breast irradiation [593]A1c. The NSABP B-51/RTOG 1304 trial further demonstrated that regional nodal irradiation can be safely omitted in patients who convert from cN1 to ypN0 after neoadjuvant chemotherapy, with no improvement in invasive breast cancer recurrence-free interval [607]A1b.
The Chemotherapy Era: From CMF to Genomically Guided Therapy
Adjuvant chemotherapy emerged with the CMF ( , , fluorouracil) regimen, later replaced by anthracycline and taxane-based combinations. The TAILORx trial refined chemotherapy selection for hormone receptor-positive, HER2-negative, node-negative breast cancer by demonstrating that patients with a 21-gene recurrence score ≤25 derived no benefit from chemotherapy added to endocrine therapy; those with scores 26-100 had a 5-year distant recurrence-free rate of 93% with chemotherapy plus endocrine therapy [1044] (NNT to prevent one distant recurrence = 14). The CREATE-X trial established that adjuvant improves outcomes after neoadjuvant chemotherapy in patients with HER2-negative residual disease (5-year disease-free survival 74.1% vs 67.6%; HR 0.70; NNT = 15) [802]A1b.
The Endocrine Therapy Revolution
Tamoxifen, approved in the 1970s, reduced annual recurrence risk by 39% in hormone receptor-positive disease. The Suppression of Ovarian Function Trial (SOFT) demonstrated that adding ovarian function suppression (OFS) to tamoxifen improves disease-free survival in premenopausal women (HR 0.82 at 12 years; NNT = 24) [990]A1b. Aromatase inhibitors surpassed tamoxifen in postmenopausal women, and the MAP.3 trial showed exemestane reduces invasive breast cancer incidence by 65% in high-risk postmenopausal women, establishing its role in chemoprevention [165]D5.
The HER2-Targeted Therapy Era
The advent of transformed HER2-positive breast cancer from the most aggressive subtype to one with favorable outcomes. The CLEOPATRA trial established pertuzumab plus trastuzumab and as first-line therapy for metastatic disease, yielding a median overall survival of vs 40.8 months (HR 0.68; NNT = 9) [790]A1b. In the neoadjuvant setting, NeoSphere showed higher pathological complete response (pCR) with dual blockade (vs 29.0%) [793]A1b. The KATHERINE trial demonstrated that adjuvant trastuzumab emtansine (T-DM1) for residual disease after neoadjuvant therapy halves invasive recurrence risk (HR 0.50; NNT = 9) [803]A1b. More recently, DESTINY-Breast03 showed trastuzumab deruxtecan (T-DXd) superior to T-DM1 in previously treated metastatic disease (12-month PFS 75.8% vs 34.1%; HR 0.28; NNT = 3) [39]A1b. The HER2CLIMB trial added tucatinib to trastuzumab and capecitabine, improving overall survival in patients with (median OS 21.6 vs 12.5 months; HR 0.60; NNT = 5) [827]A1b. In contrast, the ALTTO trial found no benefit from adding lapatinib to trastuzumab and chemotherapy, and the regimen was abandoned [33]A1b.
The CDK4/6 Inhibitor Revolution
Cyclin-dependent kinase 4/6 inhibitors (palbociclib, ribociclib, abemaciclib) became the backbone of first-line therapy for hormone receptor-positive advanced breast cancer. MONALEESA-2 showed ribociclib plus letrozole extended progression-free survival to 25.3 months vs 16.0 months (HR 0.568; NNT = 6) [776]A1b. MONARCH 3 demonstrated abemaciclib plus nonsteroidal aromatase inhibitor improved median OS by 13.1 months (66.8 vs 53.7 months; HR 0.804; NNT = 10) [774]A1b. In the adjuvant setting, NATALEE showed ribociclib plus NSAI improved invasive disease-free survival (HR 0.72 at 4 years; absolute benefit 4.9%; NNT = 20) [51]A1b, while monarchE demonstrated abemaciclib plus endocrine therapy reduced recurrence risk in high-risk node-positive disease (; NNT = 12) [529]A1b. The SONIA trial challenged the sequencing dogma, finding no overall survival difference between first-line and second-line CDK4/6 inhibitor use (HR 0.91;) [812]A1b.
Immunotherapy and Beyond
KEYNOTE-522 established neoadjuvant plus chemotherapy followed by adjuvant pembrolizumab as standard for stage II-III triple-negative breast cancer, improving 5-year overall survival from 81.7% to 86.6% (HR 0.63; NNT = 15) [923]A1b. The CAPItello-291 trial added capivasertib to fulvestrant in AKT pathway-altered tumors, extending progression-free survival from 3.1 to 7.3 months (HR 0.50; NNT = 4) [798]A1b. INAVO120 demonstrated inavolisib plus palbociclib-fulvestrant in PIK3CA-mutated advanced breast cancer doubled progression-free survival (15.0 vs 7.3 months; HR 0.43; NNT = 5) [38]A1b. The ASCENT trial showed sacituzumab govitecan improves survival in metastatic triple-negative breast cancer (median OS 12.1 vs 6.7 months; HR 0.48; NNT = 4) [995]A1b. DESTINY-Breast06 expanded the HER2-targeting horizon to HER2-low and HER2-ultralow disease, with T-DXd improving progression-free survival (13.2 vs 8.1 months; HR 0.62) [800]A1b.
Pearl: The evolution of breast cancer treatment is a story of progressive de-escalation where safe and escalation where needed, guided by biomarker-driven trials that have transformed the disease from one treated by radical surgery alone to a molecularly targeted, multidisciplinary paradigm with steadily improving survival.
Prognosis and Prognostic Factors
- ▸Prognosis in breast cancer is determined by the interaction of stage, tumor biology (subtype, grade, genomic profile), and host factors (age, comorbidities, body composition).
- ▸The 5-year overall survival exceeds 90% for stage I disease but drops to approximately 30% for stage IV; recurrence risk peaks early for triple-negative breast cancer (within 3 years) and persists late for hormone receptor-positive disease.
- ▸Validated prognostic tools (Oncotype DX, RCB, HER2DX, PAM50) refine risk stratification and guide treatment decisions, particularly in HR+/HER2- early breast cancer.
Treatment advances have transformed outcomes, yet prognosis remains heterogeneous, driven by tumor biology, stage, and host factors. The 5-year overall survival for all breast cancers exceeds 90% in high-income countries, but this masks wide variation: stage I disease carries a 5-year survival of approximately 99%, while stage IV disease has a 5-year survival of approximately 30% [539]B2a. Even among patients with early-stage disease, recurrence risk differs dramatically by subtype and genomic profile.
Survival by Stage and Subtype
Among patients with hormone receptor (HR)-positive, HER2-negative early breast cancer, the 4-year invasive disease-free survival (iDFS) is 88-91% with standard chemotherapy [1076]. For triple-negative breast cancer (TNBC), the 5-year event-free survival after neoadjuvant chemoimmunotherapy is 86% in patients who achieve pathologic complete response (pCR) versus 68% in those who do not [998]C4. For HER2-positive disease, the 8-year overall survival with adjuvant plus pertuzumab is 92.7% in node-positive patients [992]A1b. In the metastatic setting, median overall survival ranges from 12.1 months for TNBC (sacituzumab govitecan) [995]A1b to 24.7 months for HER2-positive disease (tucatinib combination) [807]A1b.
Prognostic Factors
| Factor | Good Prognosis | Poor Prognosis |
|---|---|---|
| stage | Stage I | Stage IV |
| Histologic grade | Grade 1 | Grade 3 |
| ER/PR status | Positive | Negative |
| HER2 status | Amplified (targeted therapy available) | Triple-negative (TNBC) |
| Ki-67 index | Low (<10%) | High (≥20%) |
| Stromal TILs | High (≥60%) | Low (0-10%) |
| Lymphovascular invasion (LVI) | Absent | Present |
| Nodal involvement | Node-negative | ≥4 positive nodes |
| Molecular subtype | Luminal A | Basal-like, HER2-enriched |
| Genomic risk (RS) | Low (≤11) | High (≥31) |
| Residual cancer burden (RCB) | RCB-0 (pCR) | RCB-III |
| Age at diagnosis | <40 years (paradoxical? see below) | >70 years |
| TILs, tumor-infiltrating lymphocytes; RS, recurrence score (Oncotype DX). |
Ki-67 is a strong independent prognostic marker in HR-positive disease, with higher levels associated with increased risk of recurrence [863]D5. Stromal TILs predict pCR and long-term outcomes in TNBC and HER2-positive disease: each 10% increase in TILs reduces the risk of recurrence by 7% (HR 0.93) in TNBC [218]A1a. LVI is a robust predictor of nodal involvement and worse prognosis, with an odds ratio of 8.22 for sentinel lymph node metastasis [683]B2b.
Validated Prognostic Scores
Oncotype DX recurrence score (RS): The 21-gene assay stratifies risk in HR+/HER2- early breast cancer. Patients with RS ≤11 have excellent outcomes with endocrine therapy alone (5-year iDFS 93.9%), while those with RS ≥31 derive significant benefit from anthracycline-based chemotherapy (5-year distant recurrence-free interval 96.1% vs 91.0% with taxane alone) [1084][1086].
Residual cancer burden (RCB): After neoadjuvant chemotherapy, RCB index provides independent prognostic information beyond pCR status. The 10-year relapse-free survival ranges from 86% (RCB-0) to 23% (RCB-III) for TNBC, and from 97% to 52% for HR+/HER2- disease [1087].
HER2DX genomic test: For stage I-III HER2-positive breast cancer, HER2DX provides a risk score and pCR score, guiding therapy de-escalation or intensification [860]D5.
PAM50 intrinsic subtype: The 50-gene classifier identifies luminal A, luminal B, HER2-enriched, and basal-like subtypes, with independent prognostic value beyond standard clinicopathologic factors [562]B2b.
Recurrence Risk Over Time
Recurrence patterns differ by subtype. TNBC has a sharp peak of distant recurrence within 3 years of diagnosis, after which risk declines rapidly [586]B2b. In contrast, HR-positive disease carries a persistent risk of late recurrence out to 15 years and beyond. Among patients who achieve pCR after neoadjuvant chemotherapy, node positivity at baseline predicts early recurrence (within 1 year), while ER positivity predicts late recurrence (5-10 years) [1081].
Long-term Sequelae
Survivors face chronic toxicities that impair quality of life. Endocrine therapy causes hot flashes (60-80%), sexual dysfunction (40-50%), weight gain, and musculoskeletal symptoms (arthralgias in 30-50%) [217]D5. Taxane-based chemotherapy induces in up to 50% of patients, with grade ≥2 neuropathy occurring in 29% despite hand cooling [50]A1b. Sarcopenia (low muscle mass) is present in 34% of newly diagnosed patients and confers a 41% increased risk of overall mortality (HR 1.41) [575]B2b. Fatigue, cognitive impairment, and psychological distress (anxiety, depression) are common and often underrecognized [964]B2b.
Pearl: In early-stage breast cancer, the combination of anatomic stage and tumor biology (subtype, grade, genomic risk) provides the most accurate prognosis; molecular residual disease detection via ctDNA is emerging as a powerful dynamic risk stratifier that can identify patients destined to relapse months to years before clinical recurrence [888]B2b[889]B2b.
Special Populations
- ▸Pregnancy-associated breast cancer has a pooled HR for death of 1.44 versus non-pregnancy-related breast cancer, with worse outcomes for postpartum diagnoses [1110].
- ▸In women ≥70 years with low-risk, ER+ breast cancer, omission of radiotherapy after lumpectomy is safe and does not affect survival [810,163].
- ▸Fertility preservation should be discussed early; oocyte, embryo, and sperm cryopreservation are standard, while GnRHa is an adjunct only in breast cancer [520,519].
Prognosis in special populations requires careful modification of standard approaches, as age, pregnancy, and immune status each alter the risk-benefit calculus. The following subsections outline population-specific considerations for diagnosis, treatment, and follow-up.
Pregnancy and Lactation
Pregnancy-associated breast cancer (PABC), defined as diagnosis during pregnancy or within 1 year postpartum, carries a significantly worse prognosis. A meta-analysis of 30 studies (3,628 cases) reported a pooled hazard ratio for death of 1.44 compared with non-pregnancy-related breast cancer [1110]. The outcome is particularly poor when diagnosed postpartum (HR 1.84, 95%) [1110]. Diagnostic workup includes ultrasound and mammography with abdominal shielding; biopsy is safe. Chemotherapy can be given during the second and third trimesters but is avoided in the first trimester due to teratogenicity. is contraindicated because of ; endocrine therapy and radiotherapy are also contraindicated. Delivery is planned after 35 weeks and after completion of chemotherapy. is not recommended during active treatment. The POSITIVE trial demonstrated that temporarily interrupting endocrine therapy to attempt pregnancy did not increase short-term relapse risk [1125]. Fertility preservation should be discussed at diagnosis: sperm, oocyte, and embryo cryopreservation are standard [520]A1c. GnRHa may be offered as an adjunct to preserve ovarian function in breast cancer, but not as a replacement for established methods [519]A1c.
Geriatric Population
Older women (≥70 years) constitute a large and growing proportion of breast cancer patients. Two landmark trials inform local therapy de-escalation. CALGB 9343 included women ≥70 years with stage I, ER+ breast cancer: at 10 years, locoregional recurrence was 10% with tamoxifen alone versus 2% with tamoxifen plus radiotherapy, with no difference in breast cancer-specific or overall survival [810]A1b. PRIME II enrolled women ≥65 years with low-risk features (hormone receptor-positive, node-negative, tumor ≤3 cm, clear margins): at 5 years, ipsilateral breast tumor recurrence was 4.1% without radiotherapy versus 1.3% with radiotherapy, but again no survival difference [163]A1b. For systemic therapy, (CGA) helps predict chemotherapy tolerance. Chemotherapy benefit is clearest for ER-negative disease; for ER-positive, gains are modest and must be weighed against toxicity [1119]. Aromatase inhibitors are standard, but bone health monitoring is essential. Single-agent sequential chemotherapy is preferred over combination regimens [1118]. Trastuzumab can be used with cardiac monitoring.
Immunocompromised Patients
Data on breast cancer in patients with HIV, organ transplantation, or chronic immunosuppression are limited. Standard diagnostic and treatment algorithms generally apply, but close attention to infectious complications and drug interactions (e.g., between calcineurin inhibitors and chemotherapy) is required. Aggressive use of growth factor support is recommended. No specific dose modifications are established; should be individualized with multidisciplinary input.
Pediatric and Adolescent Breast Cancer
Breast cancer in patients <18 years is extremely rare (<0.1%). Most breast masses in this age group are benign. Malignant lesions include secretory carcinoma, phyllodes tumor, and rarely invasive ductal carcinoma. Diagnosis relies on ultrasound and biopsy. Treatment follows adult guidelines but must consider growth and development: surgery (breast-conserving or ) is standard; sentinel node biopsy is feasible. Chemotherapy and radiotherapy are used with careful long-term monitoring for cardiac, pulmonary, and secondary malignancy risks. Endocrine therapy may be used but requires monitoring of bone density and growth. Fertility preservation discussion is essential; for postpubertal adolescents, established methods such as oocyte or embryo cryopreservation are offered, while for prepubertal females, ovarian tissue cryopreservation is experimental [520]A1c.
Pearl: For women ≥70 with stage I, ER+ breast cancer, omission of radiotherapy after is a reasonable option that does not compromise survival, with an absolute increase in local recurrence of approximately 8% at 10 years.
| Population | Intervention | Evidence | Outcome |
|---|---|---|---|
| ≥70 years, stage I, ER+ | Omit breast RT after lumpectomy + tamoxifen | CALGB 9343 [810]A1b | 10-year locoregional recurrence 10% vs 2%; no OS difference |
| ≥65 years, low-risk (HR+, N0, ≤3 cm) | Omit breast RT after lumpectomy + endocrine therapy | PRIME II [163]A1b | 5-year ipsilateral recurrence 4.1% vs 1.3%; no survival difference |
| ER+ disease, low/intermediate risk | Consider endocrine therapy alone, avoid chemotherapy | Expert consensus [1119] | Reduced toxicity without clear survival benefit |
References
- [1]
Turnbull C, Achatz MI, Balmaña J et al.. “Breast cancer germline multigene panel testing in mainstream oncology based on clinical-public health utility: ESMO Precision Oncology Working Group recommendations.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40523834 ↗
L1GUIDELINECited in: Definition and Epidemiology, Genetics and Hereditary Predisposition - [2]
Chen CS, Zirpoli G, Barlow WE et al.. “Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 37935109 ↗
L2RCTCited in: Definition and Epidemiology - [3]
Chumsri S, Pai T, Ma Y et al.. “Clinical Treatment Score Post-5 Years (CTS5) and Late Recurrence Risk in Hormone Receptor-Positive, HER2-Positive Breast Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 39191270 ↗
L2RCTCited in: Definition and Epidemiology - [4]
Biganzoli L, Battisti NML, Wildiers H et al.. “Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG).” The Lancet. Oncology (2021). PMID: 34000244 ↗
L1GUIDELINECited in: Definition and Epidemiology, Risk Factors and Prevention - [5]
Smith SG, Sestak I, Forster A et al.. “Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 26646754 ↗
L2SR_OBSCited in: Definition and Epidemiology - [6]
Gianni L, Huang CS, Egle D et al.. “Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study.” Annals of oncology : official journal of the European Society for Medical Oncology (2022). PMID: 35182721 ↗
L1RCTCited in: Definition and Epidemiology - [7]
Mamounas EP, Untch M, Mano MS et al.. “Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE.” Annals of oncology : official journal of the European Society for Medical Oncology (2021). PMID: 33932503 ↗
L2RCTCited in: Definition and Epidemiology - [8]
Harbeck N, Fasching PA, Wuerstlein R et al.. “Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 37201751 ↗
L1RCTCited in: Definition and Epidemiology - [9]
Rafn BS, Christensen J, Larsen A et al.. “Prospective Surveillance for Breast Cancer-Related Arm Lymphedema: A Systematic Review and Meta-Analysis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35077194 ↗
L2SR_OBSCited in: Definition and Epidemiology - [10]
Lazzeroni M, Puntoni M, Guerrieri-Gonzaga A et al.. “Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36917758 ↗
L1RCTCited in: Definition and Epidemiology - [11]
Meattini I, Marrazzo L, Saieva C et al.. “Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-IMRT-Florence Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32840419 ↗
L1RCTCited in: Definition and Epidemiology, Special Populations - [12]
Bartels SAL, Donker M, Poncet C et al.. “Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 36383926 ↗
L1RCTCited in: Definition and Epidemiology, Biopsy and Histologic Diagnosis - [13]
Sanft T, Harrigan M, McGowan C et al.. “Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37656930 ↗
L1RCTCited in: Definition and Epidemiology, Clinical Presentation - [14]
McCormick B, Winter K, Hudis C et al.. “RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25605856 ↗
L1RCTCited in: Definition and Epidemiology, Clinical Presentation, Prognosis and Prognostic Factors - [15]
DeCensi A, Puntoni M, Guerrieri-Gonzaga A et al.. “Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 30973790 ↗
L1RCTCited in: Definition and Epidemiology - [16]
Saura C, Oliveira M, Feng YH et al.. “Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32678716 ↗
L1RCTCited in: Definition and Epidemiology - [17]
Kang D, Cho J, Zhao D et al.. “Scalp Cooling in Preventing Persistent Chemotherapy-Induced Alopecia: A Randomized Controlled Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38843479 ↗
L1RCTCited in: Definition and Epidemiology - [18]
Paramanandam VS, Dylke E, Clark GM et al.. “Prophylactic Use of Compression Sleeves Reduces the Incidence of Arm Swelling in Women at High Risk of Breast Cancer-Related Lymphedema: A Randomized Controlled Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35108031 ↗
L1RCTCited in: Definition and Epidemiology - [19]
Badwe RA, Parmar V, Nair N et al.. “Effect of Peritumoral Infiltration of Local Anesthetic Before Surgery on Survival in Early Breast Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37023374 ↗
L1RCTCited in: Definition and Epidemiology, Prognosis and Prognostic Factors - [20]
Swain SM, Ewer MS, Viale G et al.. “Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 29253081 ↗
L4TRIAL_NONRANDOMCited in: Definition and Epidemiology - [21]
Kerr AJ, Dodwell D, McGale P et al.. “Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality.” Cancer treatment reviews (2022). PMID: 35367784 ↗
L1SR_OBSCited in: Definition and Epidemiology, Management Overview - [22]
Hua M, Xiong F, Chong S et al.. “Abemaciclib increases the risk of venous thromboembolism in breast cancer: Integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation.” Cancer treatment reviews (2024). PMID: 39278067 ↗
L2SR_OBSCited in: Definition and Epidemiology - [23]
Santoni M, Guerra F, Conti A et al.. “Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies.” Cancer treatment reviews (2017). PMID: 28818671 ↗
L1SR_OBSCited in: Definition and Epidemiology - [24]
Soares LR, Vilbert M, Rosa VDL et al.. “Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis.” ESMO open (2023). PMID: 37481956 ↗
L2SR_OBSCited in: Definition and Epidemiology - [25]
Caparica R, Bruzzone M, Agostinetto E et al.. “Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis.” ESMO open (2021). PMID: 33639601 ↗
L2SR_OBSCited in: Definition and Epidemiology - [26]
DiSipio T, Rye S, Newman B et al.. “Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis.” The Lancet. Oncology (2013). PMID: 23540561 ↗
L1SR_OBSCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation - [27]
. “Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.” The Lancet. Oncology (2017). PMID: 29242041 ↗
L1SR_OBSCited in: Definition and Epidemiology, Risk Factors and Prevention, Staging, Management Overview, Prognosis and Prognostic Factors - [28]
Paap E, Verbeek ALM, Puliti D et al.. “Breast cancer screening case-control study design: impact on breast cancer mortality.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 20924073 ↗
L5SR_OBSCited in: Definition and Epidemiology, Risk Factors and Prevention - [29]
Klepin H, Mohile S, Hurria A. “Geriatric assessment in older patients with breast cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2009). PMID: 19200420 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology - [30]
Helvie MA, Bevers TB. “Screening Mammography for Average-Risk Women: The Controversy and NCCN's Position.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30442738 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation - [31]
Chlebowski RT, Aragaki AK, Anderson GL. “Menopausal Hormone Therapy Influence on Breast Cancer Outcomes in the Women's Health Initiative.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 26150583 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology - [32]
Jacob S, Mayer EL, Kacik N et al.. “TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer.” ESMO open (2026). PMID: 41812623 ↗
L1RCTCited in: Definition and Epidemiology, History and Evolution of Treatment, Prognosis and Prognostic Factors - [33]
de Azambuja E, Piccart-Gebhart M, Fielding S et al.. “Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)].” ESMO open (2024). PMID: 39418883 ↗
L1RCTCited in: Definition and Epidemiology, History and Evolution of Treatment, Prognosis and Prognostic Factors - [34]
Wang SL, Fang H, Song YW et al.. “Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial.” The Lancet. Oncology (2019). PMID: 30711522 ↗
L1RCTCited in: Definition and Epidemiology - [35]
Poortmans PM, Weltens C, Fortpied C et al.. “Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial.” The Lancet. Oncology (2020). PMID: 33152277 ↗
L1RCTCited in: Definition and Epidemiology, Imaging, Staging - [36]
Bartelink H, Maingon P, Poortmans P et al.. “Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial.” The Lancet. Oncology (2014). PMID: 25500422 ↗
L1RCTCited in: Definition and Epidemiology, Staging - [37]
Schmid P, Cortes J, Pusztai L et al.. “Pembrolizumab for Early Triple-Negative Breast Cancer.” The New England journal of medicine (2020). PMID: 32101663 ↗
L1RCTCited in: Definition and Epidemiology, Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations - [38]
Turner NC, Im SA, Saura C et al.. “Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer.” The New England journal of medicine (2024). PMID: 39476340 ↗
L1RCTCited in: Definition and Epidemiology, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations - [39]
Cortés J, Kim SB, Chung WP et al.. “Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.” The New England journal of medicine (2022). PMID: 35320644 ↗
L1RCTCited in: Definition and Epidemiology, Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations - [40]
Jhaveri KL, Neven P, Casalnuovo ML et al.. “Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.” The New England journal of medicine (2024). PMID: 39660834 ↗
L1RCTCited in: Definition and Epidemiology, Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors, Special Populations - [41]
Tolaney SM, Jiang Z, Zhang Q et al.. “Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.” The New England journal of medicine (2025). PMID: 41160818 ↗
L1RCTCited in: Definition and Epidemiology, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors, Special Populations - [42]
Jhaveri KL, Im SA, Saura C et al.. “Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer.” The New England journal of medicine (2025). PMID: 40454641 ↗
L1RCTCited in: Definition and Epidemiology - [43]
Manson JE, Cook NR, Lee IM et al.. “Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease.” The New England journal of medicine (2018). PMID: 30415629 ↗
L1RCTCited in: Definition and Epidemiology - [44]
Cortés J, Punie K, Barrios C et al.. “Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.” The New England journal of medicine (2025). PMID: 41124233 ↗
L1RCTCited in: Definition and Epidemiology, Clinical Presentation - [45]
Tolaney SM, de Azambuja E, Kalinsky K et al.. “Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.” The New England journal of medicine (2026). PMID: 41564397 ↗
L1RCTCited in: Definition and Epidemiology - [46]
Kunkler IH, Williams LJ, Jack WJL et al.. “Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer.” The New England journal of medicine (2023). PMID: 36791159 ↗
L1RCTCited in: Definition and Epidemiology, Staging - [47]
Bakker MF, de Lange SV, Pijnappel RM et al.. “Supplemental MRI Screening for Women with Extremely Dense Breast Tissue.” The New England journal of medicine (2019). PMID: 31774954 ↗
L1RCTCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation, Imaging - [48]
Villacampa G, Navarro V, Matikas A et al.. “Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer: A Systematic Review and Meta-Analysis.” JAMA oncology (2024). PMID: 39207778 ↗
L1SR_OBSCited in: Definition and Epidemiology, Management Overview - [49]
Spring LM, Gupta A, Reynolds KL et al.. “Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis.” JAMA oncology (2016). PMID: 27367583 ↗
L1SR_OBSCited in: Definition and Epidemiology, Management Overview, Prognosis and Prognostic Factors - [50]
Michel LL, Schwarz D, Romar P et al.. “Efficacy of Hand Cooling and Compression in Preventing Taxane-Induced Neuropathy: The POLAR Randomized Clinical Trial.” JAMA oncology (2025). PMID: 40048176 ↗
L1RCTCited in: Definition and Epidemiology, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations - [51]
Fasching PA, Stroyakovskiy D, Yardley DA et al.. “Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.” JAMA oncology (2025). PMID: 40996773 ↗
L1RCTCited in: Definition and Epidemiology, Imaging, Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations - [52]
Partridge AH, Niman SM, Ruggeri M et al.. “Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.” The New England journal of medicine (2023). PMID: 37133584 ↗
L4TRIAL_NONRANDOMCited in: Definition and Epidemiology, Clinical Presentation - [53]
. “Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.” The Lancet. Oncology (2022). PMID: 35123662 ↗
L1SR_OBSCited in: Definition and Epidemiology - [54]
. “Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials.” The Lancet. Oncology (2021). PMID: 34339645 ↗
L1SR_OBSCited in: Definition and Epidemiology - [55]
Bilancia D, Rosati G, Dinota A et al.. “Lapatinib in breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17591827 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology - [56]
Boyle P. “Triple-negative breast cancer: epidemiological considerations and recommendations.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 23012306 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation - [57]
Autier P, Boniol M, Middleton R et al.. “Advanced breast cancer incidence following population-based mammographic screening.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21252058 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Staging - [58]
Bines J, Earl H, Buzaid AC et al.. “Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter?” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 24625452 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology - [59]
Vasan N, Toska E, Scaltriti M. “Overview of the relevance of PI3K pathway in HR-positive breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 31859348 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology - [60]
Arthur DW, Winter KA, Kuerer HM et al.. “Effectiveness of Breast-Conserving Surgery and 3-Dimensional Conformal Partial Breast Reirradiation for Recurrence of Breast Cancer in the Ipsilateral Breast: The NRG Oncology/RTOG 1014 Phase 2 Clinical Trial.” JAMA oncology (2020). PMID: 31750868 ↗
L4TRIAL_NONRANDOMCited in: Definition and Epidemiology, Management Overview - [61]
Zhong J, Wu L, Song Z et al.. “TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study.” Cancer cell (2025). PMID: 41135519 ↗
L4TRIAL_NONRANDOMCited in: Definition and Epidemiology, Special Populations - [62]
Johansson H, Macis D, Oliva M et al.. “Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40293268 ↗
L1RCTCited in: Definition and Epidemiology - [63]
Nozawa K, Iwata H, Mukohara T et al.. “Effectiveness of post-trastuzumab deruxtecan treatments and incidence of interstitial lung disease in HER2-positive metastatic breast cancer: a real-world, observational cohort study.” ESMO open (2025). PMID: 40714515 ↗
L2COHORTCited in: Definition and Epidemiology, Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations - [64]
Jourdain H, Di Meglio A, Mansouri I et al.. “Use and outcomes of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer in a real-world setting: a nationwide cohort study.” ESMO open (2024). PMID: 39662227 ↗
L3COHORTCited in: Definition and Epidemiology, History and Evolution of Treatment, Prognosis and Prognostic Factors - [65]
de Andrade KC, Khincha PP, Hatton JN et al.. “Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study.” The Lancet. Oncology (2021). PMID: 34780712 ↗
L2COHORTCited in: Definition and Epidemiology, Risk Factors and Prevention, Genetics and Hereditary Predisposition, Clinical Presentation - [66]
de Haan J, Verheecke M, Van Calsteren K et al.. “Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients.” The Lancet. Oncology (2018). PMID: 29395867 ↗
L2COHORTCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation - [67]
Kirkham AA, Jerzak KJ. “Prevalence of Breast Cancer Survivors Among Canadian Women.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 36075384 ↗
L2OTHERCited in: Definition and Epidemiology - [68]
Park C, Liu YS, Kenawy AS et al.. “Cardiovascular Adverse Events and Associated Costs of CDK4/6 Inhibitors in Patients With Breast Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 40250478 ↗
L3OTHERCited in: Definition and Epidemiology - [69]
Koroukian SM, Dong W, Albert JM et al.. “Treatment Patterns and Survival Outcomes in Patients With Breast Cancer on Medicaid, Pre- and Post-Expansion.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 38498974 ↗
L3OTHERCited in: Definition and Epidemiology - [70]
Niu C, Zhang J, Singh H et al.. “Impact of Concomitant Proton Pump Inhibitor Use on the Efficacy of Immune Checkpoint Inhibitors Across Multiple Cancer Types.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 41101342 ↗
L3OTHERCited in: Definition and Epidemiology - [71]
Nelson RA, Soto-Perez-de-Celis E, Chlebowski RT et al.. “Predicting All-Cause Mortality in Women With and Without Breast Cancer Using the Schonberg Index: A Women's Health Initiative Study.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 37308127 ↗
L2OTHERCited in: Definition and Epidemiology - [72]
Chahoud J, Semaan A, Rieber A. “Wealth, Health Expenditure, and Cancer: A National Perspective.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 27496113 ↗
L2OTHERCited in: Definition and Epidemiology - [73]
Mortimer JE, Barsevick AM, Bennett CL et al.. “Studying cancer-related fatigue: report of the NCCN scientific research committee.” Journal of the National Comprehensive Cancer Network : JNCCN (2010). PMID: 21147900 ↗
L5OTHERCited in: Definition and Epidemiology - [74]
Heist RS, Sands J, Bardia A et al.. “Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan.” Cancer treatment reviews (2024). PMID: 38502995 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Molecular Diagnostics and Biomarkers - [75]
Trapani D, Ginsburg O, Fadelu T et al.. “Global challenges and policy solutions in breast cancer control.” Cancer treatment reviews (2022). PMID: 35074727 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation, Management Overview - [76]
Cucciniello L, Garufi G, Di Rienzo R et al.. “Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome.” Cancer treatment reviews (2023). PMID: 37751658 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Management Overview - [77]
Gómez-Raposo C, Zambrana Tévar F, Sereno Moyano M et al.. “Male breast cancer.” Cancer treatment reviews (2010). PMID: 20193984 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation - [78]
Rached L, Laparra A, Sakkal M et al.. “Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations.” Cancer treatment reviews (2024). PMID: 38729086 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology - [79]
Bozovic-Spasojevic I, Azambuja E, McCaskill-Stevens W et al.. “Chemoprevention for breast cancer.” Cancer treatment reviews (2012). PMID: 21856081 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation - [80]
Corti C, Antonarelli G, Criscitiello C et al.. “Targeting brain metastases in breast cancer.” Cancer treatment reviews (2021). PMID: 34953200 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology - [81]
Tryfonidis K, Zardavas D, Cardoso F. “Small breast cancers: when and how to treat.” Cancer treatment reviews (2014). PMID: 25315501 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Genetics and Hereditary Predisposition, Prognosis and Prognostic Factors - [82]
Bartsch R, Jerzak KJ, Larrouquere L et al.. “Pharmacotherapy for leptomeningeal disease in breast cancer.” Cancer treatment reviews (2023). PMID: 38118373 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation, Prognosis and Prognostic Factors - [83]
Mederos N, Friedlaender A, Peters S et al.. “Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer.” ESMO open (2020). PMID: 33148544 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation, History and Evolution of Treatment - [84]
Zagouri F, Dimitrakakis C, Marinopoulos S et al.. “Cancer in pregnancy: disentangling treatment modalities.” ESMO open (2016). PMID: 27843602 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation - [85]
Pondé NF, Lambertini M, de Azambuja E. “Twenty years of anti-HER2 therapy-associated cardiotoxicity.” ESMO open (2016). PMID: 27843627 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology - [86]
Stavrou E, Winer EP, Lin NU. “How we treat HER2-positive brain metastases.” ESMO open (2021). PMID: 34482180 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology - [87]
Kerr J, Anderson C, Lippman SM. “Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence.” The Lancet. Oncology (2017). PMID: 28759385 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention - [88]
Bray F, Parkin DM. “Cancer in sub-Saharan Africa in 2020: a review of current estimates of the national burden, data gaps, and future needs.” The Lancet. Oncology (2022). PMID: 35550275 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology - [89]
Lee M, Goldenberg SM, Dávila-Conn V et al.. “Social Determinants of Health and Cardiovascular Disease-Related Outcome Disparities Among Breast Cancer Survivors: A Systematic Review.” Journal of the American Heart Association (2026). PMID: 42396821 ↗
L5SR_OBSCited in: Definition and Epidemiology, Risk Factors and Prevention, Management Overview - [90]
Tarantino P, Modi S, Tolaney SM et al.. “Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review.” JAMA oncology (2021). PMID: 34647966 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation, Molecular Diagnostics and Biomarkers, Management Overview - [91]
Hanker AB, Sudhan DR, Arteaga CL. “Overcoming Endocrine Resistance in Breast Cancer.” Cancer cell (2020). PMID: 32289273 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Management Overview - [92]
Kodack DP, Askoxylakis V, Ferraro GB et al.. “Emerging strategies for treating brain metastases from breast cancer.” Cancer cell (2015). PMID: 25670078 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Histopathology and Molecular Biology - [93]
Deng C, Wen X, Liu S et al.. “Effects of opioid-free anesthesia on postoperative anxiety in patients undergoing modified radical mastectomy for breast cancer: a randomized controlled trial.” BMC anesthesiology (2026). PMID: 42399751 ↗
L1RCTCited in: Definition and Epidemiology - [94]
Das P, Dutta S, Maji S et al.. “Safety and efficacy of Efbemalenograstim alfa for patients at risk for chemotherapy-induced neutropenia: A Systematic review and Meta-analysis.” Pharmacology (2026). PMID: 42400926 ↗
L1SR_OBSCited in: Definition and Epidemiology - [95]
Kennecke H, Yerushalmi R, Woods R et al.. “Metastatic behavior of breast cancer subtypes.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20498394 ↗
L2OTHERCited in: Definition and Epidemiology, Special Populations - [96]
Jain S, Vahdat LT. “Eribulin mesylate.” Clinical cancer research : an official journal of the American Association for Cancer Research (2011). PMID: 21859830 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology - [97]
Metzger-Filho O, Winer EP, Krop I. “Pertuzumab: optimizing HER2 blockade.” Clinical cancer research : an official journal of the American Association for Cancer Research (2013). PMID: 23942091 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology - [98]
Lin NU, Winer EP. “Brain metastases: the HER2 paradigm.” Clinical cancer research : an official journal of the American Association for Cancer Research (2007). PMID: 17363517 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation, Management Overview - [99]
Hirbe A, Morgan EA, Uluçkan O et al.. “Skeletal complications of breast cancer therapies.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 17062720 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology - [100]
Reeder-Hayes KE, Anderson BO. “Breast Cancer Disparities at Home and Abroad: A Review of the Challenges and Opportunities for System-Level Change.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28572260 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation - [101]
Friedenreich CM, Neilson HK, Farris MS et al.. “Physical Activity and Cancer Outcomes: A Precision Medicine Approach.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27407093 ↗
L2REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation - [102]
Olopade OI, Grushko TA, Nanda R et al.. “Advances in breast cancer: pathways to personalized medicine.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 19088015 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation - [103]
Bardia A, Hurvitz S. “Targeted Therapy for Premenopausal Women with HR+, HER2- Advanced Breast Cancer: Focus on Special Considerations and Latest Advances.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 29884743 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Staging - [104]
Biggar RJ. “Molecular pathways: digoxin use and estrogen-sensitive cancers--risks and possible therapeutic implications.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 22368159 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention - [105]
Aragon-Ching JB, Zujewski JA. “CNS metastasis: an old problem in a new guise.” Clinical cancer research : an official journal of the American Association for Cancer Research (2007). PMID: 17363516 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology - [106]
Facondo G, Prisco A, Reverberi C et al.. “Incidence and Predictors of Fat Necrosis After Single-Fraction Stereotactic Partial Breast Irradiation for Early-Stage Breast Cancer: Results From a Phase II Clinical Trial.” International journal of radiation oncology, biology, physics (2026). PMID: 42425251 ↗
L4TRIAL_NONRANDOMCited in: Definition and Epidemiology, Clinical Presentation - [107]
Hassoub G, El-Bassiouny NA, Abdelkader Y et al.. “Coenzyme Q10 as an adjunctive strategy to reduce paclitaxel-induced toxicities in breast cancer: a randomized controlled trial.” BMC pharmacology & toxicology (2026). PMID: 42401951 ↗
L1RCTCited in: Definition and Epidemiology, Management Overview, History and Evolution of Treatment, Special Populations - [108]
Chowdhury AM, Halaseh SA, Joseph D et al.. “Breast cancer clinical trials in low- and middle-income countries (LMICs).” Ecancermedicalscience (2026). PMID: 42416228 ↗
L2TRIAL_NONRANDOMCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation - [109]
Powell CA, Modi S, Iwata H et al.. “Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies.” ESMO open (2022). PMID: 35963179 ↗
L4OTHERCited in: Definition and Epidemiology, Clinical Presentation, Special Populations - [110]
Huang Z, Wang J, Liu H et al.. “Global trends in adolescent and young adult female cancer burden, 1990-2021: insights from the Global Burden of Disease study.” ESMO open (2024). PMID: 39426082 ↗
L2OTHERCited in: Definition and Epidemiology - [111]
Kong W, He Z, Li D et al.. “Impact of depression on treatment response and survival among patients with breast cancer: A multi-institutional retrospective cohort study.” Breast (Edinburgh, Scotland) (2026). PMID: 42419252 ↗
L3COHORTCited in: Definition and Epidemiology - [112]
Gentilini OD, Botteri E, Sangalli C et al.. “Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial.” JAMA oncology (2023). PMID: 37733364 ↗
L1OTHERCited in: Definition and Epidemiology, Biopsy and Histologic Diagnosis, Imaging, Management Overview - [113]
Giannakeas V, Lim DW, Narod SA. “Bilateral Mastectomy and Breast Cancer Mortality.” JAMA oncology (2024). PMID: 39052262 ↗
L2OTHERCited in: Definition and Epidemiology, Management Overview, Special Populations - [114]
McVicker L, Labeit AM, Coupland CAC et al.. “Vaginal Estrogen Therapy Use and Survival in Females With Breast Cancer.” JAMA oncology (2024). PMID: 37917089 ↗
L3OTHERCited in: Definition and Epidemiology, Clinical Presentation, Management Overview, Special Populations - [115]
Chen S, Cao Z, Prettner K et al.. “Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050.” JAMA oncology (2023). PMID: 36821107 ↗
L5OTHERCited in: Definition and Epidemiology, Management Overview - [116]
Montagna G, Mrdutt MM, Sun SX et al.. “Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy.” JAMA oncology (2024). PMID: 38662396 ↗
L3OTHERCited in: Definition and Epidemiology, Biopsy and Histologic Diagnosis, Imaging, Staging, Management Overview, Prognosis and Prognostic Factors, Special Populations - [117]
Fitzmaurice C, Abate D, Abbasi N et al.. “Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study.” JAMA oncology (2019). PMID: 31560378 ↗
L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention - [118]
Yofe I, Shami T, Cohen N et al.. “Spatial and Temporal Mapping of Breast Cancer Lung Metastases Identify TREM2 Macrophages as Regulators of the Metastatic Boundary.” Cancer discovery (2023). PMID: 37756565 ↗
L5OTHERCited in: Definition and Epidemiology - [119]
Saura C, Ortiz C, Matito J et al.. “Early-Stage Breast Cancer Detection in Breast Milk.” Cancer discovery (2023). PMID: 37704212 ↗
L4OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation, Molecular Diagnostics and Biomarkers - [120]
Shiels MS, Lipkowitz S, Campos NG et al.. “Opportunities for Achieving the Cancer Moonshot Goal of a 50% Reduction in Cancer Mortality by 2047.” Cancer discovery (2023). PMID: 37067240 ↗
L5OTHERCited in: Definition and Epidemiology - [121]
Pradat Y, Viot J, Yurchenko AA et al.. “Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer.” Cancer discovery (2023). PMID: 36862804 ↗
L4OTHERCited in: Definition and Epidemiology, Histopathology and Molecular Biology - [122]
Sreekumar A, Blankemeyer E, Sterner CJ et al.. “Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy.” Cancer discovery (2026). PMID: 41370830 ↗
L5OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention - [123]
. “By the Numbers: Cancer Mortality, 2011-2015.” Cancer discovery (2018). PMID: 30076139 ↗
L5OTHERCited in: Definition and Epidemiology - [124]
Cann CG, Eng C. “Cancer in the Prime of Life: Etiologic Insights and Supportive Oncologic Interventions for the Rising Burden of Young Adult Cancer.” Cancer discovery (2025). PMID: 40605507 ↗
L5OTHERCited in: Definition and Epidemiology - [125]
Liu H, Paddock MN, Wang H et al.. “The INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple-Negative Breast Cancer.” Cancer discovery (2020). PMID: 32513774 ↗
L5OTHERCited in: Definition and Epidemiology - [126]
Feng Y, Pan TC, Pant DK et al.. “SPSB1 promotes breast cancer recurrence by potentiating c-MET signaling.” Cancer discovery (2014). PMID: 24786206 ↗
L5OTHERCited in: Definition and Epidemiology - [127]
Pinato DJ, Zambelli A, Aguilar-Company J et al.. “Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients.” Cancer discovery (2020). PMID: 32737082 ↗
L2OTHERCited in: Definition and Epidemiology - [128]
Martini R, Delpe P, Chu TR et al.. “African Ancestry-Associated Gene Expression Profiles in Triple-Negative Breast Cancer Underlie Altered Tumor Biology and Clinical Outcome in Women of African Descent.” Cancer discovery (2022). PMID: 36121736 ↗
L3OTHERCited in: Definition and Epidemiology, Histopathology and Molecular Biology - [129]
Sceneay J, Goreczny GJ, Wilson K et al.. “Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer.” Cancer discovery (2019). PMID: 31217296 ↗
L5OTHERCited in: Definition and Epidemiology, Clinical Presentation - [130]
Xiao Y, Cong M, Li J et al.. “Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation.” Cancer cell (2021). PMID: 33450198 ↗
L5OTHERCited in: Definition and Epidemiology - [131]
Rozalén C, Sangrador I, Avalle S et al.. “TIM3+ breast cancer cells license immune evasion during micrometastasis outbreak.” Cancer cell (2025). PMID: 40645187 ↗
L5OTHERCited in: Definition and Epidemiology - [132]
Sreekumar A, Lu M, Choudhury B et al.. “B3GALT6 promotes dormant breast cancer cell survival and recurrence by enabling heparan sulfate-mediated FGF signaling.” Cancer cell (2023). PMID: 38065100 ↗
L5OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Genetics and Hereditary Predisposition - [133]
Chang G, Shi L, Ye Y et al.. “YTHDF3 Induces the Translation of m6A-Enriched Gene Transcripts to Promote Breast Cancer Brain Metastasis.” Cancer cell (2020). PMID: 33125861 ↗
L4OTHERCited in: Definition and Epidemiology - [134]
Ooms LM, Binge LC, Davies EM et al.. “The Inositol Polyphosphate 5-Phosphatase PIPP Regulates AKT1-Dependent Breast Cancer Growth and Metastasis.” Cancer cell (2015). PMID: 26267533 ↗
L5OTHERCited in: Definition and Epidemiology - [135]
Grolleman JE, de Voer RM, Elsayed FA et al.. “Mutational Signature Analysis Reveals NTHL1 Deficiency to Cause a Multi-tumor Phenotype.” Cancer cell (2019). PMID: 30753826 ↗
L4OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Genetics and Hereditary Predisposition, Histopathology and Molecular Biology - [136]
Sgroi DC. “Breast cancer SRC activity: bad to the bone.” Cancer cell (2009). PMID: 19573804 ↗
L5OTHERCited in: Definition and Epidemiology - [137]
Khan M, Dekate K, Dhorajiwala S et al.. “Establishing The Role of Transforming Growth Factor Beta Regulator 4 In Cancer Progression: A Systematic Review.” Journal of stomatology, oral and maxillofacial surgery (2026). PMID: 42419424 ↗
L2SR_OBSCited in: Definition and Epidemiology - [138]
Liu Z, Wang X, Gai J et al.. “Comparative effectiveness and safety of adjuvant trastuzumab plus pertuzumab versus trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world retrospective study.” Frontiers in oncology (2026). PMID: 42434737 ↗
L2COHORTCited in: Definition and Epidemiology - [139]
Hussein AM. “The state of cancer in Somalia: a comprehensive six-year retrospective study.” BMC cancer (2026). PMID: 42432552 ↗
L4COHORTCited in: Definition and Epidemiology - [140]
de Almeida CC, Santos DH, Machado Magalhães PL et al.. “Ten-year temporal distribution of brain metastases after breast cancer: a global cohort study.” Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2026). PMID: 42419089 ↗
L2COHORTCited in: Definition and Epidemiology, Clinical Presentation - [141]
Wen Q, Zhang Y, Qiao L et al.. “Burden of cardiovascular diseases in breast cancer survivors: a 9-year retrospective cohort study based on regional medical data in Inner Mongolia China.” Cardio-oncology (London, England) (2026). PMID: 42415223 ↗
L2COHORTCited in: Definition and Epidemiology, Clinical Presentation - [142]
Abelman RO, Wu B, Barnes H et al.. “TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39745368 ↗
L2OTHERCited in: Definition and Epidemiology - [143]
Daly MB, Pal T, Berry MP et al.. “Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 33406487 ↗
L1GUIDELINECited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Management Overview, History and Evolution of Treatment - [144]
Bevers TB, Ward JH, Arun BK et al.. “Breast Cancer Risk Reduction, Version 2.2015.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 26150582 ↗
L1GUIDELINECited in: Risk Factors and Prevention, History and Evolution of Treatment - [145]
Bevers TB, Helvie M, Bonaccio E et al.. “Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30442736 ↗
L1GUIDELINECited in: Risk Factors and Prevention, Clinical Presentation, Biopsy and Histologic Diagnosis - [146]
Vogelbaum MA, Brown PD, Messersmith H et al.. “Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34932393 ↗
L1GUIDELINECited in: Risk Factors and Prevention, History and Evolution of Treatment - [147]
Runowicz CD, Leach CR, Henry NL et al.. “American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 26644543 ↗
L1GUIDELINECited in: Risk Factors and Prevention, Clinical Presentation, History and Evolution of Treatment - [148]
Park KH, Loibl S, Sohn J et al.. “Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer.” ESMO open (2024). PMID: 38796284 ↗
L1GUIDELINECited in: Risk Factors and Prevention, Staging - [149]
Ruddy KJ, Winer EP. “Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23425944 ↗
L2SR_OBSCited in: Risk Factors and Prevention - [150]
Islami F, Liu Y, Jemal A et al.. “Breastfeeding and breast cancer risk by receptor status--a systematic review and meta-analysis.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 26504151 ↗
L2SR_OBSCited in: Risk Factors and Prevention - [151]
Di Leo A, Jerusalem G, Petruzelka L et al.. “Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20855825 ↗
L1RCTCited in: Risk Factors and Prevention - [152]
Wu AH, Wu J, Tseng C et al.. “Air Pollution and Breast Cancer Incidence in the Multiethnic Cohort Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39378392 ↗
L2COHORTCited in: Risk Factors and Prevention - [153]
Mayer EL, Fesl C, Hlauschek D et al.. “Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 34995105 ↗
L1RCTCited in: Risk Factors and Prevention - [154]
Chen T, Xu T, Li Y et al.. “Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis.” Cancer treatment reviews (2010). PMID: 20952131 ↗
L1SR_OBSCited in: Risk Factors and Prevention - [155]
Lambertini M, Santoro L, Del Mastro L et al.. “Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies.” Cancer treatment reviews (2016). PMID: 27529149 ↗
L2SR_OBSCited in: Risk Factors and Prevention, Special Populations - [156]
Wen H, Deng G, Shi X et al.. “Body mass index, weight change, and cancer prognosis: a meta-analysis and systematic review of 73 cohort studies.” ESMO open (2024). PMID: 38442453 ↗
L2SR_OBSCited in: Risk Factors and Prevention - [157]
Di Lauro V, Barchiesi G, Martorana F et al.. “Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review.” ESMO open (2022). PMID: 36399953 ↗
L2SR_OBSCited in: Risk Factors and Prevention - [158]
Yazgan SC, Yekedüz E, Akkuş E et al.. “Venous thromboembolic event risk with PARP inhibitors in solid tumors: a systematic review and meta-analysis.” ESMO open (2025). PMID: 41027069 ↗
L1SR_OBSCited in: Risk Factors and Prevention - [159]
. “Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies.” The Lancet. Oncology (2012). PMID: 23084519 ↗
L2SR_OBSCited in: Risk Factors and Prevention, Histopathology and Molecular Biology, Special Populations - [160]
Kim GM, Kim MH, Park HS et al.. “A prospective study for brain metastasis imaging screening in patients with advanced HER2-positive or triple-negative breast cancer.” ESMO open (2026). PMID: 41818850 ↗
L4COHORTCited in: Risk Factors and Prevention, Imaging - [161]
Lång K, Josefsson V, Larsson AM et al.. “Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study.” The Lancet. Oncology (2023). PMID: 37541274 ↗
L1RCTCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition - [162]
Krag DN, Anderson SJ, Julian TB et al.. “Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.” The Lancet. Oncology (2010). PMID: 20863759 ↗
L1RCTCited in: Risk Factors and Prevention, Biopsy and Histologic Diagnosis - [163]
Kunkler IH, Williams LJ, Jack WJ et al.. “Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial.” The Lancet. Oncology (2015). PMID: 25637340 ↗
L1RCTCited in: Risk Factors and Prevention, Histopathology and Molecular Biology, Staging, Special Populations - [164]
Meattini I, De Santis MC, Visani L et al.. “Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial.” The Lancet. Oncology (2024). PMID: 39675376 ↗
L1RCTCited in: Risk Factors and Prevention, Staging - [165]
Decensi A, Dunn BK, Puntoni M et al.. “Exemestane for breast cancer prevention: a critical shift?” Cancer discovery (2012). PMID: 22585166 ↗
L5RCTCited in: Risk Factors and Prevention, History and Evolution of Treatment, Special Populations - [166]
Charton E, Baldini C, Fayet Y et al.. “Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study.” ESMO open (2023). PMID: 37536254 ↗
L2TRIAL_NONRANDOMCited in: Risk Factors and Prevention - [167]
Stolarova L, Kleiblova P, Zemankova P et al.. “ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 37449874 ↗
L3SR_OBSCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition - [168]
Juneja V, Keegan P, Gootenberg JE et al.. “Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18519748 ↗
L5SR_OBSCited in: Risk Factors and Prevention - [169]
Daly MB, Pal T, Maxwell KN et al.. “NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 37856201 ↗
L1OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition - [170]
Bevers TB, Niell BL, Baker JL et al.. “NCCN Guidelines® Insights: Breast Cancer Screening and Diagnosis, Version 1.2023.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 37673117 ↗
L1OTHERCited in: Risk Factors and Prevention, Clinical Presentation - [171]
Ng AK, Travis LB. “Radiation therapy and breast cancer risk.” Journal of the National Comprehensive Cancer Network : JNCCN (2009). PMID: 19930978 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention - [172]
Palesh O, Aldridge-Gerry A, Ulusakarya A et al.. “Sleep disruption in breast cancer patients and survivors.” Journal of the National Comprehensive Cancer Network : JNCCN (2013). PMID: 24335687 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Clinical Presentation - [173]
Pinsky RW, Helvie MA. “Mammographic breast density: effect on imaging and breast cancer risk.” Journal of the National Comprehensive Cancer Network : JNCCN (2010). PMID: 20971840 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Imaging - [174]
Mao X, He W, Humphreys K et al.. “Factors Associated With False-Positive Recalls in Mammography Screening.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 36791753 ↗
L2OTHERCited in: Risk Factors and Prevention - [175]
Lehman CD, Smith RA. “The role of MRI in breast cancer screening.” Journal of the National Comprehensive Cancer Network : JNCCN (2009). PMID: 19930977 ↗
L1REVIEW_NARRATIVECited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Imaging - [176]
Lee JM, Ichikawa L, Su YR et al.. “Comparative Accuracy of Digital Breast Tomosynthesis and Digital Mammography for Surveillance After Breast Cancer Treatment.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 41101341 ↗
L2OTHERCited in: Risk Factors and Prevention - [177]
Halvorsrud K, Fowler H, Hamad W et al.. “Improving Breast Cancer Outcomes by Enhanced Activities in Early Detection and Diagnosis: An Umbrella Review and Meta-Analyses of Randomised Controlled Trials in High-Income Contexts With Universal Healthcare Coverage.” Cancer control : journal of the Moffitt Cancer Center (2026). PMID: 42400473 ↗
L1SR_MA_RCTCited in: Risk Factors and Prevention, Clinical Presentation - [178]
Kim J, Munster PN. “Estrogens and breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 39522613 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention - [179]
Olmos D, Lorente D, Alameda D et al.. “Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 38417742 ↗
L2OTHERCited in: Risk Factors and Prevention - [180]
Van Baelen K, Sawyer E, Van Cauwenberge J et al.. “Clinical challenges and proposed solutions for patients with invasive lobular breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40701440 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Clinical Presentation, Imaging, Staging, Prognosis and Prognostic Factors - [181]
Niravath P. “Aromatase inhibitor-induced arthralgia: a review.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23471104 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Clinical Presentation - [182]
Gluz O, Liedtke C, Gottschalk N et al.. “Triple-negative breast cancer--current status and future directions.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19901010 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention - [183]
Akamandisa MP, Boddicker NJ, Yadav S et al.. “Association of gene variant type and location with breast cancer risk in the general population.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40288678 ↗
L3OTHERCited in: Risk Factors and Prevention, Clinical Presentation - [184]
Shiovitz S, Korde LA. “Genetics of breast cancer: a topic in evolution.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 25605744 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention - [185]
Curigliano G, Spitaleri G, Pietri E et al.. “Breast cancer vaccines: a clinical reality or fairy tale?” Annals of oncology : official journal of the European Society for Medical Oncology (2005). PMID: 16293674 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention - [186]
Hosseini SS, Oreizy HR, Savabi-Esfahani M. “Psychological consequences of mammography screening recommendations: a prospective cohort study in Iran.” BMC psychology (2026). PMID: 42432808 ↗
L2COHORTCited in: Risk Factors and Prevention, History and Evolution of Treatment - [187]
Lucarelli AP, Martins MM, Teruya MM et al.. “Systematic Review and Meta-Analysis: Association Between Circulating and Tissue Levels of Selenium and Zinc and Breast Cancer Risk.” The breast journal (2026). PMID: 42390038 ↗
L1SR_OBSCited in: Risk Factors and Prevention - [188]
Tung N, Lin NU, Kidd J et al.. “Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 26976419 ↗
L4OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Staging, Special Populations - [189]
Yala A, Mikhael PG, Strand F et al.. “Multi-Institutional Validation of a Mammography-Based Breast Cancer Risk Model.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34767469 ↗
L2OTHERCited in: Risk Factors and Prevention - [190]
Wentzensen N, Poole EM, Trabert B et al.. “Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 27325851 ↗
L2OTHERCited in: Risk Factors and Prevention, Histopathology and Molecular Biology - [191]
Paik S, Tang G, Shak S et al.. “Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2006). PMID: 16720680 ↗
L1OTHERCited in: Risk Factors and Prevention - [192]
Allen I, Hassan H, Walburga Y et al.. “Second Primary Cancer Risks After Breast Cancer in BRCA1 and BRCA2 Pathogenic Variant Carriers.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39475295 ↗
L2OTHERCited in: Risk Factors and Prevention - [193]
Phillips KA, Kotsopoulos J, Domchek SM et al.. “Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39356978 ↗
L2OTHERCited in: Risk Factors and Prevention - [194]
Tian R, Wiley B, Liu J et al.. “Clonal Hematopoiesis and Risk of Incident Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 36480766 ↗
L3OTHERCited in: Risk Factors and Prevention - [195]
Mars N, Kerminen S, Tamlander M et al.. “Comprehensive Inherited Risk Estimation for Risk-Based Breast Cancer Screening in Women.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38422475 ↗
L2OTHERCited in: Risk Factors and Prevention - [196]
Jiralerspong S, Goodwin PJ. “Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 27903149 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention - [197]
Robsahm TE, Støer NC, Bø K et al.. “Exercise trajectories and current exercise and risk of breast cancer: a cohort study of 325,953 women who participated in BreastScreen Norway.” Cancer causes & control : CCC (2026). PMID: 42400682 ↗
L2COHORTCited in: Risk Factors and Prevention - [198]
Gheysen M, Punie K, Wildiers H et al.. “Oral SERDs changing the scenery in hormone receptor positive breast cancer, a comprehensive review.” Cancer treatment reviews (2024). PMID: 39293125 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Management Overview - [199]
Qiu P, Yu X, Zheng F et al.. “Advancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications.” Cancer treatment reviews (2025). PMID: 40540857 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Clinical Presentation, Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors - [200]
Calabrese A, von Arx C, Tafuti AA et al.. “Prevention, diagnosis and clinical management of hereditary breast cancer beyond BRCA1/2 genes.” Cancer treatment reviews (2024). PMID: 38870570 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition - [201]
McCartney A, Vignoli A, Biganzoli L et al.. “Metabolomics in breast cancer: A decade in review.” Cancer treatment reviews (2018). PMID: 29775779 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Prognosis and Prognostic Factors - [202]
Nielsen I, Gordon S, Selby A. “Breast cancer-related lymphoedema risk reduction advice: a challenge for health professionals.” Cancer treatment reviews (2008). PMID: 18691823 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention - [203]
Musolino A, Boggiani D, Sikokis A et al.. “Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers.” Cancer treatment reviews (2015). PMID: 26827687 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention - [204]
Venetis K, Invernizzi M, Sajjadi E et al.. “Cellular immunotherapy in breast cancer: The quest for consistent biomarkers.” Cancer treatment reviews (2020). PMID: 32889360 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention - [205]
Albanell J, Ciruelos EM, Lluch A et al.. “Trastuzumab in small tumours and in elderly women.” Cancer treatment reviews (2013). PMID: 23659993 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention - [206]
Müller V, Bachelot T, Curigliano G et al.. “Expert consensus on the prevention of brain metastases in patients with HER2-positive breast cancer.” Cancer treatment reviews (2024). PMID: 39612906 ↗
L1REVIEW_NARRATIVECited in: Risk Factors and Prevention - [207]
Del Re M, Michelucci A, Simi P et al.. “Pharmacogenetics of anti-estrogen treatment of breast cancer.” Cancer treatment reviews (2011). PMID: 21917382 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention - [208]
Shami R, Salgado R, Bardia A et al.. “Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06.” ESMO open (2025). PMID: 40494041 ↗
L4OTHERCited in: Risk Factors and Prevention, Biopsy and Histologic Diagnosis - [209]
Tobias J, Garner-Spitzer E, Drinić M et al.. “Vaccination against Her-2/neu, with focus on peptide-based vaccines.” ESMO open (2022). PMID: 35026721 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention - [210]
Gutzeit A, Dubsky P, Matoori S et al.. “Breast cancer in Switzerland: a comparison between organized-screening versus opportunistic-screening cantons.” ESMO open (2024). PMID: 39321720 ↗
L2OTHERCited in: Risk Factors and Prevention, Staging - [211]
Adams E, Wildiers H, Neven P et al.. “Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.” ESMO open (2021). PMID: 34225076 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention - [212]
Finn E, Sardo Infirri S, Clarke CS et al.. “Li Fraumeni syndrome in the UK: clinical characteristics and outcomes of TP53 carriers.” ESMO open (2025). PMID: 40840234 ↗
L4OTHERCited in: Risk Factors and Prevention, Staging - [213]
Chambers P, Forster MD, Patel A et al.. “Development and validation of a risk score (Delay-7) to predict the occurrence of a treatment delay following cycle 1 chemotherapy.” ESMO open (2022). PMID: 36542904 ↗
L2OTHERCited in: Risk Factors and Prevention - [214]
Innella G, Erini G, De Leo A et al.. “Development of a risk score based on clinical-pathological features to predict the presence of germline BRCA1/2 pathogenic variants in ovarian cancer patients.” ESMO open (2025). PMID: 40580611 ↗
L2OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition - [215]
Maurer C, Tulpin L, Moreau M et al.. “Risk factors for the development of brain metastases in patients with HER2-positive breast cancer.” ESMO open (2018). PMID: 30425844 ↗
L2OTHERCited in: Risk Factors and Prevention - [216]
Fan L, Strasser-Weippl K, Li JJ et al.. “Breast cancer in China.” The Lancet. Oncology (2014). PMID: 24872111 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Clinical Presentation, Management Overview - [217]
Franzoi MA, Agostinetto E, Perachino M et al.. “Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer.” The Lancet. Oncology (2021). PMID: 33891888 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Clinical Presentation, Management Overview, Prognosis and Prognostic Factors - [218]
Denkert C, von Minckwitz G, Darb-Esfahani S et al.. “Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.” The Lancet. Oncology (2017). PMID: 29233559 ↗
L1OTHERCited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [219]
Darby SC, Ewertz M, McGale P et al.. “Risk of ischemic heart disease in women after radiotherapy for breast cancer.” The New England journal of medicine (2013). PMID: 23484825 ↗
L3OTHERCited in: Risk Factors and Prevention - [220]
Hu C, Hart SN, Gnanaolivu R et al.. “A Population-Based Study of Genes Previously Implicated in Breast Cancer.” The New England journal of medicine (2021). PMID: 33471974 ↗
L3OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition - [221]
Welch HG, Prorok PC, O'Malley AJ et al.. “Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness.” The New England journal of medicine (2016). PMID: 27732805 ↗
L2OTHERCited in: Risk Factors and Prevention, Staging - [222]
Chun K, Tran-Dang MP, Cornett P et al.. “Outreach to Native Hawaiian and Pacific Islander communities to increase breast cancer screening and clinical trial awareness.” BMC cancer (2026). PMID: 42420902 ↗
L4TRIAL_NONRANDOMCited in: Risk Factors and Prevention - [223]
Cheng HH, Shevach JW, Castro E et al.. “BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review.” JAMA oncology (2024). PMID: 39052257 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Management Overview - [224]
Goddard KAB, Feuer EJ, Mandelblatt JS et al.. “Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020.” JAMA oncology (2025). PMID: 39636625 ↗
L2OTHERCited in: Risk Factors and Prevention, Special Populations - [225]
Hadizadeh F, Koteci A, Karlsson T et al.. “Hormonal Contraceptive Formulations and Breast Cancer Risk in Adolescents and Premenopausal Women.” JAMA oncology (2025). PMID: 41165687 ↗
L2OTHERCited in: Risk Factors and Prevention, Clinical Presentation - [226]
Hansford S, Kaurah P, Li-Chang H et al.. “Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond.” JAMA oncology (2015). PMID: 26182300 ↗
L2OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers, Special Populations - [227]
Lubinski J, Kotsopoulos J, Moller P et al.. “MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations.” JAMA oncology (2024). PMID: 38421676 ↗
L2OTHERCited in: Risk Factors and Prevention, Imaging, Special Populations - [228]
Bolze A, Cirulli ET, Hajek C et al.. “The Potential of Genetics in Identifying Women at Lower Risk of Breast Cancer.” JAMA oncology (2024). PMID: 38153744 ↗
L2OTHERCited in: Risk Factors and Prevention, Clinical Presentation - [229]
O'Brien KM, Keil AP, Taylor JA et al.. “Pathogenic Variants, Family History, and Cumulative Risk of Breast Cancer in US Women.” JAMA oncology (2025). PMID: 41066089 ↗
L3OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition - [230]
Fitzmaurice C, Allen C, Barber RM et al.. “Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study.” JAMA oncology (2017). PMID: 27918777 ↗
L2OTHERCited in: Risk Factors and Prevention, Clinical Presentation - [231]
Wei X, Mansour L, Oxley S et al.. “Defining Lifetime Risk Thresholds for Breast Cancer Surgical Prevention.” JAMA oncology (2025). PMID: 40705362 ↗
L5OTHERCited in: Risk Factors and Prevention - [232]
Zhang Y, Rodriguez J, Mao X et al.. “Incidence and Risk Factors of Interval and Screen-Detected Breast Cancer.” JAMA oncology (2025). PMID: 40146116 ↗
L2OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition - [233]
Brantley KD, Rosenberg SM, Collins LC et al.. “Second Primary Breast Cancer in Young Breast Cancer Survivors.” JAMA oncology (2024). PMID: 38602683 ↗
L2OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition - [234]
Barac A, Chou J, Shara N et al.. “Risk Prediction Model for Development of Heart Failure or Cardiomyopathy After Breast Cancer Treatment.” JAMA oncology (2025). PMID: 41129144 ↗
L2OTHERCited in: Risk Factors and Prevention - [235]
Li T, Su YR, Lee JM et al.. “Tomosynthesis vs Digital Mammography Screening in Women with a Family History of Breast Cancer.” JAMA oncology (2025). PMID: 40402477 ↗
L2OTHERCited in: Risk Factors and Prevention - [236]
Aftimos P, Oliveira M, Irrthum A et al.. “Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative.” Cancer discovery (2021). PMID: 34183353 ↗
L4OTHERCited in: Risk Factors and Prevention, Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers - [237]
Neill NJ, Satpathy S, Krug K et al.. “Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer.” Cancer discovery (2025). PMID: 40778818 ↗
L5OTHERCited in: Risk Factors and Prevention - [238]
Langille E, Al-Zahrani KN, Ma Z et al.. “Loss of Epigenetic Regulation Disrupts Lineage Integrity, Induces Aberrant Alveogenesis, and Promotes Breast Cancer.” Cancer discovery (2022). PMID: 36108220 ↗
L5OTHERCited in: Risk Factors and Prevention - [239]
Brough R, Frankum JR, Sims D et al.. “Functional viability profiles of breast cancer.” Cancer discovery (2011). PMID: 21984977 ↗
L5OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition - [240]
Vijai J, Topka S, Villano D et al.. “A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer.” Cancer discovery (2016). PMID: 27655433 ↗
L3OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Special Populations - [241]
. “Q&A: Olufunmilayo Olopade on Genomics and Breast Cancer.” Cancer discovery (2020). PMID: 32051175 ↗
L5OTHERCited in: Risk Factors and Prevention - [242]
. “Hormone levels predict long-term breast cancer risk.” Cancer discovery (2012). PMID: 23230205 ↗
L5OTHERCited in: Risk Factors and Prevention - [243]
Liao C, Zhang Y, Fan C et al.. “Identification of BBOX1 as a Therapeutic Target in Triple-Negative Breast Cancer.” Cancer discovery (2020). PMID: 32690540 ↗
L5OTHERCited in: Risk Factors and Prevention - [244]
Littlepage LE, Adler AS, Kouros-Mehr H et al.. “The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression.” Cancer discovery (2012). PMID: 22728437 ↗
L5OTHERCited in: Risk Factors and Prevention - [245]
. “3D imaging finds more breast cancers.” Cancer discovery (2014). PMID: 25185169 ↗
L5OTHERCited in: Risk Factors and Prevention, Imaging - [246]
Chin YR, Yuan X, Balk SP et al.. “PTEN-deficient tumors depend on AKT2 for maintenance and survival.” Cancer discovery (2014). PMID: 24838891 ↗
L5OTHERCited in: Risk Factors and Prevention - [247]
Yang Z, Liu X, Zhu J et al.. “Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1.” Cancer cell (2024). PMID: 39672166 ↗
L5OTHERCited in: Risk Factors and Prevention, Management Overview - [248]
Goddard ET, Linde MH, Srivastava S et al.. “Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies.” Cancer cell (2024). PMID: 38194912 ↗
L5OTHERCited in: Risk Factors and Prevention - [249]
Polyak K. “Pregnancy and breast cancer: the other side of the coin.” Cancer cell (2006). PMID: 16530699 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Special Populations - [250]
Hutten SJ, de Bruijn R, Lutz C et al.. “A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression.” Cancer cell (2023). PMID: 37116492 ↗
L5OTHERCited in: Risk Factors and Prevention, History and Evolution of Treatment - [251]
Visvader JE. “Midkine links aging with breast cancer-A new predictor of cancer risk.” Cancer cell (2024). PMID: 39366374 ↗
L5OTHERCited in: Risk Factors and Prevention - [252]
Geuijen CAW, De Nardis C, Maussang D et al.. “Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade.” Cancer cell (2018). PMID: 29763625 ↗
L5OTHERCited in: Risk Factors and Prevention - [253]
Lu J, Guo H, Treekitkarnmongkol W et al.. “14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition.” Cancer cell (2009). PMID: 19732720 ↗
L5OTHERCited in: Risk Factors and Prevention - [254]
Fennell NB, Abukar S, Kuhn I et al.. “Experiences of implementation of personalised risk estimates for breast cancer in clinical practice: a systematic review and qualitative synthesis.” Journal of community genetics (2026). PMID: 42405977 ↗
L2SR_OBSCited in: Risk Factors and Prevention, History and Evolution of Treatment - [255]
Medford AJ, Moy B, Spring LM et al.. “Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 37477704 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Management Overview - [256]
Schneider BP, Winer EP, Foulkes WD et al.. “Triple-negative breast cancer: risk factors to potential targets.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 19088017 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Histopathology and Molecular Biology - [257]
Griguolo G, Bottosso M, Landa G et al.. “Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41661219 ↗
L4OTHERCited in: Risk Factors and Prevention - [258]
Jilderda MF, Zhang Y, Rebattu V et al.. “Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40145943 ↗
L2OTHERCited in: Risk Factors and Prevention - [259]
Barber L, Gerke T, Markt SC et al.. “Family History of Breast or Prostate Cancer and Prostate Cancer Risk.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 30082473 ↗
L2OTHERCited in: Risk Factors and Prevention - [260]
Howard FM, Fasching PA, Santa-Maria CA et al.. “Machine Learning-Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2- Early Breast Cancer Using Real-World and NATALEE Data.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41213110 ↗
L3OTHERCited in: Risk Factors and Prevention - [261]
Thursby SJ, Jin Z, Blum J et al.. “Epigenetic Instability-Based Metrics in Cell-Free DNA for Early Cancer Detection.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41591979 ↗
L3OTHERCited in: Risk Factors and Prevention - [262]
Turner NC, Reis-Filho JS. “Tackling the diversity of triple-negative breast cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2013). PMID: 24298068 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Histopathology and Molecular Biology - [263]
Miller SM, Roussi P, Daly MB et al.. “New strategies in ovarian cancer: uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2010). PMID: 20829330 ↗
L2REVIEW_NARRATIVECited in: Risk Factors and Prevention - [264]
Brand JS, Hedayati E, Humphreys K et al.. “Chemotherapy, Genetic Susceptibility, and Risk of Venous Thromboembolism in Breast Cancer Patients.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27803117 ↗
L2OTHERCited in: Risk Factors and Prevention - [265]
Sangi Nasab Lahijan A, Abdollahi S, Miri SR et al.. “Circulating Plasma Circular RNAs hsa_circ_0001785 and hsa_circ_0079876 as Promising Noninvasive Diagnostic Biomarkers for Breast Cancer: A Case-Control Study.” The breast journal (2026). PMID: 42402856 ↗
L3CASE_CONTROLCited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers - [266]
Houssa N, Abdelalim S, Elmouki I. “Algebraic evaluation of optimization in tumors classification with numerical assessments via a flask-react web interface.” Frontiers in digital health (2026). PMID: 42434374 ↗
L5OTHERCited in: Risk Factors and Prevention - [267]
Sheppard AJ, Sutradhar R, Liu N et al.. “Population-Level Outcomes for Screening Program Cancers in First Nations People in Ontario, Canada.” JAMA network open (2026). PMID: 42430169 ↗
L3OTHERCited in: Risk Factors and Prevention - [268]
Comeaux JG, Gutierrez N, Ricker CN et al.. “Breast cancer screening adherence after multigene panel testing among women with pathogenic variants in moderate-risk genes or with empirically increased breast cancer risk.” Breast cancer research and treatment (2026). PMID: 42430009 ↗
L4OTHERCited in: Risk Factors and Prevention, Imaging - [269]
Mühlhausen L, Kocher M, Karadachi HH et al.. “Leptomeningeal disease (LMD) after resection of brain metastases: results of the multicenter SUBAROMA study.” Journal of neuro-oncology (2026). PMID: 42429857 ↗
L3OTHERCited in: Risk Factors and Prevention, Imaging, Management Overview - [270]
Lundorff CMB, Njor SH, Madsen SL et al.. “Socioeconomic variation in adherence to follow-up after an abnormal screening mammogram in the Danish breast cancer screening program.” Breast cancer research and treatment (2026). PMID: 42423753 ↗
L3OTHERCited in: Risk Factors and Prevention - [271]
Telli ML, Gradishar WJ, Ward JH. “NCCN Guidelines Updates: Breast Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31117035 ↗
L1GUIDELINECited in: Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment - [272]
Carlson RW, Moench SJ, Hammond ME et al.. “HER2 testing in breast cancer: NCCN Task Force report and recommendations.” Journal of the National Comprehensive Cancer Network : JNCCN (2006). PMID: 16813731 ↗
L5GUIDELINECited in: Genetics and Hereditary Predisposition, Clinical Presentation, Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers - [273]
Hassett MJ, Somerfield MR, Baker ER et al.. “Management of Male Breast Cancer: ASCO Guideline.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32058842 ↗
L1GUIDELINECited in: Genetics and Hereditary Predisposition, Imaging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors - [274]
Bedrosian I, Somerfield MR, Achatz MI et al.. “Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38175972 ↗
L1GUIDELINECited in: Genetics and Hereditary Predisposition - [275]
Henry NL, Somerfield MR, Dayao Z et al.. “Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35759724 ↗
L1GUIDELINECited in: Genetics and Hereditary Predisposition, History and Evolution of Treatment - [276]
Blair VR, McLeod M, Carneiro F et al.. “Hereditary diffuse gastric cancer: updated clinical practice guidelines.” The Lancet. Oncology (2020). PMID: 32758476 ↗
L5GUIDELINECited in: Genetics and Hereditary Predisposition, Management Overview, History and Evolution of Treatment - [277]
Geyer CE, Garber JE, Gelber RD et al.. “Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2022). PMID: 36228963 ↗
L1RCTCited in: Genetics and Hereditary Predisposition, History and Evolution of Treatment - [278]
Robson ME, Tung N, Conte P et al.. “OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 30689707 ↗
L1RCTCited in: Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors, Special Populations - [279]
Bardia A, Tolaney SM, Punie K et al.. “Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2021). PMID: 34116144 ↗
L1RCTCited in: Genetics and Hereditary Predisposition, Biopsy and Histologic Diagnosis - [280]
Litton JK, Hurvitz SA, Mina LA et al.. “Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 32828825 ↗
L1RCTCited in: Genetics and Hereditary Predisposition - [281]
Crimini E, Repetto M, Aftimos P et al.. “Precision medicine in breast cancer: From clinical trials to clinical practice.” Cancer treatment reviews (2021). PMID: 34049187 ↗
L5TRIAL_NONRANDOMCited in: Genetics and Hereditary Predisposition - [282]
Schettini F, Venturini S, Giuliano M et al.. “Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer.” Cancer treatment reviews (2022). PMID: 36202026 ↗
L1SR_OBSCited in: Genetics and Hereditary Predisposition - [283]
Ng T, Chan M, Khor CC et al.. “The genetic variants underlying breast cancer treatment-induced chronic and late toxicities: a systematic review.” Cancer treatment reviews (2014). PMID: 25458605 ↗
L2SR_OBSCited in: Genetics and Hereditary Predisposition - [284]
Zhang B, Beeghly-Fadiel A, Long J et al.. “Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence.” The Lancet. Oncology (2011). PMID: 21514219 ↗
L3SR_OBSCited in: Genetics and Hereditary Predisposition - [285]
Morgan AJ, Giannoudis A, Palmieri C. “The genomic landscape of breast cancer brain metastases: a systematic review.” The Lancet. Oncology (2021). PMID: 33387511 ↗
L2SR_OBSCited in: Genetics and Hereditary Predisposition, Biopsy and Histologic Diagnosis - [286]
Rowlands CF, Allen S, Balmaña J et al.. “Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 38986768 ↗
L3SR_OBSCited in: Genetics and Hereditary Predisposition - [287]
Tichy JR, Lim E, Anders CK. “Breast cancer in adolescents and young adults: a review with a focus on biology.” Journal of the National Comprehensive Cancer Network : JNCCN (2013). PMID: 24029122 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Clinical Presentation - [288]
Lyons TG, Robson ME. “Resurrection of PARP Inhibitors in Breast Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30181424 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Staging, Prognosis and Prognostic Factors - [289]
Goncalves R, Bose R. “Using multigene tests to select treatment for early-stage breast cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2013). PMID: 23411384 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition - [290]
Reid S, Spalluto L, Pal T. “Breast Cancer Risk Stratification in Black Women: Current Status and Potential Solutions to Improve Accuracy.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 41671467 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition - [291]
Domchek SM, Stopfer JE, Rebbeck TR. “Bilateral risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers.” Journal of the National Comprehensive Cancer Network : JNCCN (2006). PMID: 16451773 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition - [292]
Cho EH, Kim JY, Im SA et al.. “Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11).” ESMO open (2021). PMID: 34438242 ↗
L1RCTCited in: Genetics and Hereditary Predisposition - [293]
Loibl S, O'Shaughnessy J, Untch M et al.. “Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.” The Lancet. Oncology (2018). PMID: 29501363 ↗
L1RCTCited in: Genetics and Hereditary Predisposition - [294]
Li H, Liu J, Ouyang Q et al.. “Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial.” The Lancet. Oncology (2025). PMID: 41308673 ↗
L1RCTCited in: Genetics and Hereditary Predisposition - [295]
Tutt ANJ, Garber JE, Kaufman B et al.. “Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.” The New England journal of medicine (2021). PMID: 34081848 ↗
L1RCTCited in: Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers - [296]
Robson M, Im SA, Senkus E et al.. “Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.” The New England journal of medicine (2017). PMID: 28578601 ↗
L1RCTCited in: Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers - [297]
Litton JK, Rugo HS, Ettl J et al.. “Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.” The New England journal of medicine (2018). PMID: 30110579 ↗
L1RCTCited in: Genetics and Hereditary Predisposition - [298]
Cardoso F, van't Veer LJ, Bogaerts J et al.. “70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.” The New England journal of medicine (2016). PMID: 27557300 ↗
L1RCTCited in: Genetics and Hereditary Predisposition, Histopathology and Molecular Biology, Staging - [299]
Tung NM, Robson ME, Ventz S et al.. “TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 33119476 ↗
L4TRIAL_NONRANDOMCited in: Genetics and Hereditary Predisposition - [300]
Kaufman B, Shapira-Frommer R, Schmutzler RK et al.. “Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 25366685 ↗
L4TRIAL_NONRANDOMCited in: Genetics and Hereditary Predisposition, Prognosis and Prognostic Factors - [301]
Toss A, Blondeaux E, Tenedini E et al.. “Association between type and location of germline BRCA1/2 pathogenic or likely pathogenic variants with phenotype and prognosis in young patients with breast cancer: results from an international cohort study.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 41260260 ↗
L2COHORTCited in: Genetics and Hereditary Predisposition - [302]
Chen S, Parmigiani G. “Meta-analysis of BRCA1 and BRCA2 penetrance.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17416853 ↗
L1SR_OBSCited in: Genetics and Hereditary Predisposition - [303]
Yu KD, Ye FG, He M et al.. “Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.” JAMA oncology (2020). PMID: 32789480 ↗
L1RCTCited in: Genetics and Hereditary Predisposition, Prognosis and Prognostic Factors - [304]
Boni V, Pistilli B, Braña I et al.. “Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study.” ESMO open (2022). PMID: 36037567 ↗
L4TRIAL_NONRANDOMCited in: Genetics and Hereditary Predisposition - [305]
Ródon J, Arkenau HT, Funchain P et al.. “A phase II study of the AKT inhibitor TAS-117 in patients with advanced solid tumors and germline PTEN mutations.” ESMO open (2025). PMID: 41475241 ↗
L4TRIAL_NONRANDOMCited in: Genetics and Hereditary Predisposition - [306]
Van Baelen K, Geukens T, Maetens M et al.. “Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2022). PMID: 35605746 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Clinical Presentation, Biopsy and Histologic Diagnosis, Prognosis and Prognostic Factors - [307]
Lynch HT, Snyder C, Casey MJ. “Hereditary ovarian and breast cancer: what have we learned?” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 24131978 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition - [308]
Rizzolo P, Silvestri V, Tommasi S et al.. “Male breast cancer: genetics, epigenetics, and ethical aspects.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 24131976 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition - [309]
Cooper BT, Murphy JO, Sacchini V et al.. “Local approaches to hereditary breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 24131971 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition - [310]
Paradiso A, Formenti S. “Hereditary breast cancer: clinical features and risk reduction strategies.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21285148 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition - [311]
. “Olaparib Keeps Hereditary Breast Tumors in Check.” Cancer discovery (2017). PMID: 28583909 ↗
L5TRIAL_NONRANDOMCited in: Genetics and Hereditary Predisposition - [312]
Vora SR, Juric D, Kim N et al.. “CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.” Cancer cell (2014). PMID: 25002028 ↗
L5TRIAL_NONRANDOMCited in: Genetics and Hereditary Predisposition - [313]
Fasching PA, Schmatloch S, Hauke J et al.. “Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD-Long-term Survival of the GeparOLA Study.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39998850 ↗
L1RCTCited in: Genetics and Hereditary Predisposition - [314]
Blondeaux E, Sonnenblick A, Agostinetto E et al.. “Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study.” The Lancet. Oncology (2025). PMID: 40347973 ↗
L2COHORTCited in: Genetics and Hereditary Predisposition, Clinical Presentation - [315]
Saad M, Mokrab Y, Halabi N et al.. “Genetic predisposition to cancer across people of different ancestries in Qatar: a population-based, cohort study.” The Lancet. Oncology (2022). PMID: 35150601 ↗
L2COHORTCited in: Genetics and Hereditary Predisposition - [316]
Manchanda R, Sun L, Sobocan M et al.. “Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 38866043 ↗
L2OTHERCited in: Genetics and Hereditary Predisposition - [317]
Nielsen SM, Russell EM, Ellsworth RE et al.. “Utilization of Cancer Screening, Prevention, and Treatment in Women With Variants of Uncertain Significance in Breast Cancer Susceptibility Genes.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 40306323 ↗
L2OTHERCited in: Genetics and Hereditary Predisposition - [318]
Lynce F, Graham N, Kochupurakkal BS et al.. “A Phase Ib Study of Sapacitabine and Olaparib in Patients with BRCA1/2-Mutated Metastatic Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41335237 ↗
L4TRIAL_NONRANDOMCited in: Genetics and Hereditary Predisposition - [319]
Guiu S, Balmaña J, Lemercier P et al.. “Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2- Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40986529 ↗
L4TRIAL_NONRANDOMCited in: Genetics and Hereditary Predisposition - [320]
Pensabene M, Calabrese A, von Arx C et al.. “Cancer genetic counselling for hereditary breast cancer in the era of precision oncology.” Cancer treatment reviews (2024). PMID: 38452709 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Clinical Presentation, Management Overview - [321]
Blondeaux E, Arecco L, Punie K et al.. “Germline TP53 pathogenic variants and breast cancer: A narrative review.” Cancer treatment reviews (2023). PMID: 36739824 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition - [322]
Economopoulou P, Dimitriadis G, Psyrri A. “Beyond BRCA: new hereditary breast cancer susceptibility genes.” Cancer treatment reviews (2014). PMID: 25467110 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, History and Evolution of Treatment - [323]
Lambertini M, Goldrat O, Toss A et al.. “Fertility and pregnancy issues in BRCA-mutated breast cancer patients.” Cancer treatment reviews (2017). PMID: 28750297 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Clinical Presentation, Special Populations - [324]
Serpico D, Molino L, Di Cosimo S. “microRNAs in breast cancer development and treatment.” Cancer treatment reviews (2013). PMID: 24286642 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Prognosis and Prognostic Factors, Special Populations - [325]
Kamaraju S, Conroy M, Harris A et al.. “Challenges to genetic testing for germline mutations associated with breast cancer among African Americans.” Cancer treatment reviews (2024). PMID: 38325071 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition - [326]
Amir E, Seruga B, Serrano R et al.. “Targeting DNA repair in breast cancer: a clinical and translational update.” Cancer treatment reviews (2010). PMID: 20385443 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition - [327]
Yap YS. “Outcomes in breast cancer-does ethnicity matter?” ESMO open (2023). PMID: 37290358 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Clinical Presentation - [328]
Mazzeo R, Sears J, Palmero L et al.. “Liquid biopsy in triple-negative breast cancer: unlocking the potential of precision oncology.” ESMO open (2024). PMID: 39288656 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Biopsy and Histologic Diagnosis - [329]
Loong HH, Shimizu T, Prawira A et al.. “Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group.” ESMO open (2023). PMID: 37356359 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition - [330]
Huntley C, Torr B, Sud A et al.. “Utility of polygenic risk scores in UK cancer screening: a modelling analysis.” The Lancet. Oncology (2023). PMID: 37178708 ↗
L2REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition - [331]
Brewster AM, Chavez-MacGregor M, Brown P. “Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry.” The Lancet. Oncology (2014). PMID: 25456381 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition - [332]
Even-Sapir E, Inbar M. “PET in women with high risk for breast or ovarian cancer.” The Lancet. Oncology (2010). PMID: 20615754 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Imaging - [333]
D'Andrea AD. “Susceptibility pathways in Fanconi's anemia and breast cancer.” The New England journal of medicine (2010). PMID: 20484397 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition - [334]
Khan S, Fagerholm R, Rafiq S et al.. “Polymorphism at 19q13.41 Predicts Breast Cancer Survival Specifically after Endocrine Therapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 25964295 ↗
L2SR_OBSCited in: Genetics and Hereditary Predisposition - [335]
Morganti S, Marra A, De Angelis C et al.. “PARP Inhibitors for Breast Cancer Treatment: A Review.” JAMA oncology (2024). PMID: 38512229 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Management Overview, Prognosis and Prognostic Factors - [336]
Tarantino P, Hortobagyi G, Tolaney SM et al.. “Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer: A Review.” JAMA oncology (2024). PMID: 39264638 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition - [337]
Moasser MM, Krop IE. “The Evolving Landscape of HER2 Targeting in Breast Cancer.” JAMA oncology (2015). PMID: 26204261 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition - [338]
Moser SC, Jonkers J. “Thirty Years of BRCA1: Mechanistic Insights and Their Impact on Mutation Carriers.” Cancer discovery (2025). PMID: 40025950 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, History and Evolution of Treatment - [339]
Alix-Panabières C, Pantel K. “Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.” Cancer discovery (2016). PMID: 26969689 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Biopsy and Histologic Diagnosis, Prognosis and Prognostic Factors - [340]
Liang H. “More reliable breast cancer risk assessment for every woman.” Cancer cell (2021). PMID: 33740422 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition - [341]
Seefat RL, Vliek SB, de Jong VMT et al.. “Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.” The Lancet. Oncology (2026). PMID: 42372741 ↗
L1RCTCited in: Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers, Staging, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations - [342]
Bhattacharyya S, Thomas JV, Prasad A et al.. “Genomic landscape of triple-negative breast cancer in South Asian populations: a systematic review.” BMC cancer (2026). PMID: 42402565 ↗
L2SR_OBSCited in: Genetics and Hereditary Predisposition - [343]
Li S, Silvestri V, Leslie G et al.. “Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35077220 ↗
L2OTHERCited in: Genetics and Hereditary Predisposition - [344]
Bougeard G, Renaux-Petel M, Flaman JM et al.. “Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 26014290 ↗
L4OTHERCited in: Genetics and Hereditary Predisposition, Clinical Presentation - [345]
Yadav S, Boddicker NJ, Na J et al.. “Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36623243 ↗
L2OTHERCited in: Genetics and Hereditary Predisposition, Clinical Presentation - [346]
Couch FJ, Hart SN, Sharma P et al.. “Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 25452441 ↗
L4OTHERCited in: Genetics and Hereditary Predisposition, Clinical Presentation - [347]
Espenschied CR, LaDuca H, Li S et al.. “Multigene Panel Testing Provides a New Perspective on Lynch Syndrome.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28514183 ↗
L4OTHERCited in: Genetics and Hereditary Predisposition - [348]
Garcia-Closas M, Chanock S. “Genetic susceptibility loci for breast cancer by estrogen receptor status.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 19088016 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition - [349]
Gorski JJ, Kennedy RD, Hosey AM et al.. “The complex relationship between BRCA1 and ERalpha in hereditary breast cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2009). PMID: 19223511 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition - [350]
Lee KL, Yam C, Zhao L et al.. “Non-BRCA germline pathogenic variants and response to neoadjuvant systemic therapy in triple-negative breast cancer patients enrolled in a prospective clinical trial.” Breast cancer research and treatment (2026). PMID: 42223695 ↗
L2TRIAL_NONRANDOMCited in: Genetics and Hereditary Predisposition - [351]
Sawyer SL, Tian L, Kähkönen M et al.. “Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype.” Cancer discovery (2014). PMID: 25472942 ↗
L4CASE_REPORTCited in: Genetics and Hereditary Predisposition - [352]
Katz ML, Schnell PM, Reiter PL et al.. “Knowledge of cancer genetics and attitudes about genetic counseling and testing: a randomized trial of the Know Your Risk intervention compared to conventional genetic counseling.” Cancer causes & control : CCC (2026). PMID: 42377622 ↗
L1RCTCited in: Genetics and Hereditary Predisposition, History and Evolution of Treatment - [353]
Luo WS, Shi A, Wang Z et al.. “Association between ERCC5 gene rs17655 polymorphism and the risk of breast cancer: an updated meta-analysis.” Environmental health and preventive medicine (2026). PMID: 42386575 ↗
L1SR_OBSCited in: Genetics and Hereditary Predisposition - [354]
Rodriguez-Hernandez A, Martínez-Sáez O, Brasó-Maristany F et al.. “Prevalence and clinical impact of germline pathogenic variants in breast cancer: a descriptive large single-center study.” ESMO open (2025). PMID: 40209283 ↗
L4OTHERCited in: Genetics and Hereditary Predisposition - [355]
Agostinetto E, Bruzzone M, Hamy AS et al.. “Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology.” ESMO open (2024). PMID: 39288653 ↗
L2OTHERCited in: Genetics and Hereditary Predisposition, Histopathology and Molecular Biology - [356]
Sánchez-Bayona R, de Nicolás-Hernández J, Saura C et al.. “Analysis of UGT1A1 germline variants in patients with advanced breast cancer treated with trastuzumab-deruxtecan: results from the PROCURE Project.” ESMO open (2026). PMID: 42114485 ↗
L2OTHERCited in: Genetics and Hereditary Predisposition - [357]
Perachino M, Blondeaux E, Delucchi V et al.. “Safety of having a subsequent pregnancy after prior diagnosis of breast cancer during pregnancy in young BRCA carriers.” ESMO open (2025). PMID: 40811881 ↗
L2OTHERCited in: Genetics and Hereditary Predisposition - [358]
Incorvaia L, Marchetti C, Brando C et al.. “BRCA functional domains associated with high risk of multiple primary tumors and domain-related sensitivity to olaparib: the Prometheus Study.” ESMO open (2025). PMID: 39847877 ↗
L2OTHERCited in: Genetics and Hereditary Predisposition - [359]
Dorling L, Carvalho S, Allen J et al.. “Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women.” The New England journal of medicine (2021). PMID: 33471991 ↗
L3OTHERCited in: Genetics and Hereditary Predisposition - [360]
Antoniou AC, Casadei S, Heikkinen T et al.. “Breast-cancer risk in families with mutations in PALB2.” The New England journal of medicine (2014). PMID: 25099575 ↗
L2OTHERCited in: Genetics and Hereditary Predisposition - [361]
Patocs A, Zhang L, Xu Y et al.. “Breast-cancer stromal cells with TP53 mutations and nodal metastases.” The New England journal of medicine (2007). PMID: 18094375 ↗
L2OTHERCited in: Genetics and Hereditary Predisposition - [362]
Shen X, Yang J, Du Y et al.. “Adjuvant chemotherapy combined with pembrolizumab immunotherapy for primary triple-negative neuroendocrine carcinoma of the breast: a case report and literature review.” Frontiers in immunology (2026). PMID: 42327776 ↗
L4CASE_REPORTCited in: Genetics and Hereditary Predisposition, Biopsy and Histologic Diagnosis, Imaging - [363]
Bychkovsky BL, Agaoglu NB, Horton C et al.. “Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care-Checking CHEK2.” JAMA oncology (2022). PMID: 36136322 ↗
L2OTHERCited in: Genetics and Hereditary Predisposition, Clinical Presentation - [364]
Rodriguez J, Grassmann F, Xiao Q et al.. “Investigation of Genetic Alterations Associated With Interval Breast Cancer.” JAMA oncology (2024). PMID: 38270937 ↗
L3OTHERCited in: Genetics and Hereditary Predisposition - [365]
Couch FJ, Shimelis H, Hu C et al.. “Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.” JAMA oncology (2017). PMID: 28418444 ↗
L3OTHERCited in: Genetics and Hereditary Predisposition - [366]
. “Tumor Profiling: Adding Proteomics to Genomics.” Cancer discovery (2016). PMID: 27354270 ↗
L5OTHERCited in: Genetics and Hereditary Predisposition - [367]
. “Metastatic ER+ Breast Cancer's Genomic Landscape.” Cancer discovery (2016). PMID: 27974416 ↗
L4OTHERCited in: Genetics and Hereditary Predisposition - [368]
. “PROMPT to detail breast cancer risk.” Cancer discovery (2014). PMID: 25477092 ↗
L5OTHERCited in: Genetics and Hereditary Predisposition - [369]
Park DJ, Tao K, Le Calvez-Kelm F et al.. “Rare mutations in RINT1 predispose carriers to breast and Lynch syndrome-spectrum cancers.” Cancer discovery (2014). PMID: 25050558 ↗
L3OTHERCited in: Genetics and Hereditary Predisposition - [370]
. “Breast cancer susceptibility genes pile up.” Cancer discovery (2015). PMID: 25851858 ↗
L5OTHERCited in: Genetics and Hereditary Predisposition - [371]
. “First PARP Inhibitor Ok'd for Breast Cancer.” Cancer discovery (2018). PMID: 29382645 ↗
L5OTHERCited in: Genetics and Hereditary Predisposition - [372]
Lin CJ, Jin X, Ma D et al.. “Genetic interactions reveal distinct biological and therapeutic implications in breast cancer.” Cancer cell (2024). PMID: 38593782 ↗
L2OTHERCited in: Genetics and Hereditary Predisposition, Prognosis and Prognostic Factors - [373]
Berger AC, Korkut A, Kanchi RS et al.. “A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.” Cancer cell (2018). PMID: 29622464 ↗
L4OTHERCited in: Genetics and Hereditary Predisposition, Prognosis and Prognostic Factors - [374]
Walsh T, King MC. “Ten genes for inherited breast cancer.” Cancer cell (2007). PMID: 17292821 ↗
L5OTHERCited in: Genetics and Hereditary Predisposition - [375]
Drost R, Bouwman P, Rottenberg S et al.. “BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.” Cancer cell (2011). PMID: 22172724 ↗
L5OTHERCited in: Genetics and Hereditary Predisposition - [376]
Knappskog S, Bjørnslett M, Myklebust LM et al.. “The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians.” Cancer cell (2011). PMID: 21316605 ↗
L3OTHERCited in: Genetics and Hereditary Predisposition, Clinical Presentation - [377]
Wan L, Lu X, Yuan S et al.. “MTDH-SND1 interaction is crucial for expansion and activity of tumor-initiating cells in diverse oncogene- and carcinogen-induced mammary tumors.” Cancer cell (2014). PMID: 24981741 ↗
L5OTHERCited in: Genetics and Hereditary Predisposition - [378]
Nevins JR. “New breast cancer genes-discovery at the intersection of complex data sets.” Cancer cell (2007). PMID: 18068627 ↗
L5OTHERCited in: Genetics and Hereditary Predisposition - [379]
Le J, Madlensky L, Retson TA et al.. “Genetics, Screening, and Risk-reducing Interventions for Breast Cancer.” The Surgical clinics of North America (2026). PMID: 42419307 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition - [380]
Etessami JD, Dalla Via G, Ferraro E et al.. “Treatment of breast cancer brain metastases in the era of novel drugs.” Cancer treatment reviews (2026). PMID: 42372577 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition - [381]
McDermott E, Khalili K, Kim TK et al.. “Stomach and beyond: imaging the linitis plastica phenotype in signet ring cell carcinoma.” Abdominal radiology (New York) (2026). PMID: 42360344 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition - [382]
Robaczyńska J, Kiljańczyk M, Maj M et al.. “The Potential Role of Vitamin D in BRCA1 Pathogenic Variant Carriers: A Narrative Review.” International journal of molecular sciences (2026). PMID: 42353259 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition - [383]
Widschwendter M, Schmutzler R, Pashayan N et al.. “Individualised progesterone receptor modulator prevention strategies for triple-negative breast cancer in BRCA1 pathogenic variant carriers.” NPJ breast cancer (2026). PMID: 42350451 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition - [384]
Rodriguez J, Grassmann F, Kaukonen D et al.. “Blood DNA methylation and breast cancer risk: a prospective nested case-control study.” EBioMedicine (2026). PMID: 42349257 ↗
L3CASE_CONTROLCited in: Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers - [385]
Sun J, Meng H, Yao L et al.. “Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28724667 ↗
L4OTHERCited in: Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers, Staging, Prognosis and Prognostic Factors - [386]
Hanenberg H, Zhang F, Malev N et al.. “Reclassification of ATM Missense Variants of Uncertain Significance by Integrating Results from Systematic Functional Assays into an ACMG Points-Based Framework.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40105422 ↗
L5OTHERCited in: Genetics and Hereditary Predisposition - [387]
Turner NC, Balmaña J, Poncet C et al.. “Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 34301749 ↗
L1OTHERCited in: Genetics and Hereditary Predisposition - [388]
Waks AG, Kim D, Jain E et al.. “Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 35101884 ↗
L2OTHERCited in: Genetics and Hereditary Predisposition - [389]
Huang H, Couch RE, Karam R et al.. “Pathogenic Variants in Cancer Susceptibility Genes Predispose to Ductal Carcinoma In Situ of the Breast.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39513960 ↗
L3OTHERCited in: Genetics and Hereditary Predisposition - [390]
Jhaveri K, Eli LD, Wildiers H et al.. “Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 37597578 ↗
L2RCTCited in: Histopathology and Molecular Biology - [391]
Huppert LA, Wolf D, Yau C et al.. “Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 39477071 ↗
L1RCTCited in: Histopathology and Molecular Biology, Staging - [392]
Houssami N, Ciatto S, Macaskill P et al.. “Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18474876 ↗
L1SR_OBSCited in: Histopathology and Molecular Biology - [393]
Yang JT, Wijetunga NA, Pentsova E et al.. “Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35802849 ↗
L1RCTCited in: Histopathology and Molecular Biology - [394]
Zhang H, Zhang N, Moran MS et al.. “Special subtypes with favorable prognosis in breast cancer: A registry-based cohort study and network meta-analysis.” Cancer treatment reviews (2020). PMID: 33075683 ↗
L2SR_OBSCited in: Histopathology and Molecular Biology, Special Populations - [395]
Trapani D, Gandini S, Corti C et al.. “Benefit of adjuvant chemotherapy in patients with lobular breast cancer: A systematic review of the literature and metanalysis.” Cancer treatment reviews (2021). PMID: 33878560 ↗
L1SR_OBSCited in: Histopathology and Molecular Biology - [396]
Blok EJ, Bastiaannet E, van den Hout WB et al.. “Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe.” Cancer treatment reviews (2017). PMID: 29175678 ↗
L2SR_OBSCited in: Histopathology and Molecular Biology - [397]
Costa R, Gill N, Rademaker AW et al.. “Systematic analysis of early phase clinical studies for patients with breast cancer: Inclusion of patients with brain metastasis.” Cancer treatment reviews (2017). PMID: 28279895 ↗
L2SR_OBSCited in: Histopathology and Molecular Biology - [398]
Matikas A, Zerdes I, Lövrot J et al.. “PD-1 protein and gene expression as prognostic factors in early breast cancer.” ESMO open (2020). PMID: 33172959 ↗
L2SR_OBSCited in: Histopathology and Molecular Biology, Prognosis and Prognostic Factors - [399]
Chatterji S, Krzoska E, Thoroughgood CW et al.. “Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cancer: a systematic review.” The Lancet. Oncology (2023). PMID: 36725152 ↗
L2SR_OBSCited in: Histopathology and Molecular Biology - [400]
Huober J, Gelber S, Goldhirsch A et al.. “Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 22707751 ↗
L2SR_OBSCited in: Histopathology and Molecular Biology, Staging - [401]
Ellis M. “Genomic analysis of breast cancer heralds a changing treatment paradigm.” Journal of the National Comprehensive Cancer Network : JNCCN (2014). PMID: 24853210 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology, Clinical Presentation - [402]
Im SA, Park K, Koh J et al.. “Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21).” ESMO open (2025). PMID: 40997746 ↗
L1RCTCited in: Histopathology and Molecular Biology, Biopsy and Histologic Diagnosis - [403]
Piccart M, van 't Veer LJ, Poncet C et al.. “70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.” The Lancet. Oncology (2021). PMID: 33721561 ↗
L1RCTCited in: Histopathology and Molecular Biology - [404]
Abdel-Fatah TMA, Agarwal D, Liu DX et al.. “SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.” The Lancet. Oncology (2016). PMID: 27312051 ↗
L2RCTCited in: Histopathology and Molecular Biology - [405]
Sparano JA, Gray RJ, Makower DF et al.. “Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.” The New England journal of medicine (2015). PMID: 26412349 ↗
L2RCTCited in: Histopathology and Molecular Biology - [406]
Yang JT, Yerramilli D, Pentsova E et al.. “Proton Craniospinal Irradiation for Patients With Leptomeningeal Metastasis: A Randomized Clinical Trial.” JAMA oncology (2025). PMID: 40906462 ↗
L1RCTCited in: Histopathology and Molecular Biology - [407]
Esserman LJ, Yau C, Thompson CK et al.. “Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.” JAMA oncology (2017). PMID: 28662222 ↗
L2RCTCited in: Histopathology and Molecular Biology - [408]
Sestak I, Buus R, Cuzick J et al.. “Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.” JAMA oncology (2018). PMID: 29450494 ↗
L2RCTCited in: Histopathology and Molecular Biology - [409]
Denkert C, Rachakonda S, Karn T et al.. “Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtyping.” Cancer cell (2025). PMID: 39933898 ↗
L2RCTCited in: Histopathology and Molecular Biology, History and Evolution of Treatment, Prognosis and Prognostic Factors - [410]
Konstantinopoulos PA, Barry WT, Birrer M et al.. “Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.” The Lancet. Oncology (2019). PMID: 30880072 ↗
L4TRIAL_NONRANDOMCited in: Histopathology and Molecular Biology - [411]
Bochtler T, Endris V, Reiling A et al.. “Integrated Histogenetic Analysis Reveals BAP1-Mutated Epithelioid Mesothelioma in a Patient With Cancer of Unknown Primary.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 29891518 ↗
L4CASE_REPORTCited in: Histopathology and Molecular Biology - [412]
Reeves GK, Beral V, Green J et al.. “Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis.” The Lancet. Oncology (2006). PMID: 17081916 ↗
L2SR_OBSCited in: Histopathology and Molecular Biology - [413]
Matikas A, Zerdes I, Lövrot J et al.. “Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 31227501 ↗
L1SR_OBSCited in: Histopathology and Molecular Biology, Biopsy and Histologic Diagnosis - [414]
Piccart-Gebhart MJ, Sotiriou C. “Adjuvant chemotherapy--yes or no? Prognostic markers in early breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 18083699 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology - [415]
Maur M, Guarneri V, Frassoldati A et al.. “Primary systemic therapy in operable breast cancer: clinical data and biological fall-out.” Annals of oncology : official journal of the European Society for Medical Oncology (2006). PMID: 16807447 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology - [416]
Matikas A, Foukakis T, Swain S et al.. “Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 31131397 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology - [417]
Fasano J, Muggia F. “Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19150941 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology - [418]
Dugo M, Huang CS, Egle D et al.. “The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 39308141 ↗
L2RCTCited in: Histopathology and Molecular Biology - [419]
Kennecke HF, Speers CH, Ennis CA et al.. “Impact of routine pathology review on treatment for node-negative breast cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 22564990 ↗
L2REVIEW_NARRATIVECited in: Histopathology and Molecular Biology - [420]
Kamath SD, Kircher SM, Benson AB. “Comparison of Cancer Burden and Nonprofit Organization Funding Reveals Disparities in Funding Across Cancer Types.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31319386 ↗
L2OTHERCited in: Histopathology and Molecular Biology - [421]
Rediti M, Fimereli D, Mileva M et al.. “Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39470686 ↗
L2TRIAL_NONRANDOMCited in: Histopathology and Molecular Biology, Imaging - [422]
Peters S, Meyer ML, André F et al.. “Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation.” ESMO open (2026). PMID: 42431135 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology - [423]
Corso G, Shen S, Criscitiello C et al.. “Invasive lobular carcinoma: Strategies and perspectives from the lobular breast cancer research group.” Cancer treatment reviews (2025). PMID: 40815983 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology, Clinical Presentation, Imaging - [424]
Nguyen NP, Almeida FS, Chi A et al.. “Molecular biology of breast cancer stem cells: potential clinical applications.” Cancer treatment reviews (2010). PMID: 20231058 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology - [425]
Eroles P, Bosch A, Pérez-Fidalgo JA et al.. “Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.” Cancer treatment reviews (2011). PMID: 22178455 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology - [426]
Wood SL, Westbrook JA, Brown JE. “Omic-profiling in breast cancer metastasis to bone: implications for mechanisms, biomarkers and treatment.” Cancer treatment reviews (2013). PMID: 23958309 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology - [427]
Garufi G, Carbognin L, Arcanà C et al.. “Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?” Cancer treatment reviews (2022). PMID: 35987149 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology - [428]
Griguolo G, Bottosso M, Vernaci G et al.. “Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2- breast cancer: Available evidence and clinical implications.” Cancer treatment reviews (2021). PMID: 34896969 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology - [429]
Sonnenblick A, Fumagalli D, Sotiriou C et al.. “Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?” Cancer treatment reviews (2014). PMID: 25151406 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology, Imaging - [430]
Fernández Y, Cueva J, Palomo AG et al.. “Novel therapeutic approaches to the treatment of metastatic breast cancer.” Cancer treatment reviews (2009). PMID: 19883980 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology - [431]
Saijo N. “Critical comments for roles of biomarkers in the diagnosis and treatment of cancer.” Cancer treatment reviews (2011). PMID: 21652149 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology - [432]
Oakman C, Moretti E, Galardi F et al.. “The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.” Cancer treatment reviews (2009). PMID: 19758759 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology - [433]
De P, Miskimins K, Dey N et al.. “Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: old targets new hope.” Cancer treatment reviews (2013). PMID: 23352077 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology - [434]
Desmedt C, Haibe-Kains B, Wirapati P et al.. “Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18698033 ↗
L5SR_OBSCited in: Histopathology and Molecular Biology - [435]
Stover DG, Coloff JL, Barry WT et al.. “The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27330058 ↗
L5SR_OBSCited in: Histopathology and Molecular Biology - [436]
Waldron L, Ogino S, Hoshida Y et al.. “Expression profiling of archival tumors for long-term health studies.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 23136189 ↗
L5SR_OBSCited in: Histopathology and Molecular Biology - [437]
Kono M, Fujii T, Lim B et al.. “Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review.” JAMA oncology (2017). PMID: 28301631 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology - [438]
Curigliano G, Burstein HJ, Gnant M et al.. “Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023.” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 37683978 ↗
L1OTHERCited in: Histopathology and Molecular Biology, Management Overview - [439]
Tetzlaff MT, Messina JL, Stein JE et al.. “Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 29945191 ↗
L1OTHERCited in: Histopathology and Molecular Biology, Biopsy and Histologic Diagnosis - [440]
Cantore T, Hoang DT, Pal LR et al.. “Predicting neoadjuvant breast cancer therapy response using BRIDGE from tumor transcriptomics and histopathology.” Annals of oncology : official journal of the European Society for Medical Oncology (2026). PMID: 42203036 ↗
L3OTHERCited in: Histopathology and Molecular Biology - [441]
Bareche Y, Venet D, Ignatiadis M et al.. “Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 29365031 ↗
L4OTHERCited in: Histopathology and Molecular Biology - [442]
Li J, Holm J, Bergh J et al.. “Breast cancer genetic risk profile is differentially associated with interval and screen-detected breast cancers.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 25488685 ↗
L3OTHERCited in: Histopathology and Molecular Biology - [443]
Viale G. “The current state of breast cancer classification.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 22987963 ↗
L5OTHERCited in: Histopathology and Molecular Biology - [444]
Korde LA, Somerfield MR, Carey LA et al.. “Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 33507815 ↗
L1OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers, Management Overview - [445]
Massarweh SA, Sledge GW, Miller DP et al.. “Molecular Characterization and Mortality From Breast Cancer in Men.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29584547 ↗
L3OTHERCited in: Histopathology and Molecular Biology - [446]
Korde LA, Zujewski JA, Kamin L et al.. “Multidisciplinary meeting on male breast cancer: summary and research recommendations.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20308661 ↗
L5OTHERCited in: Histopathology and Molecular Biology - [447]
Micheli A, Meneghini E, Secreto G et al.. “Plasma testosterone and prognosis of postmenopausal breast cancer patients.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17548841 ↗
L2OTHERCited in: Histopathology and Molecular Biology - [448]
Beitsch PD, Whitworth PW, Hughes K et al.. “Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 30526229 ↗
L2OTHERCited in: Histopathology and Molecular Biology - [449]
Mandelker D, Marra A, Zheng-Lin B et al.. “Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37607324 ↗
L4OTHERCited in: Histopathology and Molecular Biology - [450]
McKian KP, Reynolds CA, Visscher DW et al.. “Novel breast tissue feature strongly associated with risk of breast cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19805686 ↗
L3OTHERCited in: Histopathology and Molecular Biology - [451]
Plichta JK, Thomas SM, Hayes DF et al.. “Novel Prognostic Staging System for Patients With De Novo Metastatic Breast Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36944149 ↗
L2OTHERCited in: Histopathology and Molecular Biology, Imaging - [452]
Holowatyj AN, Cote ML, Ruterbusch JJ et al.. “Racial Differences in 21-Gene Recurrence Scores Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29341832 ↗
L2OTHERCited in: Histopathology and Molecular Biology - [453]
Climent J, Perez-Losada J, Quigley DA et al.. “Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20625127 ↗
L2OTHERCited in: Histopathology and Molecular Biology - [454]
King TA, Pilewskie M, Muhsen S et al.. “Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 26371145 ↗
L2OTHERCited in: Histopathology and Molecular Biology - [455]
Mayer IA, Abramson VG, Lehmann BD et al.. “New strategies for triple-negative breast cancer--deciphering the heterogeneity.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 24536073 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology - [456]
Gingras I, Desmedt C, Ignatiadis M et al.. “CCR 20th Anniversary Commentary: Gene-Expression Signature in Breast Cancer--Where Did It Start and Where Are We Now?” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 26527804 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology - [457]
Brandt B, Meyer-Staeckling S, Schmidt H et al.. “Mechanisms of egfr gene transcription modulation: relationship to cancer risk and therapy response.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 17189396 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology - [458]
Sinberger LA, Zahavi T, Keren-Khadmy N et al.. “Refining prognostic tools for luminal breast cancer: genetic insights and comprehensive analysis.” ESMO open (2025). PMID: 40305907 ↗
L3OTHERCited in: Histopathology and Molecular Biology, Prognosis and Prognostic Factors - [459]
Li L, Yin G, Liu X et al.. “Genomic and transcriptomic evaluation of primary and recurrent luminal B-like breast cancer.” ESMO open (2026). PMID: 42263480 ↗
L4OTHERCited in: Histopathology and Molecular Biology - [460]
Karlsson A, Ellonen A, Irjala H et al.. “Impact of deep learning-determined smoking status on mortality of cancer patients: never too late to quit.” ESMO open (2021). PMID: 34091262 ↗
L2OTHERCited in: Histopathology and Molecular Biology - [461]
Chiodoni C, Sangaletti S, Lecchi M et al.. “A three-gene signature marks the time to locoregional recurrence in luminal-like breast cancer.” ESMO open (2023). PMID: 37393630 ↗
L2OTHERCited in: Histopathology and Molecular Biology - [462]
Carausu M, Carton M, Darlix A et al.. “Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database.” ESMO open (2021). PMID: 33984675 ↗
L2OTHERCited in: Histopathology and Molecular Biology - [463]
Fan Y, Wang Y, He L et al.. “Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival.” ESMO open (2021). PMID: 34392135 ↗
L2OTHERCited in: Histopathology and Molecular Biology, Imaging, Staging - [464]
Nakayama I, Takahari D, Chin K et al.. “Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma.” ESMO open (2023). PMID: 37348349 ↗
L2OTHERCited in: Histopathology and Molecular Biology - [465]
Hibino Y, Ito M, Satake T et al.. “Clinical benefits of precision medicine in treating solid cancers: European Society of Medical Oncology-Magnitude of Clinical Benefit Scale score-based analysis.” ESMO open (2021). PMID: 34118770 ↗
L2OTHERCited in: Histopathology and Molecular Biology - [466]
Garcia-Pelaez J, Barbosa-Matos R, Lobo S et al.. “Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk Syndromes.” The Lancet. Oncology (2022). PMID: 36436516 ↗
L2OTHERCited in: Histopathology and Molecular Biology - [467]
Scott JG, Berglund A, Schell MJ et al.. “A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.” The Lancet. Oncology (2016). PMID: 27993569 ↗
L2OTHERCited in: Histopathology and Molecular Biology - [468]
Gao JJ, Cheng J, Bloomquist E et al.. “CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.” The Lancet. Oncology (2019). PMID: 31859246 ↗
L1OTHERCited in: Histopathology and Molecular Biology - [469]
Ciatto S, Houssami N, Bernardi D et al.. “Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): a prospective comparison study.” The Lancet. Oncology (2013). PMID: 23623721 ↗
L2OTHERCited in: Histopathology and Molecular Biology - [470]
Fan C, Oh DS, Wessels L et al.. “Concordance among gene-expression-based predictors for breast cancer.” The New England journal of medicine (2006). PMID: 16899776 ↗
L2OTHERCited in: Histopathology and Molecular Biology - [471]
Rafaelian A, Schneider M, Dubinski D et al.. “Impact of infratentorial location on survival after surgical resection of brain metastases: a multicenter retrospective study.” Neuro-oncology advances (2026). PMID: 42325607 ↗
L2COHORTCited in: Histopathology and Molecular Biology - [472]
Fernandez-Martinez A, Rediti M, Tang G et al.. “Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.” JAMA oncology (2024). PMID: 38546612 ↗
L1OTHERCited in: Histopathology and Molecular Biology, Staging - [473]
Spratt DE, Chan T, Waldron L et al.. “Racial/Ethnic Disparities in Genomic Sequencing.” JAMA oncology (2016). PMID: 27366979 ↗
L2OTHERCited in: Histopathology and Molecular Biology - [474]
Peiffer DS, Zhao F, Chen N et al.. “Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database.” JAMA oncology (2023). PMID: 36821125 ↗
L2OTHERCited in: Histopathology and Molecular Biology, Biopsy and Histologic Diagnosis, Staging - [475]
Fernandez-Martinez A, Pascual T, Singh B et al.. “Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials.” JAMA oncology (2023). PMID: 36602784 ↗
L2OTHERCited in: Histopathology and Molecular Biology - [476]
Tsai M, Lo S, Audeh W et al.. “Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay.” JAMA oncology (2018). PMID: 29075751 ↗
L3OTHERCited in: Histopathology and Molecular Biology - [477]
Bose R, Kavuri SM, Searleman AC et al.. “Activating HER2 mutations in HER2 gene amplification negative breast cancer.” Cancer discovery (2012). PMID: 23220880 ↗
L5OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers - [478]
Hamilton AM, Hoadley KA, Troester MA. “Race and Ancestry in Immune Response to Breast Cancer.” Cancer discovery (2022). PMID: 36321309 ↗
L5OTHERCited in: Histopathology and Molecular Biology - [479]
Oudin MJ, Jonas O, Kosciuk T et al.. “Tumor Cell-Driven Extracellular Matrix Remodeling Drives Haptotaxis during Metastatic Progression.” Cancer discovery (2016). PMID: 26811325 ↗
L5OTHERCited in: Histopathology and Molecular Biology - [480]
Hu Y, Petit SA, Ficarro SB et al.. “PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair.” Cancer discovery (2014). PMID: 25252691 ↗
L5OTHERCited in: Histopathology and Molecular Biology - [481]
Werner S, Brors B, Eick J et al.. “Suppression of early hematogenous dissemination of human breast cancer cells to bone marrow by retinoic Acid-induced 2.” Cancer discovery (2015). PMID: 25716347 ↗
L3OTHERCited in: Histopathology and Molecular Biology - [482]
Miller TW, Balko JM, Fox EM et al.. “ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.” Cancer discovery (2011). PMID: 22049316 ↗
L5OTHERCited in: Histopathology and Molecular Biology - [483]
Novitskiy SV, Pickup MW, Gorska AE et al.. “TGF-β receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms.” Cancer discovery (2011). PMID: 22408746 ↗
L5OTHERCited in: Histopathology and Molecular Biology - [484]
Cassetta L, Fragkogianni S, Sims AH et al.. “Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets.” Cancer cell (2019). PMID: 30930117 ↗
L3OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers, Management Overview - [485]
Dhimolea E, de Matos Simoes R, Kansara D et al.. “An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence.” Cancer cell (2021). PMID: 33417832 ↗
L5OTHERCited in: Histopathology and Molecular Biology - [486]
Melo SA, Sugimoto H, O'Connell JT et al.. “Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis.” Cancer cell (2014). PMID: 25446899 ↗
L5OTHERCited in: Histopathology and Molecular Biology - [487]
Edgren H, Kallioniemi O. “Integrated breast cancer genomics.” Cancer cell (2006). PMID: 17157784 ↗
L5OTHERCited in: Histopathology and Molecular Biology, Clinical Presentation - [488]
Chin K, DeVries S, Fridlyand J et al.. “Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.” Cancer cell (2006). PMID: 17157792 ↗
L3OTHERCited in: Histopathology and Molecular Biology - [489]
Shan L, Zhou X, Liu X et al.. “FOXK2 Elicits Massive Transcription Repression and Suppresses the Hypoxic Response and Breast Cancer Carcinogenesis.” Cancer cell (2016). PMID: 27773593 ↗
L5OTHERCited in: Histopathology and Molecular Biology - [490]
Hinohara K, Wu HJ, Vigneau S et al.. “KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance.” Cancer cell (2018). PMID: 30472020 ↗
L3OTHERCited in: Histopathology and Molecular Biology - [491]
Rios AC, Capaldo BD, Vaillant F et al.. “Intraclonal Plasticity in Mammary Tumors Revealed through Large-Scale Single-Cell Resolution 3D Imaging.” Cancer cell (2019). PMID: 30930118 ↗
L5OTHERCited in: Histopathology and Molecular Biology - [492]
Downes M, Evans RM. “Staying the distance: avoiding the proteasomal trap.” Cancer cell (2008). PMID: 18328421 ↗
L5OTHERCited in: Histopathology and Molecular Biology - [493]
Tu WB, Shiah YJ, Lourenco C et al.. “MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis.” Cancer cell (2018). PMID: 30300580 ↗
L5OTHERCited in: Histopathology and Molecular Biology - [494]
Chang CJ, Yang JY, Xia W et al.. “EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling.” Cancer cell (2011). PMID: 21215703 ↗
L5OTHERCited in: Histopathology and Molecular Biology - [495]
Evdokimova V, Tognon C, Ng T et al.. “Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition.” Cancer cell (2009). PMID: 19411069 ↗
L5OTHERCited in: Histopathology and Molecular Biology - [496]
Wu X, Ye X, Chen H et al.. “The translational roles of circular RNAs in cancers and their underlying molecular mechanisms.” Medical oncology (Northwood, London, England) (2026). PMID: 42363998 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology - [497]
Burstein MD, Tsimelzon A, Poage GM et al.. “Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 25208879 ↗
L3OTHERCited in: Histopathology and Molecular Biology - [498]
Jovanović B, Church SE, Gorman KM et al.. “Integrative Multiomic Profiling of Triple-Negative Breast Cancer for Identifying Suitable Therapies.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 39136550 ↗
L3OTHERCited in: Histopathology and Molecular Biology - [499]
Nik-Zainal S, Morganella S. “Mutational Signatures in Breast Cancer: The Problem at the DNA Level.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28572256 ↗
L5OTHERCited in: Histopathology and Molecular Biology - [500]
Akcakanat A, Zheng X, Cruz Pico CX et al.. “Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33782032 ↗
L3OTHERCited in: Histopathology and Molecular Biology - [501]
Georgescu TA, Georgescu AC, Olinca MV. “When Breast Cancer Meets the Uterus: A Quantitative Review of 105 Cases Spanning Four Decades.” Medicina (Kaunas, Lithuania) (2026). PMID: 42356217 ↗
L4REVIEW_NARRATIVECited in: Histopathology and Molecular Biology, Biopsy and Histologic Diagnosis - [502]
Hou W. “The Emerging Role of CACNA1E in Cancer: Molecular Mechanisms and Therapeutic Implications.” Journal of Cancer (2026). PMID: 42327581 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology - [503]
Basheeruddin M, Qausain S, Anjankar A et al.. “Advancements in cancer biomarker discovery over fifteen years: diagnostics and prognostic approach in somatic cancer.” Oncology reviews (2026). PMID: 42181045 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology - [504]
Huang S, Westvold SJ, Soulos PR et al.. “Tumor characteristics associated with tomosynthesis versus digital mammography in older women with screen-detected breast cancer.” Breast cancer research and treatment (2026). PMID: 42420682 ↗
L2OTHERCited in: Histopathology and Molecular Biology - [505]
Namoglu EC, Flanagan MR, Teles MS et al.. “Omission of sentinel lymph node biopsy among women age 50-70 with early-stage breast cancer: applying an updated ASCO Guideline to a real-world population.” Practical radiation oncology (2026). PMID: 42409317 ↗
L3OTHERCited in: Histopathology and Molecular Biology - [506]
Abeles E, Shui AM, Quirarte A et al.. “Omission of Axillary Surgery in Patients with Invasive Lobular Carcinoma of the Breast: Rates of Nodal Involvement in Clinically Node Negative Patients and Impact on Recurrence in a Single Institution Analysis.” Annals of surgical oncology (2026). PMID: 42406219 ↗
L2OTHERCited in: Histopathology and Molecular Biology - [507]
Pereira A, Kaser S, Varga Z et al.. “3D virtual histopathology of human breast tissues using an X-ray grating interferometry micro CT system.” Experimental and molecular pathology (2026). PMID: 42378867 ↗
L4OTHERCited in: Histopathology and Molecular Biology - [508]
Hagenaars SC, Hueting TA, Dieleman F et al.. “Added value of the tumor-stroma ratio to the PREDICT model for breast cancer.” Breast (Edinburgh, Scotland) (2026). PMID: 42372582 ↗
L2OTHERCited in: Histopathology and Molecular Biology - [509]
Cheng M, Li X, Song N et al.. “The YAP-TEAD4 inhibitor M511-0965 suppresses triple-negative breast cancer progression by downregulating TGFB2.” Translational oncology (2026). PMID: 42365824 ↗
L5OTHERCited in: Histopathology and Molecular Biology - [510]
Wang Y, Xie Y, Ye Y et al.. “Prognosis and Immunotherapy Effect of Triple-Negative Breast Cancer by Lactylation-Related Genes and Experimental Validation.” Oncology research (2026). PMID: 42358833 ↗
L5OTHERCited in: Histopathology and Molecular Biology - [511]
Metcalfe K, Narod SA, Poll A et al.. “Frequency of germline pathogenic variants in breast cancer predisposing genes in a national cohort of young women with breast cancer.” British journal of cancer (2026). PMID: 42337046 ↗
L2OTHERCited in: Histopathology and Molecular Biology - [512]
Lu X, Xie D, Cui L et al.. “FLASH radiotherapy preserves hepatic function and maintains metabolic homeostasis in a murine breast cancer model: an experimental preclinical study.” Radiation oncology (London, England) (2026). PMID: 42321761 ↗
L5OTHERCited in: Histopathology and Molecular Biology - [513]
Viart NM, Thibault L, Lazard T et al.. “Deep learning analysis of breast cancer histology predicts ATM pathogenic variant carrier status.” NPJ digital medicine (2026). PMID: 42298170 ↗
L3OTHERCited in: Histopathology and Molecular Biology - [514]
Azizy A, Dogan I, Yucel S et al.. “Effect of Primary Breast Surgery on Prognosis in Breast Cancer Patients Presenting with Isolated Bone Metastases.” Cancers (2026). PMID: 42279343 ↗
L3OTHERCited in: Histopathology and Molecular Biology - [515]
Tchurikov NA, Klushevskaya ES, Lukicheva VN et al.. “Highly Aggressive and Metastatic MDA-MB-231 and Mel Z Cancer Cells Have Common Sets of Down- and Upregulated Genes During Formation of the Vasculogenic Mimicry Phenotype.” International journal of molecular sciences (2026). PMID: 42278478 ↗
L5OTHERCited in: Histopathology and Molecular Biology - [516]
Tarantino P, Viale G, Press MF et al.. “ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 37269905 ↗
L5GUIDELINECited in: Clinical Presentation, Management Overview, History and Evolution of Treatment - [517]
Burstein HJ, Curigliano G, Thürlimann B et al.. “Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.” Annals of oncology : official journal of the European Society for Medical Oncology (2021). PMID: 34242744 ↗
L5GUIDELINECited in: Clinical Presentation, Management Overview - [518]
Gradishar W, Salerno KE. “NCCN Guidelines Update: Breast Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 27226503 ↗
L1GUIDELINECited in: Clinical Presentation, Management Overview, History and Evolution of Treatment - [519]
Oktay K, Harvey BE, Partridge AH et al.. “Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29620997 ↗
L1GUIDELINECited in: Clinical Presentation, History and Evolution of Treatment, Special Populations - [520]
Su HI, Lacchetti C, Letourneau J et al.. “Fertility Preservation in People With Cancer: ASCO Guideline Update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40106739 ↗
L1GUIDELINECited in: Clinical Presentation, History and Evolution of Treatment, Special Populations - [521]
Sakai H, Tsurutani J, Ozaki Y et al.. “A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B).” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 39284382 ↗
L1RCTCited in: Clinical Presentation - [522]
Lambertini M, Blondeaux E, Bruzzone M et al.. “Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34197218 ↗
L2SR_OBSCited in: Clinical Presentation, Special Populations - [523]
Dieli-Conwright CM, Courneya KS, Demark-Wahnefried W et al.. “Effects of Aerobic and Resistance Exercise on Metabolic Syndrome, Sarcopenic Obesity, and Circulating Biomarkers in Overweight or Obese Survivors of Breast Cancer: A Randomized Controlled Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29356607 ↗
L1RCTCited in: Clinical Presentation - [524]
Jardel P, Sauerwein W, Olivier T et al.. “Management of choroidal metastases.” Cancer treatment reviews (2014). PMID: 25451606 ↗
L2SR_OBSCited in: Clinical Presentation, Imaging, Prognosis and Prognostic Factors - [525]
Gradishar WJ. “Treatment of metastatic breast cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2014). PMID: 24853211 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers, Management Overview - [526]
Thomas PS. “Diagnosis and Management of High-Risk Breast Lesions.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30442737 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Biopsy and Histologic Diagnosis, Prognosis and Prognostic Factors - [527]
Waks AG, Partridge AH. “Fertility Preservation in Patients With Breast Cancer: Necessity, Methods, and Safety.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 26957619 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [528]
Ligibel JA. “Role of adjuvant and posttreatment exercise programs in breast health.” Journal of the National Comprehensive Cancer Network : JNCCN (2011). PMID: 21310846 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [529]
Johnston SRD, Toi M, O'Shaughnessy J et al.. “Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.” The Lancet. Oncology (2022). PMID: 36493792 ↗
L1RCTCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, History and Evolution of Treatment - [530]
Hurvitz SA, Martin M, Symmans WF et al.. “Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.” The Lancet. Oncology (2017). PMID: 29175149 ↗
L1RCTCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Staging - [531]
Diéras V, Miles D, Verma S et al.. “Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.” The Lancet. Oncology (2017). PMID: 28526536 ↗
L1RCTCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Special Populations - [532]
Bajpai J, Kapu V, Rath S et al.. “Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial.” The Lancet. Oncology (2024). PMID: 38224701 ↗
L1RCTCited in: Clinical Presentation - [533]
Winer EP, Lipatov O, Im SA et al.. “Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.” The Lancet. Oncology (2021). PMID: 33676601 ↗
L1RCTCited in: Clinical Presentation - [534]
André F, Ciruelos E, Rubovszky G et al.. “Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.” The New England journal of medicine (2019). PMID: 31091374 ↗
L1RCTCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers - [535]
von Minckwitz G, Procter M, de Azambuja E et al.. “Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.” The New England journal of medicine (2017). PMID: 28581356 ↗
L1RCTCited in: Clinical Presentation - [536]
Murthy RK, Loi S, Okines A et al.. “Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.” The New England journal of medicine (2019). PMID: 31825569 ↗
L1RCTCited in: Clinical Presentation - [537]
Cardoso F, Parke S, Brennan DJ et al.. “Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer.” The New England journal of medicine (2025). PMID: 40454634 ↗
L1RCTCited in: Clinical Presentation - [538]
Davis SR, Moreau M, Kroll R et al.. “Testosterone for low libido in postmenopausal women not taking estrogen.” The New England journal of medicine (2008). PMID: 18987368 ↗
L1RCTCited in: Clinical Presentation - [539]
Benitez Fuentes JD, Morgan E, de Luna Aguilar A et al.. “Global Stage Distribution of Breast Cancer at Diagnosis: A Systematic Review and Meta-Analysis.” JAMA oncology (2024). PMID: 37943547 ↗
L2SR_OBSCited in: Clinical Presentation, Staging, Prognosis and Prognostic Factors - [540]
Llombart-Cussac A, Pérez-García JM, Bellet M et al.. “Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial.” JAMA oncology (2021). PMID: 34617955 ↗
L1RCTCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, History and Evolution of Treatment - [541]
Choi W, Porten S, Kim S et al.. “Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.” Cancer cell (2014). PMID: 24525232 ↗
L2RCTCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Staging, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations - [542]
Galimberti V, Cole BF, Viale G et al.. “Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.” The Lancet. Oncology (2018). PMID: 30196031 ↗
L1TRIAL_NONRANDOMCited in: Clinical Presentation, Biopsy and Histologic Diagnosis - [543]
Bardia A, Mayer IA, Vahdat LT et al.. “Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.” The New England journal of medicine (2019). PMID: 30786188 ↗
L4TRIAL_NONRANDOMCited in: Clinical Presentation - [544]
Lehman CD, Gatsonis C, Kuhl CK et al.. “MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer.” The New England journal of medicine (2007). PMID: 17392300 ↗
L2TRIAL_NONRANDOMCited in: Clinical Presentation, Biopsy and Histologic Diagnosis, Imaging - [545]
Dogan BE, Turnbull LW. “Imaging of triple-negative breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 23012298 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Imaging - [546]
Kuerer HM, Valero V, Smith BD et al.. “Selective Elimination of Breast Surgery for Invasive Breast Cancer: A Nonrandomized Clinical Trial.” JAMA oncology (2025). PMID: 40152443 ↗
L4TRIAL_NONRANDOMCited in: Clinical Presentation, Biopsy and Histologic Diagnosis, Management Overview, Prognosis and Prognostic Factors, Special Populations - [547]
Chandarlapaty S, Chen D, He W et al.. “Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.” JAMA oncology (2016). PMID: 27532364 ↗
L2TRIAL_NONRANDOMCited in: Clinical Presentation, Prognosis and Prognostic Factors - [548]
Hurvitz SA, Martin M, Press MF et al.. “Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 31615937 ↗
L1RCTCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors - [549]
McGrady ME, Willard VW, Williams AM et al.. “Psychological Outcomes in Adolescent and Young Adult Cancer Survivors.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37967297 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [550]
Valenza C, Trapani D, Fusco N et al.. “The immunogram of inflammatory breast cancer.” Cancer treatment reviews (2023). PMID: 37437342 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Molecular Diagnostics and Biomarkers - [551]
De Rose F, Meduri B, De Santis MC et al.. “Rethinking breast cancer follow-up based on individual risk and recurrence management.” Cancer treatment reviews (2022). PMID: 35933845 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [552]
Cesca MG, Vian L, Cristóvão-Ferreira S et al.. “HER2-positive advanced breast cancer treatment in 2020.” Cancer treatment reviews (2020). PMID: 32534233 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [553]
Rugo HS, Bianchini G, Cortes J et al.. “Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.” ESMO open (2022). PMID: 35964548 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [554]
Wekking D, Porcu M, Pellegrino B et al.. “Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients.” ESMO open (2023). PMID: 37951130 ↗
L1REVIEW_NARRATIVECited in: Clinical Presentation, Management Overview - [555]
Le Rhun E, Preusser M, van den Bent M et al.. “How we treat patients with leptomeningeal metastases.” ESMO open (2019). PMID: 31231573 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [556]
Li S, Li L, Fu L. “Efficacy of different non-pharmacological therapies on cancer-related fatigue in breast cancer patients: a network meta-analysis.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 42400667 ↗
L1SR_OBSCited in: Clinical Presentation, Management Overview - [557]
Onkar SS, Carleton NM, Lucas PC et al.. “The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes.” Cancer discovery (2023). PMID: 36620880 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Management Overview - [558]
Rugo HS, O'Shaughnessy J, Boyle F et al.. “Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.” Annals of oncology : official journal of the European Society for Medical Oncology (2022). PMID: 35337972 ↗
L1OTHERCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers - [559]
Garcia-Murillas I, Abbott CW, Cutts RJ et al.. “Whole genome sequencing-powered ctDNA sequencing for breast cancer detection.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 39914664 ↗
L4OTHERCited in: Clinical Presentation - [560]
Di Meglio A, Havas J, Pagliuca M et al.. “A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance 2 years later.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 39098454 ↗
L2OTHERCited in: Clinical Presentation - [561]
Grinshpun A, Zick A, Perri T et al.. “Detection of antibody-drug conjugate-induced interstitial lung disease using circulating cell-free DNA.” ESMO open (2024). PMID: 39288654 ↗
L4CASE_REPORTCited in: Clinical Presentation - [562]
Parker JS, Mullins M, Cheang MC et al.. “Supervised risk predictor of breast cancer based on intrinsic subtypes.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19204204 ↗
L2OTHERCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors, Special Populations - [563]
Zhang XH, Giuliano M, Trivedi MV et al.. “Metastasis dormancy in estrogen receptor-positive breast cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2013). PMID: 24298069 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [564]
Waning DL, Guise TA. “Molecular mechanisms of bone metastasis and associated muscle weakness.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 24677373 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [565]
Body JJ. “Breast cancer: bisphosphonate therapy for metastatic bone disease.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 17062710 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [566]
Li H, Wang H, Yao J et al.. “Lymphatic and Vascular Dual-System Super-Resolution Ultrasound for Diagnosing Sentinel Lymph Node Metastasis in Breast Cancer: A Prospective Study.” Ultrasound in medicine & biology (2026). PMID: 42431777 ↗
L2COHORTCited in: Clinical Presentation - [567]
Chowdhury Q, Rahman MA, Begum FA et al.. “Breast Cancer Presentation, Treatment Patterns, and Progression-Free Survival at a Tertiary Oncology Centre in Bangladesh: A Retrospective Study.” Cancer reports (Hoboken, N.J.) (2026). PMID: 42429366 ↗
L4COHORTCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors - [568]
Rugo HS, Layman RM, Lynce F et al.. “Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting.” ESMO open (2025). PMID: 39754979 ↗
L2OTHERCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Management Overview, Special Populations - [569]
Grinda T, Antoine A, Jacot W et al.. “Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort.” ESMO open (2021). PMID: 33895695 ↗
L2OTHERCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Management Overview - [570]
Tarantino P, Rugo HS, Curigliano G et al.. “Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2- early breast cancer: a United States Electronic Health Records database analysis.” ESMO open (2025). PMID: 40516131 ↗
L4OTHERCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Management Overview, Special Populations - [571]
Hu H, Tong K, Tsang JY et al.. “Subtyping of triple-negative breast cancers: its prognostication and implications in diagnosis of breast origin.” ESMO open (2024). PMID: 38613910 ↗
L4OTHERCited in: Clinical Presentation, Biopsy and Histologic Diagnosis, Prognosis and Prognostic Factors - [572]
Loibl S, Park YH, Shao Z et al.. “Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.” The New England journal of medicine (2025). PMID: 41370739 ↗
L1OTHERCited in: Clinical Presentation - [573]
Fenton JJ, Taplin SH, Carney PA et al.. “Influence of computer-aided detection on performance of screening mammography.” The New England journal of medicine (2007). PMID: 17409321 ↗
L2OTHERCited in: Clinical Presentation, Biopsy and Histologic Diagnosis - [574]
Garcia-Murillas I, Chopra N, Comino-Méndez I et al.. “Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer.” JAMA oncology (2019). PMID: 31369045 ↗
L2OTHERCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Special Populations - [575]
Caan BJ, Cespedes Feliciano EM, Prado CM et al.. “Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer.” JAMA oncology (2018). PMID: 29621380 ↗
L2OTHERCited in: Clinical Presentation, Imaging, Staging, Prognosis and Prognostic Factors - [576]
Taylor BC, Sun X, Gonzalez-Ericsson PI et al.. “NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer.” Cancer discovery (2024). PMID: 37791898 ↗
L5OTHERCited in: Clinical Presentation - [577]
Tarantino P, Curigliano G, Tolaney SM. “Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons.” Cancer discovery (2022). PMID: 35856622 ↗
L5OTHERCited in: Clinical Presentation, History and Evolution of Treatment - [578]
Wang D, DuBois RN. “The role of the PGE2-aromatase pathway in obesity-associated breast inflammation.” Cancer discovery (2012). PMID: 22576207 ↗
L5OTHERCited in: Clinical Presentation - [579]
Foidart P, Li Z, Cai X et al.. “Whole-genome doubling drives immune evasion by silencing antigen presentation.” Cancer cell (2026). PMID: 42102810 ↗
L5OTHERCited in: Clinical Presentation, History and Evolution of Treatment - [580]
Engelhardt JJ, Boldajipour B, Beemiller P et al.. “Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells.” Cancer cell (2012). PMID: 22439936 ↗
L5OTHERCited in: Clinical Presentation - [581]
Dravis C, Chung CY, Lytle NK et al.. “Epigenetic and Transcriptomic Profiling of Mammary Gland Development and Tumor Models Disclose Regulators of Cell State Plasticity.” Cancer cell (2018). PMID: 30174241 ↗
L5OTHERCited in: Clinical Presentation - [582]
Kim HS, Kim HJ. “Effectiveness of a Smartphone-Based Self-Management App (BeHealth app) for Women with Breast Cancer: A Randomized Controlled Trial.” Iranian journal of public health (2025). PMID: 42428742 ↗
L1RCTCited in: Clinical Presentation - [583]
Bistriceanu I, Stoica RA, Iordache N et al.. “Clinicopathological and immunohistochemical profile of breast lesions diagnosed by core needle biopsy: a retrospective study from Sf. Ioan Hospital, Bucharest, Romania.” Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie (2026). PMID: 42402738 ↗
L4COHORTCited in: Clinical Presentation, Biopsy and Histologic Diagnosis - [584]
Abdalaty S, Chai GW, Sferrazza D et al.. “The impact of maternal breast cancer diagnosis on the mother-child relationship: an updated systematic review.” Current opinion in supportive and palliative care (2026). PMID: 42417076 ↗
L5SR_OBSCited in: Clinical Presentation - [585]
Rakha EA. “Flat epithelial atypia of the breast: a pragmatic, context-integrated diagnostic framework within a biological continuum.” Histopathology (2026). PMID: 42411107 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [586]
Dent R, Trudeau M, Pritchard KI et al.. “Triple-negative breast cancer: clinical features and patterns of recurrence.” Clinical cancer research : an official journal of the American Association for Cancer Research (2007). PMID: 17671126 ↗
L2OTHERCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors - [587]
Gitto SB, Whicker M, Davies G et al.. “A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 37882675 ↗
L5OTHERCited in: Clinical Presentation - [588]
Freedman RA, Partridge AH. “Emerging Data and Current Challenges for Young, Old, Obese, or Male Patients with Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28572259 ↗
L5OTHERCited in: Clinical Presentation - [589]
Rennert G, Pinchev M, Gronich N et al.. “Oral Bisphosphonates and Improved Survival of Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27683176 ↗
L3OTHERCited in: Clinical Presentation, Staging - [590]
Gradishar WJ, Anderson BO, Balassanian R et al.. “NCCN Guidelines Insights: Breast Cancer, Version 1.2017.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28404755 ↗
L1GUIDELINECited in: Biopsy and Histologic Diagnosis, Imaging, Staging, Prognosis and Prognostic Factors - [591]
Abulkhair O, Saghir N, Sedky L et al.. “Modification and implementation of NCCN guidelines on breast cancer in the Middle East and North Africa region.” Journal of the National Comprehensive Cancer Network : JNCCN (2010). PMID: 20697133 ↗
L5GUIDELINECited in: Biopsy and Histologic Diagnosis - [592]
Conte PF, Dieci MV, Bisagni G et al.. “A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40885530 ↗
L1RCTCited in: Biopsy and Histologic Diagnosis - [593]
Park KU, Somerfield MR, Anne N et al.. “Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40209128 ↗
L1GUIDELINECited in: Biopsy and Histologic Diagnosis, Staging, History and Evolution of Treatment - [594]
Allison KH, Hammond MEH, Dowsett M et al.. “Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 31928404 ↗
L1GUIDELINECited in: Biopsy and Histologic Diagnosis, History and Evolution of Treatment - [595]
Wolff AC, Somerfield MR, Dowsett M et al.. “Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37284804 ↗
L1GUIDELINECited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers, History and Evolution of Treatment - [596]
Wolff AC, Hammond MEH, Allison KH et al.. “Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29846122 ↗
L1GUIDELINECited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers, History and Evolution of Treatment - [597]
Andre F, Ismaila N, Allison KH et al.. “Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35439025 ↗
L1GUIDELINECited in: Biopsy and Histologic Diagnosis, Management Overview - [598]
Wolff AC, Hammond ME, Hicks DG et al.. “Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 24101045 ↗
L1GUIDELINECited in: Biopsy and Histologic Diagnosis - [599]
Garrigós L, Ruiz-Borrego M, Pérez-García JM et al.. “A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study.” Annals of oncology : official journal of the European Society for Medical Oncology (2026). PMID: 42097893 ↗
L4TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis - [600]
Modi S, Park H, Murthy RK et al.. “Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32058843 ↗
L4TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis - [601]
Bardia A, Mayer IA, Diamond JR et al.. “Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28291390 ↗
L4TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis - [602]
Hu X, Curigliano G, Yonemori K et al.. “Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial.” ESMO open (2025). PMID: 40441802 ↗
L1RCTCited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Special Populations - [603]
Donker M, van Tienhoven G, Straver ME et al.. “Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.” The Lancet. Oncology (2014). PMID: 25439688 ↗
L1RCTCited in: Biopsy and Histologic Diagnosis, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors - [604]
Galimberti V, Cole BF, Zurrida S et al.. “Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.” The Lancet. Oncology (2013). PMID: 23491275 ↗
L1RCTCited in: Biopsy and Histologic Diagnosis - [605]
Bonnefoi H, Lerebours F, Pulido M et al.. “Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial.” The Lancet. Oncology (2025). PMID: 39978376 ↗
L1RCTCited in: Biopsy and Histologic Diagnosis - [606]
Yuan J, Bi XW, Hua X et al.. “Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial.” The Lancet. Oncology (2025). PMID: 41308674 ↗
L1RCTCited in: Biopsy and Histologic Diagnosis - [607]
Mamounas EP, Bandos H, White JR et al.. “Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy.” The New England journal of medicine (2025). PMID: 40466065 ↗
L1RCTCited in: Biopsy and Histologic Diagnosis, Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors - [608]
Weaver DL, Ashikaga T, Krag DN et al.. “Effect of occult metastases on survival in node-negative breast cancer.” The New England journal of medicine (2011). PMID: 21247310 ↗
L1RCTCited in: Biopsy and Histologic Diagnosis - [609]
Piha-Paul SA, Tseng C, Tran HT et al.. “Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations.” ESMO open (2025). PMID: 39908697 ↗
L4TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis - [610]
Denkert C, Seither F, Schneeweiss A et al.. “Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.” The Lancet. Oncology (2021). PMID: 34252375 ↗
L2TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis - [611]
Kuemmel S, Graeser M, Schmid P et al.. “Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial.” The Lancet. Oncology (2025). PMID: 40318646 ↗
L4TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis - [612]
Dilawari A, Zhang H, Shah M et al.. “US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor-Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2-Low or Human Epidermal Growth Factor Receptor 2-Ultralow Breast Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40763319 ↗
L5RCTCited in: Biopsy and Histologic Diagnosis - [613]
Mariotti V, Han H, Ismail-Khan R et al.. “Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer: A Randomized Clinical Trial.” JAMA oncology (2021). PMID: 33151286 ↗
L1RCTCited in: Biopsy and Histologic Diagnosis - [614]
Weber WP, Davide Gentilini O, Morrow M et al.. “Uncertainties and controversies in axillary management of patients with breast cancer.” Cancer treatment reviews (2023). PMID: 37126938 ↗
L5SR_OBSCited in: Biopsy and Histologic Diagnosis - [615]
Verschoor N, Deger T, Jager A et al.. “Validity and utility of HER2/ERBB2 copy number variation assessed in liquid biopsies from breast cancer patients: A systematic review.” Cancer treatment reviews (2022). PMID: 35366566 ↗
L5SR_OBSCited in: Biopsy and Histologic Diagnosis - [616]
Yucel KB, Ilhan Y, Almuradova E et al.. “Comparison of the pathological complete response between immunohistochemistry HER2 (3 + ) and HER2 (2 + )/ISH + Early-stage breast cancer: a systematic review and meta-analysis.” Cancer treatment reviews (2026). PMID: 41512603 ↗
L1SR_OBSCited in: Biopsy and Histologic Diagnosis - [617]
Ahmed M, Purushotham AD, Douek M. “Novel techniques for sentinel lymph node biopsy in breast cancer: a systematic review.” The Lancet. Oncology (2014). PMID: 24988938 ↗
L2SR_OBSCited in: Biopsy and Histologic Diagnosis - [618]
Lehman CD, DeMartini W, Anderson BO et al.. “Indications for breast MRI in the patient with newly diagnosed breast cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2009). PMID: 19200417 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis, Imaging, Staging, Prognosis and Prognostic Factors - [619]
Anderson BO, Calhoun KE, Rosen EL. “Evolving concepts in the management of lobular neoplasia.” Journal of the National Comprehensive Cancer Network : JNCCN (2006). PMID: 16687097 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis - [620]
Allred DC, Carlson RW, Berry DA et al.. “NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry.” Journal of the National Comprehensive Cancer Network : JNCCN (2009). PMID: 19755043 ↗
L1REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis - [621]
Whelan TJ, Olivotto IA, Parulekar WR et al.. “Regional Nodal Irradiation in Early-Stage Breast Cancer.” The New England journal of medicine (2015). PMID: 26200977 ↗
L1RCTCited in: Biopsy and Histologic Diagnosis, Staging - [622]
Poortmans PM, Collette S, Kirkove C et al.. “Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer.” The New England journal of medicine (2015). PMID: 26200978 ↗
L1RCTCited in: Biopsy and Histologic Diagnosis - [623]
Wander SA, Cohen O, Gong X et al.. “The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.” Cancer discovery (2020). PMID: 32404308 ↗
L4TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis - [624]
Visvanathan K, Cope L, Fackler MJ et al.. “Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36534524 ↗
L2TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis - [625]
Tsuji J, Li T, Grinshpun A et al.. “Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 36215125 ↗
L4TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis - [626]
Wotman MT, Khalaf A, Wang K et al.. “Trastuzumab Deruxtecan in HER2-Low or HER2-Mutant Recurrent/Metastatic Secretory Gland Cancers of the Head and Neck: A Case Series.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 41213241 ↗
L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis - [627]
Penault-Llorca F, Viale G. “Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 23012297 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis - [628]
Aapro M, Wildiers H. “Triple-negative breast cancer in the older population.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 23012304 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis - [629]
Oliveira M, Cortés J, Bellet M et al.. “Management of the axilla in early breast cancer patients in the genomic era.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 23165977 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis, Imaging - [630]
Viale G, Basik M, Niikura N et al.. “Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer.” ESMO open (2023). PMID: 37562195 ↗
L4COHORTCited in: Biopsy and Histologic Diagnosis - [631]
Kuehn T, Bauerfeind I, Fehm T et al.. “Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.” The Lancet. Oncology (2013). PMID: 23683750 ↗
L2COHORTCited in: Biopsy and Histologic Diagnosis, Staging, Special Populations - [632]
Montagna G, Alvarado M, Myers S et al.. “Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study.” The Lancet. Oncology (2026). PMID: 41449148 ↗
L3COHORTCited in: Biopsy and Histologic Diagnosis - [633]
Ly A, Ono JC, Hughes KS et al.. “Fine-Needle Aspiration Biopsy of Palpable Breast Masses: Patterns of Clinical Use and Patient Experience.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 27160231 ↗
L4OTHERCited in: Biopsy and Histologic Diagnosis - [634]
Kamal AH, Power S, Broadwater G et al.. “Optimizing the quality of breast cancer biomarker use at Duke Cancer Institute.” Journal of the National Comprehensive Cancer Network : JNCCN (2014). PMID: 24614047 ↗
L4OTHERCited in: Biopsy and Histologic Diagnosis - [635]
Hamilton E, Shastry M, Shiller SM et al.. “Targeting HER2 heterogeneity in breast cancer.” Cancer treatment reviews (2021). PMID: 34534820 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers - [636]
Harbeck N, Salem M, Nitz U et al.. “Personalized treatment of early-stage breast cancer: present concepts and future directions.” Cancer treatment reviews (2010). PMID: 20554119 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis, Staging, Special Populations - [637]
Buono G, Gerratana L, Bulfoni M et al.. “Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?” Cancer treatment reviews (2019). PMID: 30682661 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis - [638]
Lin X, Liu B, Wu J et al.. “Circulating tumor DNA in breast cancer: From technological foundation to clinical implementation.” Cancer treatment reviews (2026). PMID: 41702297 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis - [639]
Perez EA, Cortés J, Gonzalez-Angulo AM et al.. “HER2 testing: current status and future directions.” Cancer treatment reviews (2013). PMID: 24080154 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis - [640]
van de Ven S, Smit VT, Dekker TJ et al.. “Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.” Cancer treatment reviews (2010). PMID: 21177040 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis - [641]
Muñoz M, Estévez LG, Alvarez I et al.. “Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer.” Cancer treatment reviews (2008). PMID: 18922644 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis, Staging - [642]
Senkus E, Cardoso MJ, Kaidar-Person O et al.. “De-escalation of axillary irradiation for early breast cancer - Has the time come?” Cancer treatment reviews (2021). PMID: 34656018 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis - [643]
Shimozaki K, Fukuoka S, Ooki A et al.. “HER2-low gastric cancer: is the subgroup targetable?” ESMO open (2024). PMID: 39178538 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers, Management Overview - [644]
Curigliano G, Dent R, Earle H et al.. “Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer.” ESMO open (2024). PMID: 38613914 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis - [645]
Henskens IJ, Dinger TL, Stekelenburg I et al.. “Fluorescence imaging using indocyanine green to identify sentinel lymph nodes during surgery for breast cancer (INFINITE): protocol for a hybrid effectiveness-implementation trial using a stepped-wedge cluster design.” BMJ open (2026). PMID: 42342397 ↗
L5TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis, Imaging - [646]
Wael N, Owid AZ, Fadlalla H. “Diagnostic performance of circulating cell-free DNA as a minimally invasive biomarker for breast cancer: a systematic review and meta-analysis of methylation, quantitative, and integrity markers.” Expert review of molecular diagnostics (2026). PMID: 42266071 ↗
L1SR_OBSCited in: Biopsy and Histologic Diagnosis - [647]
Pilewskie M, Morrow M. “Axillary Nodal Management Following Neoadjuvant Chemotherapy: A Review.” JAMA oncology (2017). PMID: 27918753 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis - [648]
Uzunparmak B, Haymaker C, Raso G et al.. “HER2-low expression in patients with advanced or metastatic solid tumors.” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 37619847 ↗
L4OTHERCited in: Biopsy and Histologic Diagnosis - [649]
Szekely B, Bossuyt V, Li X et al.. “Immunological differences between primary and metastatic breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 30203045 ↗
L3OTHERCited in: Biopsy and Histologic Diagnosis - [650]
Curigliano G, Viale G, Ghioni M et al.. “Cancer-testis antigen expression in triple-negative breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 20610479 ↗
L3OTHERCited in: Biopsy and Histologic Diagnosis, Staging - [651]
Schmid P, Wang HC, Lynce F et al.. “Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study.” Annals of oncology : official journal of the European Society for Medical Oncology (2026). PMID: 42167437 ↗
L4OTHERCited in: Biopsy and Histologic Diagnosis - [652]
Choong GM, Hoskin TL, Boughey JC et al.. “Endocrine Therapy Omission in Estrogen Receptor-Low (1%-10%) Early-Stage Breast Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40215443 ↗
L2OTHERCited in: Biopsy and Histologic Diagnosis, Staging, Management Overview - [653]
Nishikawa T, Hasegawa K, Matsumoto K et al.. “Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36977309 ↗
L4OTHERCited in: Biopsy and Histologic Diagnosis - [654]
Andre F, Dieci MV, Dubsky P et al.. “Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 23258741 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis - [655]
Yaal-Hahoshen N, Shina S, Leider-Trejo L et al.. “The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 16899591 ↗
L2REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis - [656]
Walbaum B, Martínez-Sáez O, Brasó-Maristany F et al.. “Genomic and clinical features in young women with estrogen receptor-positive, HER2-negative breast cancer.” ESMO open (2025). PMID: 40997745 ↗
L2OTHERCited in: Biopsy and Histologic Diagnosis - [657]
Pesántez D, Brasó-Maristany F, Pascual T et al.. “HER2DX ERBB2 score in advanced HER2-positive gastric cancer treated with trastuzumab and chemotherapy.” ESMO open (2025). PMID: 40913834 ↗
L2OTHERCited in: Biopsy and Histologic Diagnosis - [658]
Wu S, Shang J, Li Z et al.. “Interobserver consistency and diagnostic challenges in HER2-ultralow breast cancer: a multicenter study.” ESMO open (2025). PMID: 39891991 ↗
L4OTHERCited in: Biopsy and Histologic Diagnosis - [659]
Reimer T, Stachs A, Veselinovic K et al.. “Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial.” The New England journal of medicine (2024). PMID: 39665649 ↗
L1OTHERCited in: Biopsy and Histologic Diagnosis, Imaging, Staging, Management Overview, Prognosis and Prognostic Factors - [660]
de Boniface J, Filtenborg Tvedskov T, Rydén L et al.. “Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.” The New England journal of medicine (2024). PMID: 38598571 ↗
L1OTHERCited in: Biopsy and Histologic Diagnosis - [661]
de Boer M, van Deurzen CH, van Dijck JA et al.. “Micrometastases or isolated tumor cells and the outcome of breast cancer.” The New England journal of medicine (2009). PMID: 19675329 ↗
L2OTHERCited in: Biopsy and Histologic Diagnosis, Staging - [662]
Fernandez AI, Liu M, Bellizzi A et al.. “Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue.” JAMA oncology (2022). PMID: 35113160 ↗
L4OTHERCited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers - [663]
Montagna G, Zhang J, Sevilimedu V et al.. “Risk Factors and Racial and Ethnic Disparities in Patients With Breast Cancer-Related Lymphedema.” JAMA oncology (2022). PMID: 35679026 ↗
L2OTHERCited in: Biopsy and Histologic Diagnosis - [664]
Menes TS, Kerlikowske K, Lange J et al.. “Subsequent Breast Cancer Risk Following Diagnosis of Atypical Ductal Hyperplasia on Needle Biopsy.” JAMA oncology (2017). PMID: 27607465 ↗
L2OTHERCited in: Biopsy and Histologic Diagnosis - [665]
Waks AG, Ogayo ER, Paré L et al.. “Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab.” JAMA oncology (2023). PMID: 37103927 ↗
L2OTHERCited in: Biopsy and Histologic Diagnosis - [666]
Prat A, Bardia A, Curigliano G et al.. “An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low).” JAMA oncology (2022). PMID: 36107417 ↗
L5OTHERCited in: Biopsy and Histologic Diagnosis - [667]
Barrio AV, Montagna G, Mamtani A et al.. “Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event.” JAMA oncology (2021). PMID: 34617979 ↗
L2OTHERCited in: Biopsy and Histologic Diagnosis - [668]
Cunningham N, Turner NC. “Liquid Biopsies in Breast Milk for the Early Detection of Breast Cancer.” Cancer discovery (2023). PMID: 37794840 ↗
L5OTHERCited in: Biopsy and Histologic Diagnosis - [669]
. “Rapid Diagnostic May Improve Breast Cancer Care.” Cancer discovery (2020). PMID: 32988962 ↗
L5OTHERCited in: Biopsy and Histologic Diagnosis - [670]
Strand SH, Rivero-Gutiérrez B, Houlahan KE et al.. “Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts.” Cancer cell (2022). PMID: 36400020 ↗
L2OTHERCited in: Biopsy and Histologic Diagnosis - [671]
Liang Y, Wu K, Pan L et al.. “Tertiary lymphoid structures in breast cancer: Mechanistic insights, subtype-specific patterns, and therapeutic implications.” World journal of surgical oncology (2026). PMID: 42351178 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis - [672]
Pekarek L, García-Montero C, Casanova-Martin C et al.. “Beyond Molecular Classification in Metastatic Triple-Negative Breast Cancer: Toward Subtype-Guided Precision Oncology.” International journal of molecular sciences (2026). PMID: 42278564 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis - [673]
Scurtu AG, Sala DT, Jung I et al.. “HER2-Low Gastric and Gastroesophageal Junction Adenocarcinoma: From Assessment to Treatment Strategies.” International journal of molecular sciences (2026). PMID: 42278208 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis - [674]
Kroemer M, Lopez M, Mansi L et al.. “Evaluating the investigational drug landscape for ESR1-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.” Expert opinion on investigational drugs (2026). PMID: 42258224 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis - [675]
Balakrishnan A, Goodpaster T, Randolph-Habecker J et al.. “Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27852699 ↗
L4OTHERCited in: Biopsy and Histologic Diagnosis - [676]
Gouda MA, Gonugunta A, Dumbrava EE et al.. “Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39841861 ↗
L4OTHERCited in: Biopsy and Histologic Diagnosis, Management Overview, Prognosis and Prognostic Factors - [677]
Dolled-Filhart M, Rydén L, Cregger M et al.. “Classification of breast cancer using genetic algorithms and tissue microarrays.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 17085660 ↗
L4OTHERCited in: Biopsy and Histologic Diagnosis - [678]
Piscuoglio S, Ng CK, Murray MP et al.. “The Genomic Landscape of Male Breast Cancers.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 26960396 ↗
L4OTHERCited in: Biopsy and Histologic Diagnosis - [679]
Downs BM, Mercado-Rodriguez C, Cimino-Mathews A et al.. “DNA Methylation Markers for Breast Cancer Detection in the Developing World.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 31300453 ↗
L3OTHERCited in: Biopsy and Histologic Diagnosis - [680]
Badve S, Turbin D, Thorat MA et al.. “FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.” Clinical cancer research : an official journal of the American Association for Cancer Research (2007). PMID: 17671124 ↗
L2OTHERCited in: Biopsy and Histologic Diagnosis - [681]
Jhaveri K, Rugo HS, Cortés J et al.. “Exploratory analysis of PTEN deficiency by immunohistochemistry from the Phase III CAPItello-291 trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 42154572 ↗
L2OTHERCited in: Biopsy and Histologic Diagnosis - [682]
Stratton M, Davies J, Joshi H. “Rethinking lymphadenectomy in the immunotherapy era of colorectal cancer: A hypothesis-generating perspective.” Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland (2026). PMID: 42396616 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis - [683]
Dolu F, Ay OF, Akgün IE et al.. “Predictors of sentinel lymph node metastasis in cT1-2 cN0 breast cancer: A retrospective cohort study.” Medicine (2026). PMID: 42410794 ↗
L2COHORTCited in: Biopsy and Histologic Diagnosis, Imaging, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [684]
Surendran HP, Dutta D, Unnikrishnan MK et al.. “Concordance of Receptor Expression Status in the Primary Breast Tumor and in Breast Cancer Metastasized into the Brain: Analysis from an Indian Cohort Prospective Study (CTRI/2022/01/039599).” Indian journal of surgical oncology (2025). PMID: 42381785 ↗
L2COHORTCited in: Biopsy and Histologic Diagnosis - [685]
Perry N, Broeders M, de Wolf C et al.. “European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition--summary document.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 18024988 ↗
L1GUIDELINECited in: Imaging - [686]
Im SA, Gennari A, Park YH et al.. “Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer.” ESMO open (2023). PMID: 37178669 ↗
L1GUIDELINECited in: Imaging - [687]
Mulder RL, Kremer LC, Hudson MM et al.. “Recommendations for breast cancer surveillance for female survivors of childhood, adolescent, and young adult cancer given chest radiation: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.” The Lancet. Oncology (2013). PMID: 24275135 ↗
L1GUIDELINECited in: Imaging - [688]
Houssami N, Costelloe CM. “Imaging bone metastases in breast cancer: evidence on comparative test accuracy.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21896542 ↗
L1SR_OBSCited in: Imaging - [689]
Turner NC, Swift C, Jenkins B et al.. “Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2022). PMID: 36423745 ↗
L2RCTCited in: Imaging - [690]
Houssami N, Turner R, Macaskill P et al.. “An individual person data meta-analysis of preoperative magnetic resonance imaging and breast cancer recurrence.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 24395846 ↗
L1SR_OBSCited in: Imaging - [691]
van Geel JJL, Boers J, Elias SG et al.. “Clinical Validity of 16α-[18F]Fluoro-17β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35584346 ↗
L2SR_OBSCited in: Imaging - [692]
Woodward WA, Vinh-Hung V, Ueno NT et al.. “Prognostic value of nodal ratios in node-positive breast cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2006). PMID: 16782931 ↗
L2SR_OBSCited in: Imaging - [693]
Loibl S, Marmé F, Martin M et al.. “Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 33793299 ↗
L1RCTCited in: Imaging - [694]
García-Mosquera JJ, Pérez-García JM, Ruiz-Borrego M et al.. “Comparing [18F]FDG-positron emission tomography and breast magnetic resonance imaging to predict pathological complete response and 3-year invasive disease-free survival in HER2-positive early breast cancer patients: an unplanned exploratory analysis of the PHERGain trial.” ESMO open (2025). PMID: 41202503 ↗
L2RCTCited in: Imaging - [695]
Hatschek T, Foukakis T, Bjöhle J et al.. “Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial.” JAMA oncology (2021). PMID: 34165503 ↗
L1RCTCited in: Imaging - [696]
Pabst KM, Weber MM, Laschinsky C et al.. “[68Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial.” The Lancet. Oncology (2025). PMID: 40774265 ↗
L4TRIAL_NONRANDOMCited in: Imaging - [697]
van der Voort A, Louis FM, van Ramshorst MS et al.. “MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.” The Lancet. Oncology (2024). PMID: 38588682 ↗
L4TRIAL_NONRANDOMCited in: Imaging - [698]
Bénard F, Harsini S, Wilson D et al.. “Intra-individual comparison of 18F-sodium fluoride PET-CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial.” The Lancet. Oncology (2022). PMID: 36343655 ↗
L2TRIAL_NONRANDOMCited in: Imaging - [699]
Shih J, Bashir B, Gustafson KS et al.. “Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 26285240 ↗
L4CASE_REPORTCited in: Imaging - [700]
McDonald ES, Doot RK, Pantel AR et al.. “Positron Emission Tomography Imaging of Poly-(Adenosine Diphosphate-Ribose) Polymerase 1 Expression in Breast Cancer: A Nonrandomized Clinical Trial.” JAMA oncology (2020). PMID: 32297911 ↗
L4TRIAL_NONRANDOMCited in: Imaging - [701]
Kjeldsted E, Ammitzbøll G, Lænkholm AV et al.. “Effects of Supervised Exercise during Neoadjuvant Chemotherapy on Tumor Response in Patients with Breast Cancer (Neo-train): A Randomized Controlled Trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40788186 ↗
L1RCTCited in: Imaging, Management Overview, History and Evolution of Treatment - [702]
Formenti SC, Lee P, Adams S et al.. “Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 29476019 ↗
L1RCTCited in: Imaging - [703]
Carlson RW, Moench S, Hurria A et al.. “NCCN Task Force Report: breast cancer in the older woman.” Journal of the National Comprehensive Cancer Network : JNCCN (2008). PMID: 18597715 ↗
L1REVIEW_NARRATIVECited in: Imaging - [704]
Le-Petross HT. “Breast MRI as a screening tool: the appropriate role.” Journal of the National Comprehensive Cancer Network : JNCCN (2006). PMID: 16687098 ↗
L5REVIEW_NARRATIVECited in: Imaging - [705]
Ko H, Baghdadi Y, Love C et al.. “Clinical Utility of 18F-FDG PET/CT in Staging Localized Breast Cancer Before Initiating Preoperative Systemic Therapy.” Journal of the National Comprehensive Cancer Network : JNCCN (2020). PMID: 32886897 ↗
L2OTHERCited in: Imaging - [706]
Edge SB. “Advances in breast surgery, 2002-2012.” Journal of the National Comprehensive Cancer Network : JNCCN (2013). PMID: 23307981 ↗
L5OTHERCited in: Imaging - [707]
Kamal A, Zhang T, Power S et al.. “Is Advanced Imaging in Early-Stage Breast Cancer Ever Warranted? Reconciling Clinical Judgment With Common Quality Measures.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 27496115 ↗
L2OTHERCited in: Imaging - [708]
Di Meglio A, Lin NU, Freedman RA et al.. “Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28275032 ↗
L2OTHERCited in: Imaging - [709]
Hyland CJ, Varghese F, Yau C et al.. “Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II-III Breast Cancer: A Multicenter Value Analysis.” Journal of the National Comprehensive Cancer Network : JNCCN (2020). PMID: 33152704 ↗
L2OTHERCited in: Imaging - [710]
Sahin AA, Gilligan TD, Caudell JJ. “Challenges With the 8th Edition of the AJCC Cancer Staging Manual for Breast, Testicular, and Head and Neck Cancers.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31117030 ↗
L5OTHERCited in: Imaging - [711]
Podoloff DA, Advani RH, Allred C et al.. “NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2007). PMID: 17509259 ↗
L1OTHERCited in: Imaging - [712]
Starodub AN, Ocean AJ, Shah MA et al.. “First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 25944802 ↗
L4TRIAL_NONRANDOMCited in: Imaging, Management Overview - [713]
Kenny LM, Contractor KB, Hinz R et al.. “Reproducibility of [11C]choline-positron emission tomography and effect of trastuzumab.” Clinical cancer research : an official journal of the American Association for Cancer Research (2010). PMID: 20682702 ↗
L4TRIAL_NONRANDOMCited in: Imaging - [714]
Martín M, Stecklein SR, Gluz O et al.. “TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 39419289 ↗
L2OTHERCited in: Imaging, Staging - [715]
Woolf DK, Padhani AR, Makris A. “Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care?” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 25471332 ↗
L5REVIEW_NARRATIVECited in: Imaging - [716]
Lynch SP, Lei X, Chavez-MacGregor M et al.. “Multifocality and multicentricity in breast cancer and survival outcomes.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 22776706 ↗
L2OTHERCited in: Imaging - [717]
Cinieri S, Orlando L, Fedele P et al.. “Adjuvant strategies in breast cancer: new prospectives, questions and reflections at the end of 2007 St Gallen International Expert Consensus Conference.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17591835 ↗
L5REVIEW_NARRATIVECited in: Imaging - [718]
Pike MC, Pearce CL. “Mammographic density, MRI background parenchymal enhancement and breast cancer risk.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 24131968 ↗
L5OTHERCited in: Imaging - [719]
Sanna G, Preda L, Bruschini R et al.. “Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2006). PMID: 16936182 ↗
L2OTHERCited in: Imaging - [720]
Wishart GC, Greenberg DC, Chou P et al.. “Treatment and survival in breast cancer in the Eastern Region of England.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19502647 ↗
L2OTHERCited in: Imaging - [721]
Bernsdorf M, Berthelsen AK, Wielenga VT et al.. “Preoperative PET/CT in early-stage breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 22357250 ↗
L2OTHERCited in: Imaging - [722]
Winchester DJ, Singh L, Edge SB et al.. “Novel Postneoadjuvant Prognostic Breast Cancer Staging System.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40215445 ↗
L2OTHERCited in: Imaging, Staging - [723]
Orel S. “Who should have breast magnetic resonance imaging evaluation?” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18258977 ↗
L5REVIEW_NARRATIVECited in: Imaging - [724]
Hodgson NC, Gulenchyn KY. “Is there a role for positron emission tomography in breast cancer staging?” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18258978 ↗
L5REVIEW_NARRATIVECited in: Imaging - [725]
Zakhireh J, Fowble B, Esserman LJ. “Application of screening principles to the reconstructed breast.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19884555 ↗
L5REVIEW_NARRATIVECited in: Imaging - [726]
Cooke R, Baxter P, Wyld L et al.. “Factors influencing women's preferences and decision making regarding the extent of axillary surgery in breast cancer: A systematic review.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 42330708 ↗
L2SR_OBSCited in: Imaging - [727]
Bartram A, Gilbert F, Thompson A et al.. “Breast MRI in DCIS size estimation, breast-conserving surgery and oncoplastic breast surgery.” Cancer treatment reviews (2021). PMID: 33610127 ↗
L5REVIEW_NARRATIVECited in: Imaging - [728]
Miglietta F, Fabi A, Generali D et al.. “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review.” Cancer treatment reviews (2023). PMID: 36638600 ↗
L5REVIEW_NARRATIVECited in: Imaging - [729]
Pantaleo MA, Nannini M, Maleddu A et al.. “Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy.” Cancer treatment reviews (2007). PMID: 18055120 ↗
L5REVIEW_NARRATIVECited in: Imaging - [730]
Persano I, Licata L, Piras M et al.. “De-escalation strategies for axillary management at primary surgery in early breast cancer: insights and implications for medical oncology practice.” Cancer treatment reviews (2026). PMID: 41570550 ↗
L5REVIEW_NARRATIVECited in: Imaging - [731]
Ponzone R, Ruatta F, Gatti M et al.. “Omission of axillary dissection after a positive sentinel lymph-node: Implications in the multidisciplinary treatment of operable breast cancer.” Cancer treatment reviews (2016). PMID: 27262016 ↗
L5REVIEW_NARRATIVECited in: Imaging - [732]
Valle I, Ribeiro JM, Grinda T et al.. “Progress toward personalized management of stage II/III triple negative breast cancer.” Cancer treatment reviews (2026). PMID: 42068737 ↗
L5REVIEW_NARRATIVECited in: Imaging - [733]
Li Z, Kang D, Xu S et al.. “Collagen signature adds prognostically significant information to staging for breast cancer.” ESMO open (2024). PMID: 39577107 ↗
L2OTHERCited in: Imaging, Staging - [734]
Wu S, Hong G, Xu A et al.. “Artificial intelligence-based model for lymph node metastases detection on whole slide images in bladder cancer: a retrospective, multicentre, diagnostic study.” The Lancet. Oncology (2023). PMID: 36893772 ↗
L2OTHERCited in: Imaging - [735]
Fowler AM, Strigel RM. “Clinical advances in PET-MRI for breast cancer.” The Lancet. Oncology (2022). PMID: 34973230 ↗
L5REVIEW_NARRATIVECited in: Imaging - [736]
Fouad TM, Barrera AMG, Reuben JM et al.. “Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system.” The Lancet. Oncology (2017). PMID: 28368261 ↗
L5REVIEW_NARRATIVECited in: Imaging - [737]
Costelloe CM, Rohren EM, Madewell JE et al.. “Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis.” The Lancet. Oncology (2009). PMID: 19482249 ↗
L5REVIEW_NARRATIVECited in: Imaging - [738]
Jatoi I, Benson JR, Toi M. “De-escalation of axillary surgery in early breast cancer.” The Lancet. Oncology (2016). PMID: 27733269 ↗
L5REVIEW_NARRATIVECited in: Imaging - [739]
van Kruchten M, de Vries EGE, Brown M et al.. “PET imaging of oestrogen receptors in patients with breast cancer.” The Lancet. Oncology (2013). PMID: 24079874 ↗
L5REVIEW_NARRATIVECited in: Imaging - [740]
Anderson BO, Cazap E, El Saghir NS et al.. “Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus, 2010.” The Lancet. Oncology (2011). PMID: 21463833 ↗
L1OTHERCited in: Imaging - [741]
Pfob A, Pham TH, de Boniface J et al.. “Lymph node surgery and CDK4/6 inhibitors in early breast cancer: a pooled analysis from five randomised trials.” The Lancet. Oncology (2026). PMID: 42061372 ↗
L1OTHERCited in: Imaging - [742]
Tomala J, Upadhyay N. “Comparative Analysis of CEM and Breast MRI: A Retrospective Study.” Journal of surgical oncology (2026). PMID: 42394378 ↗
L3COHORTCited in: Imaging - [743]
van Hemert AKE, van Loevezijn AA, Baas MPD et al.. “Iodine Seed-Marking Protocol for Response-Guided Axillary Treatment After Systemic Therapy for Node-Positive Breast Cancer.” JAMA oncology (2025). PMID: 40875213 ↗
L2OTHERCited in: Imaging - [744]
Geuzinge HA, Obdeijn IM, Rutgers EJT et al.. “Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.” JAMA oncology (2020). PMID: 32729887 ↗
L2OTHERCited in: Imaging - [745]
Arnaout A, Catley C, Booth CM et al.. “Use of Preoperative Magnetic Resonance Imaging for Breast Cancer: A Canadian Population-Based Study.” JAMA oncology (2015). PMID: 26402040 ↗
L2OTHERCited in: Imaging - [746]
Cho N, Han W, Han BK et al.. “Breast Cancer Screening With Mammography Plus Ultrasonography or Magnetic Resonance Imaging in Women 50 Years or Younger at Diagnosis and Treated With Breast Conservation Therapy.” JAMA oncology (2017). PMID: 28655029 ↗
L2OTHERCited in: Imaging - [747]
Mittendorf EA, Vila J, Tucker SL et al.. “The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment.” JAMA oncology (2016). PMID: 26986538 ↗
L2OTHERCited in: Imaging - [748]
Weiss A, Chavez-MacGregor M, Lichtensztajn DY et al.. “Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer.” JAMA oncology (2018). PMID: 29222540 ↗
L2OTHERCited in: Imaging - [749]
Patnaik A, Rosen LS, Tolaney SM et al.. “Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.” Cancer discovery (2016). PMID: 27217383 ↗
L4OTHERCited in: Imaging, Staging, Prognosis and Prognostic Factors - [750]
Junankar S, Shay G, Jurczyluk J et al.. “Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer.” Cancer discovery (2014). PMID: 25312016 ↗
L5OTHERCited in: Imaging - [751]
van Kruchten M, de Vries EG, Glaudemans AW et al.. “Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.” Cancer discovery (2014). PMID: 25380844 ↗
L4OTHERCited in: Imaging - [752]
Ros S, Wright AJ, D'Santos P et al.. “Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer.” Cancer cell (2020). PMID: 32976773 ↗
L5OTHERCited in: Imaging - [753]
Yang Y, Lin T, Li J et al.. “Clinical and Imaging Characteristics in the Diagnosis and Surgical Management of Nipple Discharge Without Clinically Palpable Masses: A Retrospective Cohort Study.” Thoracic cancer (2026). PMID: 42338287 ↗
L3COHORTCited in: Imaging - [754]
Mao J, Song J, Liu Y et al.. “Dynamic contrast-enhanced magnetic resonance imaging-derived three-dimensional tumor volume improves prognostic stratification in breast cancer: a retrospective cohort study.” Gland surgery (2026). PMID: 42299284 ↗
L3COHORTCited in: Imaging, Staging - [755]
Linden HM, Mankoff DA. “Can Molecular Imaging Find a Path to Navigate Evolving Breast Cancer Treatments?” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36988617 ↗
L5OTHERCited in: Imaging - [756]
Diot G, Metz S, Noske A et al.. “Multispectral Optoacoustic Tomography (MSOT) of Human Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28899968 ↗
L4OTHERCited in: Imaging - [757]
Iqbal R, Yaqub M, Bektas HO et al.. “[18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36735488 ↗
L4OTHERCited in: Imaging - [758]
Gough M, Kwah KKX, Khan T et al.. “Receptor CDCP1 Is a Potential Target for Personalized Imaging and Treatment of Poor Outcome HER2+, Triple-Negative, and Metastatic ER+/HER2- Breast Cancers.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39869307 ↗
L4OTHERCited in: Imaging - [759]
Cheng VWT, de Pennington N, Zakaria R et al.. “VCAM-1-targeted MRI Improves Detection of the Tumor-brain Interface.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 35312755 ↗
L5OTHERCited in: Imaging - [760]
Andreassen MMS, Rodríguez-Soto AE, Conlin CC et al.. “Discrimination of Breast Cancer from Healthy Breast Tissue Using a Three-component Diffusion-weighted MRI Model.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 33148675 ↗
L2OTHERCited in: Imaging - [761]
Nie P, Kalidindi T, Nagle VL et al.. “Imaging of Cancer γ-Secretase Activity Using an Inhibitor-Based PET Probe.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 34475100 ↗
L5OTHERCited in: Imaging - [762]
Mishra A, Kumar D, Gupta K et al.. “Gallium-68-labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36449662 ↗
L5OTHERCited in: Imaging - [763]
Contractor KB, Kenny LM, Stebbing J et al.. “[11C]choline positron emission tomography in estrogen receptor-positive breast cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2009). PMID: 19706823 ↗
L4OTHERCited in: Imaging - [764]
Yang W, Li H, Shen D et al.. “Report of a case of renal hilum Castleman disease complicated with Paget's disease of the breast.” Frontiers in medicine (2026). PMID: 42318394 ↗
L4CASE_REPORTCited in: Imaging - [765]
Taleb I, Witmeyer S, Huck C et al.. “Adenoid cystic carcinoma of the breast: a case series of 26 patients.” Breast cancer research and treatment (2026). PMID: 42283891 ↗
L4CASE_REPORTCited in: Imaging - [766]
Toyota PR, Hounjet CD, Liu E et al.. “Tumor-to-Tumor Metastasis Involving Vestibular Schwannoma: Case Report and Literature Review.” Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology (2026). PMID: 42283164 ↗
L4CASE_REPORTCited in: Imaging - [767]
Zhang L, Birla S, Tang SX et al.. “Impact of Total and Positive Lymph Node Count on Recurrence in Young Women with Node-Positive Breast Cancer Undergoing Neoadjuvant Chemotherapy.” Annals of surgical oncology (2026). PMID: 42420636 ↗
L3OTHERCited in: Imaging - [768]
Venkatesh H, Castro Gierach G, Kanzaki L et al.. “Pregnancy-Associated Breast Cancer: A Trimester and Subtype Based Clinical Decision Framework for the Surgeon and Surgical Trainee.” Annals of surgical oncology (2026). PMID: 42390665 ↗
L5REVIEW_NARRATIVECited in: Imaging - [769]
Giordano SH, Elias AD, Gradishar WJ. “NCCN Guidelines Updates: Breast Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 29784737 ↗
L1GUIDELINECited in: Molecular Diagnostics and Biomarkers, Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors - [770]
Yang SX, Yu J, Wang M. “21-Gene Recurrence Score and Survival Outcomes in the Phase III Multicenter TAILORx Clinical Trial.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 39019060 ↗
L2RCTCited in: Molecular Diagnostics and Biomarkers - [771]
Wu W, Yang Y, Yang W et al.. “Tailoring Escalation Adjuvant Therapy for Early-Stage Triple-Negative Breast Cancer in the CBCSG010 Clinical Trial Biomarker Analysis.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 39413834 ↗
L2TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Staging, Prognosis and Prognostic Factors - [772]
Hortobagyi GN, Lacko A, Sohn J et al.. “A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 39442617 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations - [773]
Harbeck N, Modi S, Pusztai L et al.. “Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 41130363 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Special Populations - [774]
Goetz MP, Toi M, Huober J et al.. “Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 38729566 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations - [775]
Schneeweiss A, Chia S, Hickish T et al.. “Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23704196 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment - [776]
Hortobagyi GN, Stemmer SM, Burris HA et al.. “Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 29718092 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Special Populations - [777]
Johnston S, Martin M, O'Shaughnessy J et al.. “Overall survival with abemaciclib in early breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 41110697 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations - [778]
Harbeck N, Rastogi P, Martin M et al.. “Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.” Annals of oncology : official journal of the European Society for Medical Oncology (2021). PMID: 34656740 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [779]
Johnston SRD, Harbeck N, Hegg R et al.. “Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32954927 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors - [780]
Bidard FC, Kaklamani VG, Neven P et al.. “Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35584336 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers - [781]
Goetz MP, Toi M, Campone M et al.. “MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28968163 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Special Populations - [782]
Bardia A, Jhaveri K, Im SA et al.. “Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39265124 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers - [783]
Sledge GW, Toi M, Neven P et al.. “MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28580882 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [784]
Bardia A, Rugo HS, Tolaney SM et al.. “Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38422473 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers - [785]
Slamon DJ, Neven P, Chia S et al.. “Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29860922 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers - [786]
Saura C, Modi S, Krop I et al.. “Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01).” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 38092229 ↗
L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers - [787]
Bardia A, Krop IE, Kogawa T et al.. “Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38652877 ↗
L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers - [788]
Crown J, Stroyakovskii D, Yardley DA et al.. “Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.” ESMO open (2025). PMID: 41320342 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations - [789]
Hurvitz SA, Kim SB, Chung WP et al.. “Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.” ESMO open (2024). PMID: 38796287 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations - [790]
Swain SM, Miles D, Kim SB et al.. “Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.” The Lancet. Oncology (2020). PMID: 32171426 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations - [791]
Bidard FC, Hardy-Bessard AC, Dalenc F et al.. “Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.” The Lancet. Oncology (2022). PMID: 36183733 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors - [792]
van Ramshorst MS, van der Voort A, van Werkhoven ED et al.. “Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.” The Lancet. Oncology (2018). PMID: 30413379 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors - [793]
Gianni L, Pienkowski T, Im YH et al.. “Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.” The Lancet. Oncology (2011). PMID: 22153890 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations - [794]
Gianni L, Pienkowski T, Im YH et al.. “5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.” The Lancet. Oncology (2016). PMID: 27179402 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations - [795]
Cristofanilli M, Turner NC, Bondarenko I et al.. “Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.” The Lancet. Oncology (2016). PMID: 26947331 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations - [796]
Oliveira M, Rugo HS, Howell SJ et al.. “Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.” The Lancet. Oncology (2024). PMID: 39214106 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors, Special Populations - [797]
Toi M, Imoto S, Ishida T et al.. “Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.” The Lancet. Oncology (2021). PMID: 33387497 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors, Special Populations - [798]
Turner NC, Oliveira M, Howell SJ et al.. “Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.” The New England journal of medicine (2023). PMID: 37256976 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment - [799]
Modi S, Jacot W, Yamashita T et al.. “Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.” The New England journal of medicine (2022). PMID: 35665782 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment - [800]
Bardia A, Hu X, Dent R et al.. “Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.” The New England journal of medicine (2024). PMID: 39282896 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations - [801]
Slamon D, Lipatov O, Nowecki Z et al.. “Ribociclib plus Endocrine Therapy in Early Breast Cancer.” The New England journal of medicine (2024). PMID: 38507751 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment - [802]
Masuda N, Lee SJ, Ohtani S et al.. “Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.” The New England journal of medicine (2017). PMID: 28564564 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations - [803]
von Minckwitz G, Huang CS, Mano MS et al.. “Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.” The New England journal of medicine (2018). PMID: 30516102 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations - [804]
Verma S, Miles D, Gianni L et al.. “Trastuzumab emtansine for HER2-positive advanced breast cancer.” The New England journal of medicine (2012). PMID: 23020162 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers - [805]
Modi S, Saura C, Yamashita T et al.. “Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.” The New England journal of medicine (2019). PMID: 31825192 ↗
L4RCTCited in: Molecular Diagnostics and Biomarkers - [806]
André F, Ciruelos EM, Juric D et al.. “Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 33246021 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers - [807]
Curigliano G, Mueller V, Borges V et al.. “Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.” Annals of oncology : official journal of the European Society for Medical Oncology (2021). PMID: 34954044 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [808]
Gambardella V, Accordino MK, Bedard PL et al.. “Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374).” ESMO open (2025). PMID: 40513140 ↗
L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Special Populations - [809]
Tan AR, Im SA, Mattar A et al.. “Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.” The Lancet. Oncology (2020). PMID: 33357420 ↗
L1TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Staging, Management Overview, Prognosis and Prognostic Factors - [810]
Hughes KS, Schnaper LA, Bellon JR et al.. “Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 23690420 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Staging, Management Overview, Special Populations - [811]
Sledge GW, Toi M, Neven P et al.. “The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.” JAMA oncology (2020). PMID: 31563959 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment - [812]
Wortelboer N, van Ommen-Nijhof A, Konings IR et al.. “Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer: A Randomized Clinical Trial.” JAMA oncology (2026). PMID: 41712229 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations - [813]
Martin M, Hegg R, Kim SB et al.. “Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.” JAMA oncology (2022). PMID: 35653145 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Prognosis and Prognostic Factors - [814]
van der Voort A, van Ramshorst MS, van Werkhoven ED et al.. “Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial.” JAMA oncology (2021). PMID: 34014249 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment - [815]
Munzone E, Regan MM, Cinieri S et al.. “Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial.” JAMA oncology (2023). PMID: 37440239 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Special Populations - [816]
Shao Z, Pang D, Yang H et al.. “Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial.” JAMA oncology (2020). PMID: 31647503 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers - [817]
O'Leary B, Cutts RJ, Liu Y et al.. “The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.” Cancer discovery (2018). PMID: 30206110 ↗
L3RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Prognosis and Prognostic Factors - [818]
Pusztai L, Yau C, Wolf DM et al.. “Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.” Cancer cell (2021). PMID: 34143979 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations - [819]
Fan L, Zhang WJ, Li HP et al.. “Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrial.” Cancer cell (2025). PMID: 41349543 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations - [820]
Schettini F, Nucera S, Pascual T et al.. “Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis.” Cancer treatment reviews (2024). PMID: 39709655 ↗
L1SR_OBSCited in: Molecular Diagnostics and Biomarkers - [821]
de Almeida LFC, Leite LF, Cappellaro AP et al.. “Sequencing antibody-drug conjugates in metastatic breast cancer: A systematic review.” Cancer treatment reviews (2025). PMID: 41401644 ↗
L5SR_OBSCited in: Molecular Diagnostics and Biomarkers - [822]
Yang Z, Meng J, Mei X et al.. “Brain Radiotherapy With Pyrotinib and Capecitabine in Patients With ERBB2-Positive Advanced Breast Cancer and Brain Metastases: A Nonrandomized Phase 2 Trial.” JAMA oncology (2024). PMID: 38175627 ↗
L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers - [823]
Tsurutani J, Iwata H, Krop I et al.. “Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.” Cancer discovery (2020). PMID: 32213540 ↗
L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Special Populations - [824]
Filho OM, Viale G, Stein S et al.. “Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab.” Cancer discovery (2021). PMID: 33941592 ↗
L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors, Special Populations - [825]
Ma D, Dai LJ, Wu XR et al.. “Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer.” Cancer cell (2025). PMID: 40215979 ↗
L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors - [826]
Lu YS, Im SA, Colleoni M et al.. “Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 34965945 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment - [827]
Lin NU, Murthy RK, Abramson V et al.. “Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial.” JAMA oncology (2023). PMID: 36454580 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment - [828]
O'Regan RM, Zhang Y, Fleming GF et al.. “Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer.” JAMA oncology (2024). PMID: 39145953 ↗
L3RCTCited in: Molecular Diagnostics and Biomarkers, Staging - [829]
Ademuyiwa FO, Ma CX, Weilbaecher K et al.. “Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40116350 ↗
L2TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Staging, Management Overview, Prognosis and Prognostic Factors - [830]
Arpino G, de la Haba Rodríguez J, Ferrero JM et al.. “Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36716289 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment - [831]
Masuda N, Saji S, Kojima Y et al.. “Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD.” Breast cancer research and treatment (2026). PMID: 42420599 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations - [832]
Peiffer DS, Maloney C, Chen N. “What is Optimal Neoadjuvant Therapy in HER2-Positive Breast Cancer?” Journal of the National Comprehensive Cancer Network : JNCCN (2026). PMID: 42425154 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Staging, Management Overview - [833]
Keenan TE, Tolaney SM. “Role of Immunotherapy in Triple-Negative Breast Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2020). PMID: 32259782 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors - [834]
Telli ML, Witteles RM. “Trastuzumab-related cardiac dysfunction.” Journal of the National Comprehensive Cancer Network : JNCCN (2011). PMID: 21310845 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview - [835]
Santa-Maria CA, Nanda R. “Immune Checkpoint Inhibitor Therapy in Breast Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30323094 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [836]
Spring LM, Bar Y, Isakoff SJ. “The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 35714678 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [837]
Schwartzberg LS. “Use of Biomarkers and Multigene Assays in Breast Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28515241 ↗
L5OTHERCited in: Molecular Diagnostics and Biomarkers, Staging - [838]
Stabellini N, Cao L, Towe CW et al.. “Validation of the PREDICT Prognostication Tool in US Patients With Breast Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 37856198 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers - [839]
Kwon JS, Pansegrau G, Nourmoussavi M et al.. “Costs and Benefits of Extended Endocrine Strategies for Premenopausal Breast Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28784863 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers - [840]
Eroglu Z, Fielder O, Somlo G. “Analysis of circulating tumor cells in breast cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2013). PMID: 23946176 ↗
L5OTHERCited in: Molecular Diagnostics and Biomarkers - [841]
Yao H, Zhao R, Lai X et al.. “A multi-centre, phase 1a/1b dose escalation and expansion study of the HER2-directed antibody-drug conjugate T-Bren (BL-M07D1) in advanced breast cancer and other solid tumours.” EBioMedicine (2026). PMID: 42349255 ↗
L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Staging, Prognosis and Prognostic Factors - [842]
Balaha M, Aldosari SA, Alamer AA et al.. “Tissue-Agnostic Targeting in Solid Tumors: A PRISMA-Compliant Meta-Analysis of Efficacy, Safety, and Resistance Determinants Across Histologies.” Oncology research (2026). PMID: 42358834 ↗
L1SR_OBSCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [843]
Goldhirsch A, Winer EP, Coates AS et al.. “Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23917950 ↗
L1OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview - [844]
Magbanua MJM, Swigart LB, Wu HT et al.. “Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 33232761 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers - [845]
Provenzano L, Dieci MV, Curigliano G et al.. “Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40204155 ↗
L3OTHERCited in: Molecular Diagnostics and Biomarkers - [846]
Rastogi P, O'Shaughnessy J, Martin M et al.. “Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38194616 ↗
L1OTHERCited in: Molecular Diagnostics and Biomarkers - [847]
Lin J, Xu H, Zhou Y et al.. “Prognostic significance of ctDNA mutations in advanced HER2-positive breast cancer treated with targeted therapy: A meta-analysis.” Advances in clinical and experimental medicine : official organ Wroclaw Medical University (2026). PMID: 42345502 ↗
L1SR_OBSCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [848]
Cantini L, Trapani D, Guidi L et al.. “Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer.” Cancer treatment reviews (2023). PMID: 38141462 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview - [849]
Boscolo Bielo L, Trapani D, Nicolò E et al.. “The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer.” Cancer treatment reviews (2024). PMID: 38772169 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview - [850]
von Arx C, De Placido P, Caltavituro A et al.. “The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.” Cancer treatment reviews (2022). PMID: 36587473 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers - [851]
Berton Giachetti PPM, Carnevale Schianca A, Trapani D et al.. “Current controversies in the use of Oncotype DX in early breast cancer.” Cancer treatment reviews (2025). PMID: 40048856 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors - [852]
Buonaiuto R, Botticelli A, Criscitiello C et al.. “Key decision factors in second-line therapy: Expert insights on HR+/HER2-metastatic breast cancer post-CDK4/6 inhibitor progression.” Cancer treatment reviews (2025). PMID: 40450825 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview - [853]
Sahin TK, Rizzo A, Guven DC et al.. “Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer.” Cancer treatment reviews (2025). PMID: 40121890 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers - [854]
Tray N, Taff J, Adams S. “Therapeutic landscape of metaplastic breast cancer.” Cancer treatment reviews (2019). PMID: 31491663 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Staging, Prognosis and Prognostic Factors - [855]
Dieci MV, Miglietta F, Griguolo G et al.. “Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors.” Cancer treatment reviews (2020). PMID: 32622272 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment - [856]
Pondé N, Brandão M, El-Hachem G et al.. “Treatment of advanced HER2-positive breast cancer: 2018 and beyond.” Cancer treatment reviews (2018). PMID: 29751334 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers - [857]
Tolaney SM, Punie K, Carey LA et al.. “Real-world treatment patterns and outcomes in patients with HR+/HER2- metastatic breast cancer treated with chemotherapy in the United States.” ESMO open (2024). PMID: 39241499 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors, Special Populations - [858]
Llombart-Cussac A, Pérez-García JM, Bellet M et al.. “Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial.” ESMO open (2025). PMID: 40532361 ↗
L1OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview, Special Populations - [859]
Tarantino P, Lee D, Foldi J et al.. “Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer.” ESMO open (2025). PMID: 40532362 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors, Special Populations - [860]
Tolaney SM, Tung N, Wolff AC et al.. “HER2DX genomic test in early-stage HER2-positive breast cancer.” ESMO open (2024). PMID: 39710442 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Staging, Prognosis and Prognostic Factors - [861]
Rugo HS, Layman RM, Lynce F et al.. “Real-world progression-free survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR-positive/HER2-negative metastatic breast cancer in United States routine clinical practice.” ESMO open (2025). PMID: 40896879 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors - [862]
Schlam I, Loi S, Salgado R et al.. “Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges.” ESMO open (2025). PMID: 39826475 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [863]
Yerushalmi R, Woods R, Ravdin PM et al.. “Ki67 in breast cancer: prognostic and predictive potential.” The Lancet. Oncology (2010). PMID: 20152769 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [864]
Yau C, Osdoit M, van der Noordaa M et al.. “Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.” The Lancet. Oncology (2021). PMID: 34902335 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview - [865]
Foulkes WD, Smith IE, Reis-Filho JS. “Triple-negative breast cancer.” The New England journal of medicine (2010). PMID: 21067385 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors - [866]
Vela-Ruiz JM, Morante Z, Ferreyra Y et al.. “Plasma cytokine profiles in breast cancer patients and their association with therapeutic response in Peru: a prospective cohort study.” Frontiers in immunology (2026). PMID: 42344913 ↗
L2COHORTCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [867]
Zheng Y, Chen Y, Lin W et al.. “Association between tumor genomic mutations and the risk of PD-1 inhibitor-induced hypophysitis: a retrospective cohort study.” Frontiers in endocrinology (2026). PMID: 42339089 ↗
L2COHORTCited in: Molecular Diagnostics and Biomarkers - [868]
Garrido-Castro AC, Lin NU, Polyak K. “Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment.” Cancer discovery (2019). PMID: 30679171 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors - [869]
Song KW, Edgar KA, Hanan EJ et al.. “RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy.” Cancer discovery (2021). PMID: 34544753 ↗
L5OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview - [870]
Wilding B, Woelflingseder L, Baum A et al.. “Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers.” Cancer discovery (2025). PMID: 39248702 ↗
L5OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview - [871]
Chen W, Gupta A, Mai N et al.. “Trastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding.” Cancer discovery (2026). PMID: 41212147 ↗
L4OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview - [872]
Chang CA, Jen J, Jiang S et al.. “Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer.” Cancer discovery (2022). PMID: 34911733 ↗
L5OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview - [873]
Dashzeveg NK, Jia Y, Zhang Y et al.. “Dynamic Glycoprotein Hyposialylation Promotes Chemotherapy Evasion and Metastatic Seeding of Quiescent Circulating Tumor Cell Clusters in Breast Cancer.” Cancer discovery (2023). PMID: 37272843 ↗
L5OTHERCited in: Molecular Diagnostics and Biomarkers - [874]
Alam R, Reva A, Edwards DG et al.. “Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast Cancer.” Cancer discovery (2025). PMID: 39835789 ↗
L5OTHERCited in: Molecular Diagnostics and Biomarkers - [875]
Jerusalem G, Park YH, Yamashita T et al.. “Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis.” Cancer discovery (2022). PMID: 36255231 ↗
L4OTHERCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment - [876]
. “T-DXd Keeps Shining in Breast Cancer.” Cancer discovery (2023). PMID: 36484540 ↗
L5OTHERCited in: Molecular Diagnostics and Biomarkers - [877]
Jiang YZ, Ma D, Suo C et al.. “Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.” Cancer cell (2019). PMID: 30853353 ↗
L4OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [878]
Razavi P, Chang MT, Xu G et al.. “The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.” Cancer cell (2018). PMID: 30205045 ↗
L3OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview, Special Populations - [879]
Gan S, Macalinao DG, Shahoei SH et al.. “Distinct tumor architectures and microenvironments for the initiation of breast cancer metastasis in the brain.” Cancer cell (2024). PMID: 39270646 ↗
L5OTHERCited in: Molecular Diagnostics and Biomarkers - [880]
Magbanua MJM, Brown Swigart L, Ahmed Z et al.. “Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.” Cancer cell (2023). PMID: 37146605 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers - [881]
Wolf DM, Yau C, Wulfkuhle J et al.. “Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.” Cancer cell (2022). PMID: 35623341 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview - [882]
Meyer L, Jackson HW, Eling N et al.. “A stratification system for breast cancer based on basoluminal tumor cells and spatial tumor architecture.” Cancer cell (2025). PMID: 40680742 ↗
L4OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [883]
Li JY, Perry SR, Muniz-Medina V et al.. “A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy.” Cancer cell (2016). PMID: 26766593 ↗
L5OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [884]
Jassowicz L, Feng F, Warta R et al.. “Dissecting the cellular architecture of breast cancer brain metastases reveals prognostically distinct immune landscapes.” Cancer cell (2026). PMID: 42049023 ↗
L4OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [885]
Goel S, Wang Q, Watt AC et al.. “Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.” Cancer cell (2016). PMID: 26977878 ↗
L5OTHERCited in: Molecular Diagnostics and Biomarkers - [886]
Shen M, Jiang YZ, Wei Y et al.. “Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling.” Cancer cell (2019). PMID: 30612941 ↗
L5OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [887]
Tan Y, Ye Y, Zhao W et al.. “Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude versus low-altitude regions: a multi-center retrospective study.” Cancer biology & therapy (2026). PMID: 42337391 ↗
L2COHORTCited in: Molecular Diagnostics and Biomarkers - [888]
Elliott MJ, Howarth K, Main S et al.. “Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39785866 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers, Staging, Prognosis and Prognostic Factors - [889]
Coombes RC, Page K, Salari R et al.. “Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 30992300 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [890]
Kabraji S, Ni J, Sammons S et al.. “Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36074155 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [891]
Lin CA, Chica-Parrado MR, Unni N et al.. “ESR1 Y537S and D538G Mutations Drive Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39992682 ↗
L3OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview - [892]
Lloyd MR, Weipert CM, Ali A et al.. “Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41201834 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers - [893]
Meric-Bernstam F, Yuca E, Evans KW et al.. “Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39585341 ↗
L5OTHERCited in: Molecular Diagnostics and Biomarkers - [894]
Rugo HS, Kaklamani V, McArthur H et al.. “Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41235919 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [895]
Emens LA. “Breast Cancer Immunotherapy: Facts and Hopes.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28801472 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors - [896]
Priedigkeit N, Harrison B, Shue R et al.. “Clinicogenomic Characterization of Inflammatory Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40378057 ↗
L3OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors - [897]
Martins-Branco D, Lobo-Martins S, Aftimos P et al.. “EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study.” Breast cancer research and treatment (2026). PMID: 42429895 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview - [898]
Di Cosimo S, Appierto V, Reduzzi C et al.. “Circulating tumor DNA in early breast cancer: Evidence, challenges, next steps.” Cancer (2026). PMID: 42421646 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview - [899]
Rafii S, Al-Shamsi HO, Brufsky A. “SERENA-6 and the regulatory limits of radiologic progression in modern oncology.” Breast cancer research and treatment (2026). PMID: 42418030 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers - [900]
Gradishar WJ, Moran MS, Abraham J et al.. “Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2026). PMID: 42425164 ↗
L1GUIDELINECited in: Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors - [901]
Gradishar WJ, Moran MS, Abraham J et al.. “NCCN Guidelines® Insights: Breast Cancer, Version 5.2025.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 41213254 ↗
L1GUIDELINECited in: Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors - [902]
Gradishar WJ, Anderson BO, Balassanian R et al.. “Breast Cancer Version 2.2015.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 25870381 ↗
L1GUIDELINECited in: Staging, History and Evolution of Treatment, Prognosis and Prognostic Factors - [903]
Gradishar WJ, Anderson BO, Balassanian R et al.. “Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 26957618 ↗
L1GUIDELINECited in: Staging, History and Evolution of Treatment - [904]
Coyle C, Cafferty FH, Vale C et al.. “Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 27681864 ↗
L1SR_OBSCited in: Staging - [905]
Yang SH, Yang KH, Li YP et al.. “Breast conservation therapy for stage I or stage II breast cancer: a meta-analysis of randomized controlled trials.” Annals of oncology : official journal of the European Society for Medical Oncology (2008). PMID: 18187486 ↗
L1SR_MA_RCTCited in: Staging - [906]
Pusztai L, Denkert C, O'Shaughnessy J et al.. “Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 38369015 ↗
L1RCTCited in: Staging, Management Overview, History and Evolution of Treatment, Special Populations - [907]
Gnant M, Dueck AC, Frantal S et al.. “Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34874182 ↗
L1RCTCited in: Staging, Management Overview, Prognosis and Prognostic Factors - [908]
Jones SE, Savin MA, Holmes FA et al.. “Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2006). PMID: 17135639 ↗
L1RCTCited in: Staging - [909]
Tolaney SM, Tayob N, Dang C et al.. “Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34077270 ↗
L1RCTCited in: Staging - [910]
Chen X, Huang J, Shi H et al.. “Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 41365333 ↗
L1RCTCited in: Staging - [911]
Li JJ, Zhang WJ, Zeng XH et al.. “Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 41289548 ↗
L1RCTCited in: Staging - [912]
Schettini F, Pascual T, Conte B et al.. “HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis.” Cancer treatment reviews (2020). PMID: 32000054 ↗
L1SR_OBSCited in: Staging - [913]
Al-Mubarak M, Sacher AG, Ocana A et al.. “Fulvestrant for advanced breast cancer: a meta-analysis.” Cancer treatment reviews (2013). PMID: 23764179 ↗
L1SR_OBSCited in: Staging - [914]
Saleh RR, Nadler MB, Desnoyers A et al.. “Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis.” Cancer treatment reviews (2021). PMID: 34530283 ↗
L1SR_OBSCited in: Staging - [915]
Gonzalez-Conchas GA, Rodriguez-Romo L, Hernandez-Barajas D et al.. “Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis.” Cancer treatment reviews (2017). PMID: 29126017 ↗
L1SR_OBSCited in: Staging - [916]
Bramati A, Girelli S, Torri V et al.. “Efficacy of biological agents in metastatic triple-negative breast cancer.” Cancer treatment reviews (2014). PMID: 24529896 ↗
L1SR_OBSCited in: Staging, Special Populations - [917]
Villacampa G, Pascual T, Tarantino P et al.. “HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis.” The Lancet. Oncology (2025). PMID: 40675165 ↗
L1SR_OBSCited in: Staging - [918]
Zelnak AB, O'Regan RM. “Optimizing Endocrine Therapy for Breast Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 26285250 ↗
L5REVIEW_NARRATIVECited in: Staging, Prognosis and Prognostic Factors - [919]
Kuemmel S, Jung KH, Andrade L et al.. “Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib study.” ESMO open (2025). PMID: 41297162 ↗
L4RCTCited in: Staging - [920]
Tripathy D, Im SA, Colleoni M et al.. “Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.” The Lancet. Oncology (2018). PMID: 29804902 ↗
L1RCTCited in: Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors - [921]
Chen XC, Jiao DC, Qiao JH et al.. “De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial.” The Lancet. Oncology (2024). PMID: 39612919 ↗
L1RCTCited in: Staging - [922]
Martin M, Holmes FA, Ejlertsen B et al.. “Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.” The Lancet. Oncology (2017). PMID: 29146401 ↗
L1RCTCited in: Staging - [923]
Schmid P, Cortes J, Dent R et al.. “Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.” The New England journal of medicine (2024). PMID: 39282906 ↗
L1RCTCited in: Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations - [924]
Kunkler IH, Russell NS, Anderson N et al.. “Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer.” The New England journal of medicine (2025). PMID: 41191939 ↗
L1RCTCited in: Staging - [925]
Hortobagyi GN, Stemmer SM, Burris HA et al.. “Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.” The New England journal of medicine (2016). PMID: 27717303 ↗
L1RCTCited in: Staging - [926]
von Minckwitz G, Eidtmann H, Rezai M et al.. “Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.” The New England journal of medicine (2012). PMID: 22276820 ↗
L1RCTCited in: Staging - [927]
Swain SM, Jeong JH, Geyer CE et al.. “Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.” The New England journal of medicine (2010). PMID: 20519679 ↗
L1RCTCited in: Staging - [928]
Jhaveri KL, Accordino MK, Bedard PL et al.. “Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39236276 ↗
L4TRIAL_NONRANDOMCited in: Staging - [929]
Munhoz RR, Pereira AA, Sasse AD et al.. “Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.” JAMA oncology (2016). PMID: 26426573 ↗
L1SR_OBSCited in: Staging - [930]
Radovich M, Jiang G, Hancock BA et al.. “Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.” JAMA oncology (2020). PMID: 32644110 ↗
L2RCTCited in: Staging, Prognosis and Prognostic Factors - [931]
Nanda R, Liu MC, Yau C et al.. “Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.” JAMA oncology (2020). PMID: 32053137 ↗
L1RCTCited in: Staging, History and Evolution of Treatment - [932]
Ligibel JA, Ballman KV, McCall L et al.. “Impact of a Weight Loss Intervention on 1-Year Weight Change in Women With Stage II/III Breast Cancer: Secondary Analysis of the Breast Cancer Weight Loss (BWEL) Trial.” JAMA oncology (2025). PMID: 40839373 ↗
L1RCTCited in: Staging - [933]
Rios-Hoyo A, Dai J, Noel T et al.. “Immune-related adverse events are associated with better event-free survival in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage triple-negative breast cancer.” ESMO open (2025). PMID: 40107153 ↗
L4TRIAL_NONRANDOMCited in: Staging - [934]
Kuerer HM, Smith BD, Krishnamurthy S et al.. “Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial.” The Lancet. Oncology (2022). PMID: 36306810 ↗
L4TRIAL_NONRANDOMCited in: Staging - [935]
Oakman C, Sapino A, Marchiò C et al.. “Chemotherapy with or without trastuzumab.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 20943603 ↗
L5REVIEW_NARRATIVECited in: Staging - [936]
Azambuja E, Durbecq V, Rosa DD et al.. “HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17872901 ↗
L5REVIEW_NARRATIVECited in: Staging - [937]
Aapro M, Andre F, Blackwell K et al.. “Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 24667713 ↗
L5REVIEW_NARRATIVECited in: Staging - [938]
Banys-Paluchowski M, Solbach C, Kühn T et al.. “AGO Breast Committee recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2026.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 42173036 ↗
L1GUIDELINECited in: Staging - [939]
Sharma P, Kimler BF, O'Dea A et al.. “Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP).” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 33208340 ↗
L1RCTCited in: Staging, Management Overview, History and Evolution of Treatment - [940]
Llombart-Cussac A, Pérez-García J, Brasó-Maristany F et al.. “HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38995291 ↗
L1RCTCited in: Staging - [941]
de Groot AF, Cohen D, Heijns JB et al.. “Ribociclib-Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01).” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40495424 ↗
L1RCTCited in: Staging - [942]
Martín M, Guerrero-Zotano ÁL, Pérez-López ME et al.. “Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2- Highly Proliferative Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41385615 ↗
L1RCTCited in: Staging - [943]
Fasching PA, Slamon D, Nowecki Z et al.. “Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40019493 ↗
L1RCTCited in: Staging - [944]
Kim J, Kim J, Seo KH et al.. “Survival outcomes of young-age female patients with early breast cancer: an international multicenter cohort study.” ESMO open (2024). PMID: 39413678 ↗
L2COHORTCited in: Staging - [945]
Joko-Fru WY, Griesel M, Mezger NCS et al.. “Breast Cancer Diagnostics, Therapy, and Outcomes in Sub-Saharan Africa: A Population-Based Registry Study.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 34965508 ↗
L2OTHERCited in: Staging - [946]
Telli ML, Timms KM, Reid J et al.. “Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 26957554 ↗
L4TRIAL_NONRANDOMCited in: Staging - [947]
Corti C, Binboğa Kurt B, Koca B et al.. “Estrogen Signaling in Early-Stage Breast Cancer: Impact on Neoadjuvant Chemotherapy and Immunotherapy.” Cancer treatment reviews (2024). PMID: 39571402 ↗
L5REVIEW_NARRATIVECited in: Staging, History and Evolution of Treatment, Prognosis and Prognostic Factors - [948]
Yang SX, Polley E, Lipkowitz S. “New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.” Cancer treatment reviews (2016). PMID: 26995633 ↗
L5REVIEW_NARRATIVECited in: Staging - [949]
Criscitiello C, Esposito A, Trapani D et al.. “Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer.” Cancer treatment reviews (2016). PMID: 27744144 ↗
L5REVIEW_NARRATIVECited in: Staging - [950]
Megerdichian C, Olimpiadi Y, Hurvitz SA. “nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer.” Cancer treatment reviews (2014). PMID: 24560997 ↗
L5REVIEW_NARRATIVECited in: Staging, Special Populations - [951]
Shi M, Guo N. “MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer.” Cancer treatment reviews (2009). PMID: 19171434 ↗
L5REVIEW_NARRATIVECited in: Staging - [952]
Marra A, Viale G, Pileri SA et al.. “Breast implant-associated anaplastic large cell lymphoma: A comprehensive review.” Cancer treatment reviews (2020). PMID: 31958739 ↗
L5REVIEW_NARRATIVECited in: Staging - [953]
Carbognin L, Sperduti I, Nortilli R et al.. “Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: sensitivity analysis of randomized trials.” Cancer treatment reviews (2015). PMID: 25683304 ↗
L1REVIEW_NARRATIVECited in: Staging - [954]
Speers C, Pierce LJ. “Postoperative Radiotherapy After Breast-Conserving Surgery for Early-Stage Breast Cancer: A Review.” JAMA oncology (2016). PMID: 27243924 ↗
L5REVIEW_NARRATIVECited in: Staging - [955]
Goldhirsch A, Wood WC, Coates AS et al.. “Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21709140 ↗
L5OTHERCited in: Staging - [956]
Kaidar-Person O, Weltens CG, Fortpied C et al.. “Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer.” The Lancet. Oncology (2026). PMID: 42372743 ↗
L1RCTCited in: Staging, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations - [957]
Kaidar-Person O, Weltens CG, Fortpied C et al.. “Twenty-year results of the randomized European Organization for Research and Treatment of Cancer trial 22922/10925 evaluating internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer.” CA: a cancer journal for clinicians (2026). PMID: 42141924 ↗
L1RCTCited in: Staging - [958]
Brunt AM, Cafferty FH, Kirby AM et al.. “Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy.” The Lancet. Oncology (2026). PMID: 42134381 ↗
L1RCTCited in: Staging - [959]
Fall AD, Veses V, Sheth CC. “Stage at Diagnosis and Molecular Subtype Distribution of Breast Cancer in Sub-Saharan Africa: A Systematic Review.” Cancer reports (Hoboken, N.J.) (2026). PMID: 42266142 ↗
L2SR_OBSCited in: Staging - [960]
Liedtke C, Mazouni C, Hess KR et al.. “Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18250347 ↗
L2OTHERCited in: Staging - [961]
Hunter NB, Parsons HA, Cope L et al.. “The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2026). PMID: 41805422 ↗
L2OTHERCited in: Staging - [962]
Caudle AS, Yang WT, Krishnamurthy S et al.. “Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 26811528 ↗
L2OTHERCited in: Staging - [963]
Montagna G, Laws A, Ferrucci M et al.. “Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39509672 ↗
L3OTHERCited in: Staging - [964]
Ahmed S, Mannala S, Mondal P et al.. “Role of individualized intervention(s) on quality of life and adherence to adjuvant endocrine therapy in premenopausal women with early-stage breast cancer: MyCHOICE study.” Breast cancer research and treatment (2026). PMID: 42360361 ↗
L2TRIAL_NONRANDOMCited in: Staging, Prognosis and Prognostic Factors - [965]
Breidenbach C, Hage AM, Schellack SK et al.. “Providers' perspectives on implementing alert-based patient-reported outcome monitoring for stage IV breast cancer.” Journal of patient-reported outcomes (2026). PMID: 42236639 ↗
L5RCTCited in: Staging - [966]
Elliott MJ, Kim J, Dou A et al.. “Comprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circulating tumor DNA in early-stage breast cancer.” ESMO open (2025). PMID: 40472659 ↗
L3OTHERCited in: Staging - [967]
de Graaf M, Gielen RCAM, Balduzzi S et al.. “Pathological complete response and survival after neoadjuvant chemotherapy in patients with stage I TNBC: a registry-based study.” ESMO open (2025). PMID: 41352286 ↗
L3OTHERCited in: Staging - [968]
Corti C, Chu X, Exman P et al.. “Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study.” ESMO open (2025). PMID: 40714511 ↗
L2OTHERCited in: Staging - [969]
Raghavendra AS, Zakon DB, Jin Q et al.. “Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆.” ESMO open (2024). PMID: 39500139 ↗
L3OTHERCited in: Staging - [970]
Seitz K, Goossens C, Huebner H et al.. “Prognosis prediction with the IHC3 score in patients with node-negative, hormone receptor-positive, HER2-negative early breast cancer.” ESMO open (2024). PMID: 39461262 ↗
L3OTHERCited in: Staging - [971]
Borea R, Blondeaux E, Carmisciano L et al.. “Validation of PREDICT tool v2.2 in patients with early-stage breast cancer enrolled in the GIM and MIG trials.” ESMO open (2026). PMID: 41499989 ↗
L2OTHERCited in: Staging - [972]
Yang Z, Ni P, Wang Y et al.. “Neoadjuvant Chemotherapy for Male Breast Cancer: A Retrospective Cohort Study.” Cancer medicine (2026). PMID: 42204769 ↗
L3COHORTCited in: Staging - [973]
Geurts VCM, Balduzzi S, Steenbruggen TG et al.. “Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With Chemotherapy.” JAMA oncology (2024). PMID: 38935352 ↗
L3OTHERCited in: Staging - [974]
Hoskins KF, Calip GS, Huang HC et al.. “Association of Social Determinants and Tumor Biology With Racial Disparity in Survival From Early-Stage, Hormone-Dependent Breast Cancer.” JAMA oncology (2023). PMID: 36795405 ↗
L3OTHERCited in: Staging - [975]
. “MammaPrint Reduces Breast Cancer Overtreatment.” Cancer discovery (2016). PMID: 27095361 ↗
L5OTHERCited in: Staging, Prognosis and Prognostic Factors - [976]
Wang H, Yu C, Gao X et al.. “The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells.” Cancer cell (2015). PMID: 25600338 ↗
L5OTHERCited in: Staging - [977]
Wang L, Deng H, Fang X et al.. “Clinical and Pathological Characteristics and Prognosis of Breast Cancer During Pregnancy and Postpartum: A Multicenter Retrospective Study.” Cancer reports (Hoboken, N.J.) (2026). PMID: 42243585 ↗
L3COHORTCited in: Staging - [978]
Maitland ML, Sachdev JC, Sharma MR et al.. “First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 34083232 ↗
L4OTHERCited in: Staging - [979]
Licata L, Mariani M, Viale G et al.. “Timing of Recurrence after Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40689866 ↗
L2OTHERCited in: Staging, Management Overview - [980]
Garrido-Castro AC, Spurr LF, Hughes ME et al.. “Genomic Characterization of de novo Metastatic Breast Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 33293374 ↗
L2OTHERCited in: Staging - [981]
Barajas-Garcia MZ, Hernández-Sánchez EN, Ayala-Andrade MM et al.. “Challenges and outcomes of breast reconstruction in advanced-stage breast cancer: a comprehensive review.” Cirugia y cirujanos (2026). PMID: 42184403 ↗
L5SR_OBSCited in: Staging - [982]
Gradishar WJ, Moran MS, Abraham J et al.. “Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 39019058 ↗
L1GUIDELINECited in: Management Overview, History and Evolution of Treatment - [983]
Gradishar WJ, Moran MS, Abraham J et al.. “Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 35714673 ↗
L1GUIDELINECited in: Management Overview - [984]
Gradishar WJ, Anderson BO, Blair SL et al.. “Breast cancer version 3.2014.” Journal of the National Comprehensive Cancer Network : JNCCN (2014). PMID: 24717572 ↗
L1GUIDELINECited in: Management Overview, History and Evolution of Treatment - [985]
Salgado R, Denkert C, Demaria S et al.. “The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 25214542 ↗
L1GUIDELINECited in: Management Overview, History and Evolution of Treatment - [986]
Mosele MF, Westphalen CB, Stenzinger A et al.. “Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 38834388 ↗
L1GUIDELINECited in: Management Overview, History and Evolution of Treatment - [987]
Jimenez RB, Abdou Y, Anderson P et al.. “Postmastectomy Radiation Therapy: An ASTRO-ASCO-SSO Clinical Practice Guideline.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40955654 ↗
L1GUIDELINECited in: Management Overview, History and Evolution of Treatment - [988]
Burstein HJ, Lacchetti C, Anderson H et al.. “Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 30452337 ↗
L1GUIDELINECited in: Management Overview - [989]
Pagani O, Walley BA, Fleming GF et al.. “Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 36521078 ↗
L1RCTCited in: Management Overview, Prognosis and Prognostic Factors - [990]
Francis PA, Fleming GF, Láng I et al.. “Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 36493334 ↗
L1RCTCited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors - [991]
Piccart M, Procter M, Fumagalli D et al.. “Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 33539215 ↗
L1RCTCited in: Management Overview - [992]
Loibl S, Jassem J, Sonnenblick A et al.. “Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39259927 ↗
L1RCTCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations - [993]
Behroozian T, Bonomo P, Patel P et al.. “Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recommendations.” The Lancet. Oncology (2023). PMID: 36990615 ↗
L1GUIDELINECited in: Management Overview, History and Evolution of Treatment - [994]
Rugo HS, Oliveira M, Howell SJ et al.. “Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study.” ESMO open (2024). PMID: 39241495 ↗
L1RCTCited in: Management Overview, History and Evolution of Treatment, Special Populations - [995]
Bardia A, Hurvitz SA, Tolaney SM et al.. “Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.” The New England journal of medicine (2021). PMID: 33882206 ↗
L1RCTCited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations - [996]
Eisen A, Somerfield MR, Accordino MK et al.. “Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35041467 ↗
L1SR_OBSCited in: Management Overview - [997]
Asleh K, Lluch A, Goytain A et al.. “Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36346687 ↗
L3RCTCited in: Management Overview, History and Evolution of Treatment - [998]
Sharma P, Stecklein SR, Yoder R et al.. “Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial.” JAMA oncology (2024). PMID: 37991778 ↗
L4TRIAL_NONRANDOMCited in: Management Overview, Prognosis and Prognostic Factors - [999]
Gentry AL, Sereika SM, Erickson KI et al.. “The relationship of neighborhood socioeconomic disadvantage and pretreatment cancer-related cognitive impairment in women with breast cancer: A post hoc analysis of a randomized controlled trial.” Cancer (2026). PMID: 42421660 ↗
L3RCTCited in: Management Overview, History and Evolution of Treatment, Special Populations - [1000]
Dushkin H, Cristofanilli M. “Inflammatory breast cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2011). PMID: 21310844 ↗
L5REVIEW_NARRATIVECited in: Management Overview